View Filing Data

Print Document View Excel Document

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
Document and Entity Information - USD ($) $ in Millions	Dec. 31, 2018	Mar. 05, 2019	Jun. 30, 2018
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Trading Symbol	ZYME
Entity Registrant Name	Zymeworks Inc.
Entity Central Index Key	0001403752
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Common Stock, Shares Outstanding		32,025,299
Entity Public Float			$ 406.9

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 42,205	$ 35,946
Short-term investments (note 4)	157,959	51,851
SR&ED receivables (note 11)	997	2,092
Accounts receivable	358	238
Prepaid expenses and other current assets	2,850	2,208
Total current assets	204,369	92,335
Deferred financing fees	265
Acquired in-process research and development (note 5)	18,396	18,396
Goodwill (note 5)	12,016	12,016
Long-term prepaid assets	1,135	1,215
Property and equipment, net (note 6)	6,484	7,178
Intangible assets, net (note 7)	1,614	748
Deferred tax assets (note 14)	84	67
Total assets	244,363	131,955
Current liabilities:
Accounts payable and accrued liabilities (note 8)	13,403	9,053
Warrant liabilities (note 9b)		1,348
Fair value of liability classified options (note 2)	12,603	3,945
Deferred revenue (note 12)	3,530
Other current liabilities (note 8)	450	315
Total current liabilities	29,986	14,661
Long-term portion of deferred revenue (note 12)	32,941
Other long-term liabilities (note 8)	946	866
Total liabilities	63,873	15,527
Shareholders' equity:
Common shares, no par value; unlimited authorized shares at December 31, 2018 and 2017; 31,977,668 and 25,444,006 shares issued and outstanding at December 31, 2018 and 2017, respectively (note 10a)	320,074	222,991
Additional paid-in capital	12,347	8,812
Accumulated other comprehensive loss	(6,659)	(6,659)
Accumulated deficit	(145,272)	(108,716)
Total shareholders' equity	180,490	116,428
Total liabilities, redeemable convertible preferred shares and shareholders' equity	$ 244,363	$ 131,955

Consolidated Balance Sheets (Parenthetical) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Common shares, authorized	Unlimited	Unlimited
Common shares, no par value	$ 0	$ 0
Common shares, issued	31,977,668	25,444,006
Common shares, outstanding	31,977,668	25,444,006

Consolidated Statements of Loss and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Revenue:
Research and development collaborations (note 12)	$ 53,019	$ 51,762	$ 11,009
Operating expenses:
Research and development	56,684	41,749	36,816
Government grants and credits	5	(1,075)	(1,265)
Net research and development	56,689	40,674	35,551
General and administrative	29,457	18,550	12,554
Impairment on acquired IPR&D		1,536	768
Total operating expenses	86,146	60,760	48,873
Loss from operations	(33,127)	(8,998)	(37,864)
Other income (expense):
Interest and other expense	(166)	(422)	(950)
Change in fair value of warrant liabilities	(3,565)	2,450	(808)
Accretion expense		(248)	(576)
Gain on equity investment, net			79
Interest and other income	2,638	743	308
Foreign exchange gain	72	97	927
Loss on debt extinguishment		(3,114)
Change in contingent consideration (note 15)	(237)	(470)
Total other income (expense), net	(1,258)	(964)	(1,020)
Loss before income taxes	(34,385)	(9,962)	(38,884)
Current income tax (expense)	(2,188)	(429)	(430)
Deferred income tax recovery (expense)	17	(15)	5,505
Net loss and comprehensive loss	$ (36,556)	$ (10,406)	$ (33,809)
Net loss per common share:
Basic	$ (1.26)	$ (0.51)	$ (2.65)
Diluted	$ (1.26)	$ (0.64)	$ (2.65)
Weighted-average common shares outstanding:
Basic	29,089,896	21,249,414	12,736,567
Diluted	29,089,896	21,321,209	12,736,567

Consolidated Statements of Changes in Redeemable Convertible Preferred Shares and Shareholders' Equity - USD ($) $ in Thousands	Total	Redeemable Convertible Class A Preferred Shares [Member]	Common Shares [Member]	Warrant liabilities [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Additional Paid-in Capital [Member]
Temporary equity, balance at Dec. 31, 2015		$ 0
Temporary equity, balance shares at Dec. 31, 2015		0
Issuance of redeemable convertible preferred shares, net of share issuance costs		$ 58,860
Issuance of redeemable convertible preferred shares, net of share issuance costs		5,260,404
Temporary equity, balance at Dec. 31, 2016		$ 58,860
Temporary equity, balance share at Dec. 31, 2016		5,260,404
Balance balance at Dec. 31, 2015	$ 18,239		$ 83,605	$ 333	$ (63,922)	$ (6,659)	$ 4,882
Beginning balance, shares at Dec. 31, 2015			11,299,051
Issuance of common shares for Kairos Acquisition	22,973		$ 22,973
Issuance of common shares for Kairos Acquisition, shares			1,822,657
Issuance of common shares on exercise of options	17		$ 17
Issuance of common shares on exercise of options, shares			4,540
Fair value adjustments upon reclassification of options to liabilities	(947)				(124)		(823)
Share-based compensation	2,797						2,797
Fair value adjustment upon reclassification of warrants to liabilities	(268)			$ (333)	65
Net loss	(33,809)				(33,809)
Ending balance at Dec. 31, 2016	$ 9,002		$ 106,595		(97,790)	(6,659)	6,856
Ending balance, shares at Dec. 31, 2016			13,126,248
Conversion of redeemable convertible class A preferred shares to common shares in connection with initial public offering		$ (58,860)
Conversion of redeemable convertible class A preferred shares to common shares in connection with initial public offering		(5,260,404)
Temporary equity, balance at Dec. 31, 2017		$ 0
Temporary equity, balance share at Dec. 31, 2017	0	0
Issuance of common shares on exercise of options	$ 1,265		$ 1,777				(512)
Issuance of common shares on exercise of options, shares	207,777		207,777
Issuance of common shares on exercise of warrants	$ 1,563		$ 1,563
Issuance of common shares on exercise of warrants, shares			117,320
Fair value adjustments upon reclassification of options to liabilities	(2,879)						(2,879)
Share-based compensation	4,827						4,827
Beneficial conversion feature recognized on the conversion of redeemable convertible class A preferred shares					(520)		520
Conversion of redeemable convertible class A preferred shares to common shares in connection with initial public offering	58,860		$ 58,860
Conversion of redeemable convertible class A preferred shares to common shares in connection with initial public offering, shares			7,098,194
Issuance of common shares in connection with initial public offering, net of offering costs	54,196		$ 54,196
Issuance of common shares in connection with public offering, net of offering costs, shares			4,894,467
Net loss	(10,406)				(10,406)
Ending balance at Dec. 31, 2017	$ 116,428		$ 222,991		(108,716)	(6,659)	8,812
Ending balance, shares at Dec. 31, 2017	25,444,006		25,444,006
Temporary equity, balance share at Dec. 31, 2018	0
Issuance of common shares on exercise of options	$ 825		$ 1,166				(341)
Issuance of common shares on exercise of options, shares	94,812		94,812
Issuance of common shares on exercise of warrants	$ 4,913		$ 4,913
Issuance of common shares through employee share purchase plan	252		$ 252
Issuance of common shares on exercise of warrants, shares			206,361
Issuance of common shares through employee share purchase plan, shares			22,489
Share-based compensation	3,876						3,876
Issuance of common shares in connection with initial public offering, net of offering costs	90,752		$ 90,752
Issuance of common shares in connection with public offering, net of offering costs, shares			6,210,000
Net loss	(36,556)				(36,556)
Ending balance at Dec. 31, 2018	$ 180,490		$ 320,074		$ (145,272)	$ (6,659)	$ 12,347
Ending balance, shares at Dec. 31, 2018	31,977,668		31,977,668

Consolidated Statements of Changes in Redeemable Convertible Preferred Shares and Shareholders' Equity (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Issuance of common shares in connection with initial public offering, offering costs	$ 7,056	$ 9,392
Redeemable Convertible Class A Preferred Shares [Member]
Issuance of redeemable convertible preferred shares, net of share issuance costs			$ 2,658

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities:
Loss for the year	$ (36,556)	$ (10,406)	$ (33,809)
Items not involving cash:
Depreciation of property and equipment	1,880	1,681	541
Amortization of intangible assets	1,750	1,058	484
Equity loss on investment			98
Gain on fair value of equity investment			(177)
Accretion on long-term debt		248	576
Loss on debt extinguishment		3,114
Share-based compensation (note 10e)	13,441	3,429	4,291
Deferred income tax (recovery) expense	(17)	15	(5,505)
Impairment on acquired IPR&D		1,536	768
Change in fair value of warrant liabilities (note 9b)	3,565	(2,450)	808
Change in fair value of contingent consideration (note 15)	237	470
Unrealized foreign exchange gain	(48)	(254)	(954)
Changes in non-cash operating working capital:
Accounts receivable	(119)	2,409	(592)
SR&ED receivables	1,093	(175)	(780)
Prepaid expenses and other current assets	(1,344)	(27)	(3,141)
Accounts payable and accrued liabilities	3,684	(358)	1,934
Deferred revenue	36,471
Income taxes payable	140	(71)	212
Net cash generated from (used in) operating activities	24,177	219	(35,246)
Cash flows from financing activities:
Proceeds from initial public offering, net of issuance costs (note 1)		55,791
Proceeds from subsequent public offering, net of issuance costs (note 1)	90,752
Issuance of preferred shares from private placement, net of issuance costs			58,860
Issuance of common shares on exercise of options (note 10e)	682	965	17
Issuance of common shares on exercise of warrants (note 9b)		1,018
Issuance of common shares through employee share purchase plan (note 10f)	233
Debt financing (note 9a)			6,953
Repayment of debt (note 9a)		(7,814)
Deferred financing fees	(225)		(1,046)
Capital lease payments	(11)	(9)	(7)
Net cash provided by financing activities	91,431	49,951	64,777
Cash flows from investing activities:
Short-term investments	(105,626)	(27,767)	(20,067)
Acquisition of property and equipment	(803)	(2,015)	(4,425)
Acquisition of intangible assets	(2,617)	(1,106)	(1,039)
Cash acquired from Kairos, net of cash consideration			78
Net cash used in investing activities	(109,046)	(30,888)	(25,453)
Effect of exchange rate changes on cash and cash equivalents	(303)	227	840
Net change in cash and cash equivalents	6,259	19,509	4,918
Cash and cash equivalents, beginning of year	35,946	16,437	11,519
Cash and cash equivalents, end of year	42,205	35,946	16,437
Supplemental disclosure of non-cash investing and finance items:
Share issue costs and deferred financing fees in accounts payable and accrued liabilities	40		910
Acquisition of property and equipment in accounts payable and accrued liabilities	382	$ 123	2,055
Cashless exercise of warrants (note 9b)	$ 4,913
Class A Preferred Shares Warrant issued in connection with debt			3,266
Common Shares issued in connection with the Kairos acquisition			$ 22,973

Nature of Operations	12 Months Ended
Nature of Operations	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations	1. Nature of Operations Zymeworks Inc. (the “Company” or “Zymeworks”) was incorporated on September 8, 2003 under the laws of the Canada Business Corporations Act. On October 22, 2003, the Company was registered as an extra-provincial company under the Company Act (British Columbia). On May 2, 2017, the Company continued under the Business Corporations Act (British Columbia). Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Since its inception, the Company has devoted substantially all of its resources to research and development activities, including developing its therapeutic platforms, identifying and developing potential product candidates by undertaking preclinical studies and clinical trials. The Company supports these activities through general and administrative support, as well as by raising capital, conducting business planning and protecting its intellectual property. *Share Consolidation* On April 13, 2017, the Company effected a 1 for 2.3866 share consolidation (reverse share split) of the Company’s issued and outstanding common shares and redeemable convertible preferred shares. Accordingly, (i) every 2.3866 common shares were combined into one common share, (ii) every 2.3866 redeemable convertible preferred shares were combined into one redeemable convertible preferred share, (iii) the number of common shares into which each outstanding option and warrant to purchase common shares and the number of preferred shares into which each outstanding warrant to purchase preferred shares is exercisable were proportionately decreased on a 1 for 2.3866 basis, and (iv) the exercise price for each such outstanding option and warrant to purchase common shares or preferred shares were proportionately increased on a 1 for 2.3866 basis. All of the share numbers, share prices, and exercise prices in these financial statements have been adjusted, on a retroactive basis, to reflect this 1 for 2.3866 reverse share split. *Initial Public Offering* On April 27, 2017, the Company’s registration statement on Form F-1 (File No. 333-217100) relating to its initial public offering (“IPO”) of its common shares was declared effective by the U.S. Securities and Exchange Commission (“SEC”) and a final base PREP prospectus was filed with the securities commissions or similar securities regulatory authorities in each of the provinces and territories of Canada. A supplemented PREP prospectus containing pricing information and other important information relating to the common shares was also filed with the securities commissions or similar securities regulatory authorities in each of the provinces and territories of Canada. The Company’s common shares began trading on the New York Stock Exchange (“NYSE”) and Toronto Stock Exchange (“TSX”) on April 28, 2017 under the symbol “ZYME”. The public offering price of the shares sold in the IPO was $13.00 per share. The IPO closed on May 3, 2017, pursuant to which the Company sold 4,894,467 shares of common shares including the sale of 394,467 shares of common shares to the underwriters upon their partial exercise of their over-allotment option to purchase additional shares on May 31, 2017. The Company received net proceeds of approximately $54.2 million, after underwriting discounts, commissions and offering expenses. Immediately prior to the consummation of the IPO, all outstanding shares of redeemable convertible preferred stock were converted into 7,098,194 common shares (note 10c) and the Redeemable Convertible Class A Preferred Shares Warrants were converted into common share warrants to purchase up to 398,076 common shares of the Company at an exercise price of $8.67 per share (note 9). *Subsequent Public Offering* On May 24, 2018, the Company’s U.S. shelf registration statement on Form F-10 (File No. 333-224623) was declared effective by the SEC and a final base shelf prospectus was filed with the securities commissions or similar securities regulatory authorities in each of the provinces and territories of Canada. The U.S. shelf registration statement and Canadian base shelf prospectus allow Zymeworks to issue securities with a total aggregate offering price of up to $250 million pursuant to prospectus supplements. On June 6, 2018, the Company filed with the SEC, as well as with the securities commissions or similar securities regulatory authorities in each of the provinces and territories of Canada, a preliminary prospectus supplement to complete an underwritten public offering of $85.0 million of its common shares plus an over-allotment option for the underwriters to purchase up to an additional $12.8 million of its common shares (the “Offering”). On June 7, 2018, the Company filed a final prospectus supplement relating to the Offering with the SEC, as well as with the securities commissions or similar securities regulatory authorities in each of the provinces and territories of Canada, setting forth an offering price of $15.75 per share. The Offering closed on June 11, 2018 pursuant to which the Company sold 6,210,000 shares of common shares including the sale of 810,000 shares of common shares to the underwriters upon their full exercise of their over-allotment option. The Company received net proceeds of approximately $90.8 million, after underwriting discounts, commissions and offering expenses.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Basis of Presentation and Principles of Consolidation

The consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). The consolidated financial statements include the accounts of Zymeworks Inc. and its wholly owned subsidiaries, Zymeworks Biopharmaceuticals Inc., which was incorporated in the State of Washington on December 5, 2014, and Zymeworks Biochemistry Inc. (formerly Kairos Therapeutics Inc. (“Kairos”)), which was acquired on March 18, 2016. Kairos’ financial statements have been consolidated within the Company’s consolidated financial statements from the date of acquisition until December 31, 2016 as the Company completed an amalgamation with Zymeworks Biochemistry Inc. on January 1, 2017. All inter-company accounts and transactions have been eliminated in consolidation.

All amounts expressed in the consolidated financial statements of the Company and the accompanying notes thereto are expressed in thousands of U.S. dollars, except for per share data and where otherwise indicated. References to “$” are to U.S. dollars and references to “C$” are to Canadian dollars. Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.

Use of Estimates

The preparation of the financial statements in accordance with U.S. GAAP requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, some of which are those related to revenue recognition including estimated timing of completion of performance obligations required to meet revenue recognition criteria, Scientific Research and Experimental Development (“SR&ED”) Program, share-based compensation, warrants, accrual of expenses, preclinical study accruals, valuation allowance for deferred taxes, other contingencies and valuation of assets acquired in a business combination. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ from these estimates.

Foreign Currency Translation and Functional Currency Conversion

Prior to January 1, 2016, the Company’s functional currency was the Canadian dollar.

The Company reassessed its functional currency and determined as at January 1, 2016, its functional currency changed from the Canadian dollar to the U.S. dollar based on management’s analysis of the changes in the primary economic environment in which the Company operates. The change in functional currency is accounted for prospectively from January 1, 2016 and prior year financial statements have not been restated for the change in functional currency.

For periods prior to January 1, 2016, the effects of exchange rate fluctuations on translating foreign currency monetary assets and liabilities into Canadian dollars were included in the statement of loss and comprehensive loss as foreign exchange gain/loss. Revenue and expense transactions were translated into the U.S. dollar reporting currency at the average exchange rate during the period, and assets and liabilities were translated at end of period exchange rates, except for equity transactions, which were translated at historical exchange rates. Translation gains and losses from the application of the U.S. dollar as the reporting currency while the Canadian dollar was the functional currency are included as part of the cumulative foreign currency translation adjustment, which is reported as a component of shareholders’ equity under accumulated other comprehensive loss.

For periods commencing January 1, 2016, monetary assets and liabilities denominated in foreign currencies are translated into U.S. dollars using exchange rates in effect at the balance sheet date. Opening balances related to non-monetary assets and liabilities are based on prior period translated amounts, and non-monetary assets and non-monetary liabilities incurred after January 1, 2016 are translated at the approximate exchange rate prevailing at the date of the transaction. Revenue and expense transactions are translated at the approximate exchange rate in effect at the time of the transaction. Foreign exchange gains and losses are included in the statement of loss and comprehensive loss as foreign exchange gain (loss).

The functional currency of Zymeworks Biopharmaceuticals Inc. and Zymeworks Biochemistry Inc. is also the U.S. dollar.

Liability Classified Awards

Awards accounted for under Accounting Standards Codification (“ASC”) 718 “Compensation—Stock Options” (“ASC 718”), with an exercise price which is not denominated in: (a) the currency of a market in which a substantial portion of the Company’s equity securities trades, (b) the currency in which the individual’s pay is denominated, or (c) the Company’s functional currency, are required to be classified as liabilities. For awards accounted for under ASC 815 “Derivatives and Hedging” (“ASC 815”), any warrant or option that provides for an exercise price which is not denominated in the Company’s functional currency are required to be classified as liabilities.

Upon the change of the functional currency from Canadian dollars to U.S. dollars effective January 1, 2016, certain options previously classified as equity awards with total fair value of $251 and common share warrants previously classified as equity awards with a total fair value of $268 have been reclassified as liability awards. Under ASC 815, upon the change in classification, the change in fair value of the options and common share warrants while they were classified as equity is recorded as an adjustment to the accumulated deficit. Additionally, upon the change of the compensation currency for certain directors from Canadian dollars to U.S. dollars effective November 9, 2016, options held by such directors which were previously classified as equity awards with total fair value of $1,341 have been classified as liability awards.

Upon the change of the compensation currency for certain executives from Canadian dollars to U.S. dollars effective January 1, 2017, options held by such executives which were previously classified as equity awards with a total fair value of $7,371 on January 1, 2017 have been reclassified as liability awards of which $2,879 was reclassified from additionalpaid-in capital and the remaining $4,492 was recorded to the statement of loss on January 1, 2017 as under ASC 718, upon the change in classification, the change in fair value of the options while they were classified as equity is recorded as an adjustment to the statement of loss.

Liability classified awards are subsequently measured at fair value at each balance sheet date until exercised or cancelled, with changes in fair value recognized as compensation cost or additional paid-in capital (ASC 718 awards) or other income and expenses (ASC 815 awards) for the period. Under ASC 718, when an award is reclassified from equity to liability, if at the reclassification date the original vesting conditions are expected to be satisfied, then the minimum amount of compensation cost to be recognized is based on the grant date fair value of the original award. Fair value changes below this minimum amount are recorded in additional paid-in capital. Fair value is calculated using the Black-Scholes option pricing model. The Black-Scholes option pricing model uses various inputs to measure fair value, including fair value of the Company’s underlying common shares at the grant date, expected term, estimated volatility, risk-free interest rate and expected dividend yields of the Company’s common shares.

Revenue Recognition

Effective January 1, 2018, the Company adopted on a modified retrospective basis Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (“ASC 606” or “Topic 606”). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. In accordance with ASC 606, the Company recognizes revenue when the Company’s customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expect to receives in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of Topic 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as the Company satisfies a performance obligation.

The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration that it is entitled to in exchange for the goods and services transferred to the customer. At contract inception, the Company assesses the goods or services promised within each contract that falls under the scope of Topic 606, to identify distinct performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. For collaborative arrangements that fall within the scope of ASC 808, Collaborative Arrangements (“ASC 808”), the Company applies the revenue recognition model under ASC 606 to part or all of the arrangement, when deemed appropriate.

As of December 31, 2018, the Company has entered into a number of license and collaboration agreements that fall within the scope of ASC 606. Promised deliverables within these agreements may include: (i) grants of licenses, or options to obtain licenses, to our intellectual property, (ii) research and development services, and (iii) participation on joint research and/or development committees. The terms of these agreements typically include one or more of the following types of payments to the Company:

Licenses of intellectual property including platform technology access: If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are not distinct from other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition accordingly.

Milestone payments: At the inception of each arrangement that includes research, development or regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment. The process of successfully achieving the criteria for the milestone payments is highly uncertain. Consequently, there is a significant risk that the Company may not earn all of the milestone payments from each of its strategic partners.

Research and development milestones in the Company’s collaboration agreements may include some, but not necessarily all, of the following types of events:

•

completion of preclinical research and development work leading to selection of product candidates;

•

initiation of Phase 1, Phase 2 and Phase 3 clinical trials; and

•

achievement of certain other technical, scientific or development criteria.

Regulatory milestone payments may include the following types of events:

•

filing of regulatory applications for marketing approval in the United States, Europe or Japan, including Investigational New Drug (“IND”) applications and Biologics License Application (“BLA”); and

•

marketing approval in major markets, such as the United States, Europe or Japan.

Royalties and commercial milestones: For arrangements that include sales-based royalties, including commercial milestone payments based on pre-specified level of sales, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Achievement of these royalties and commercial milestones may solely depend upon performance of the licensee. Since inception to date, the Company has not recognized any royalty revenue or commercial milestone from any of its out-licensing arrangements.

Research support payments: Payments by the licensees in exchange for research activities performed by the Company on behalf of the licensee are recognized upon performance of such activities at rates consistent with prevailing market rates.

If the expectation at contract inception is such that the period between payment by the licensee and the completion of related performance obligations will be one year or less, the Company assumes that the contract does not have a significant financing component.

Prior to ASC 606 Adoption

The Company recognized revenue when all of the following criteria were met: persuasive evidence of an arrangement existed, the fee was fixed or determinable, delivery or performance was substantially completed and collectability was reasonably assured.

The Company analyzed agreements with more than one element, or deliverable, based on the guidance in ASC 605-25, Revenue Recognition—Multiple Element Arrangements (“ASC605-25”). Each required deliverable was evaluated to determine whether it qualified as a separate unit of accounting. A delivered item or items were considered a separate unit of accounting if they had value to the collaborator or licensee on a stand-alone basis and, if the agreement included a general right of return, the delivery or performance of undelivered items was considered probable and within the control of the Company.

In assessing whether an item or items have stand-alone value, the Company considered if the deliverable or deliverables were sold separately on a stand-alone basis. Additional factors considered included research capabilities of the strategic partner or licensee, the availability of the associated expertise in the general market place, whether the delivered item or items could be used for their intended purpose without receipt of the remaining item(s), whether the value of the delivered item(s) was dependent on the undelivered item(s) and whether there were other vendors that could provide the undelivered item(s).

Arrangement consideration that was fixed or determinable was allocated at the inception of the agreement to all identified units of accounting based on the relative estimated selling prices in accordance with the selling price hierarchy. The selling price of each deliverable was determined using vendor specific objective evidence of selling prices, if it existed; otherwise, third-party evidence of selling prices. If neither vendor specific objective evidence nor third-party evidence existed, the Company used its best estimate of the selling price for each deliverable. Management exercised considerable judgment in estimating the selling prices of identified units of accounting under its agreements. The arrangement consideration otherwise allocable to delivered units was limited to the amount that was not contingent on the delivery of additional items or fulfillment of other performance conditions.

When the Company determined that a license and the related therapeutic platform had stand-alone value to the licensee, these items were considered a unit of accounting and arrangement consideration allocated to this unit of accounting was recognized upon delivery of the therapeutic platform. When research services related to the transfer of the technical information were required, then the license, the applicable research services, and therapeutic platform were considered a unit of accounting and the Company had to determine the period over which the performance obligations were performed, which generally related to the period the research services would be performed, and over which revenue would be recognized. If the Company could not reasonably estimate the timing and the level of effort to complete its performance obligations under the arrangement, then revenue under the arrangement was recognized on a straight-line basis over the period the Company was expected to complete its performance obligations.

The Company recognized other research support payments as revenue upon the performance of activities which were eligible for research support payments from its strategic partners, in accordance with the respective licensing and collaboration agreements.

The Company analyzed milestones based on the guidance in ASC 605-28, Revenue Recognition—Milestone Method (“ASC 605-28”). The Company evaluated milestone payments on an individual basis and recognizes revenue from non-refundable milestone payments when the earnings process was complete and the payment was reasonably assured. Non-refundable milestone payments related to arrangements under which the Company had continuing performance obligations were recognized as revenue upon achievement of the associated milestone, provided that the milestone event was substantive and its achievability was not reasonably assured at the inception of the agreement. A milestone event was considered substantive if (i) the milestone was commensurate with either (a) the Company’s performance to achieve the milestone or (b) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the Company’s performance to achieve the milestone; (ii) it related solely to past performance and (iii) it was reasonable relative to all of the deliverables and payment terms (including other potential milestone consideration) within the arrangement. If any portion of the milestone payment did not relate to the Company’s performance, did not relate solely to past performance or was refundable or adjustable based on future performance, the milestone was not considered to be substantive. Certain milestones in the agreements did not meet the ASC 605-28 definition of a milestone because achievement of the milestone solely depended on the performance of the licensee. Any revenue from these contingent payments was subject to an allocation of arrangement consideration and was recognized over the remaining period of performance obligations, if any, relating to the arrangement. If there were no remaining performance obligations under the arrangement at the time the contingent payment was triggered, the contingent payment was recognized as revenue in full upon the triggering event occurring.

Options for future deliverables were considered substantive if, at the inception of the arrangement, the Company was at risk as to whether the licensee would choose to exercise the option. Factors that the Company considered in evaluating whether an option was substantive included the overall objective of the arrangement, the benefit the licensee might obtain from the arrangement without exercising the option, the cost to exercise the option and the likelihood that the option would be exercised. For arrangements under which an option was considered substantive, the Company did not consider the item underlying the option to be a deliverable at the inception of the arrangement and the associated option fees were not included in the initial consideration, assuming the option was not priced at a significant and incremental discount. Conversely, for arrangements under which an option was not considered substantive or if an option was priced at a significant and incremental discount, the Company would consider the item underlying the option to be a deliverable at the inception of the arrangement and a corresponding amount would be included in the initial consideration.

Since inception, the Company did not have any royalty income.

Contract assets and liabilities

Contract assets are mainly comprised of trade receivables net of allowance for doubtful debts, which includes amounts billed and currently due from customers.

Contract liabilities are mainly comprised of deferred revenues. Amounts received prior to satisfying all revenue recognition criteria are recorded as deferred revenue in the Company’s consolidated financial statements. Amounts not expected to be recognized as revenue within the next twelve months of the consolidated balance sheet date are classified as long-term deferred revenue.

Cash and Cash Equivalents

The Company considers all highly liquid investments purchased with original maturities of 90 days or less at the date of acquisition to be cash equivalents. Cash and cash equivalents consist primarily of money market funds and are recorded at cost, which approximates fair value.

Short-Term Investments

The Company’s short-term investments consist of guaranteed investment certificates with original maturities exceeding three months and less than one year. The carrying value of these investments are recorded at cost plus accrued interest, which approximates their fair value.

Accounts Receivable

Accounts receivable are reported in the consolidated balance sheets at outstanding amounts, net of any provisions for uncollectible amounts. At all periods presented, the Company has no allowance for doubtful accounts.

The Company evaluates the collectability of accounts receivable on a regular basis based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience.

Deferred Financing Costs

Deferred financing costs consist of incremental fees charged by underwriters, attorneys, accountants and printers that are directly attributable to future financing transactions. These costs are deferred and subsequently charged against the gross proceeds of the related financing transaction.

Segment Information

The Company operates and manages its business in one segment, which is the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance.

Property and Equipment

Property and equipment are recorded at cost net of accumulated depreciation. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred.

The Company records depreciation using the straight-line method over the estimated useful lives of the capital assets as follows:


Asset Class		Rate
Computer hardware		3 years
Office equipment		3 years
Furniture and fixtures		5 years
Laboratory equipment		7 years
Leasehold improvements		Shorter of the initial lease term or useful life

Property and equipment, acquired or disposed of during the year, are depreciated proportionately for the period they are in use.

Patents and Intellectual Property Costs

The costs of acquiring patents and of prosecuting and maintaining intellectual property rights are expensed as incurred to general and administrative due to the uncertainty surrounding the drug development process and the uncertainty of future benefits. Patents and intellectual property acquired from third parties are capitalized and amortized over the remaining life of the patent, if for approved products or if there are alternative future uses. No patent or intellectual property costs have been capitalized to date.

Impairment of Long-Lived Assets

The Company assesses the recoverability of its long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or assets. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets classified as held for sale are reported at the lower of the carrying amount or fair value, less costs to sell. As of December 31, 2018 and 2017, the Company determined that there were no impaired assets and no assets held-for-sale.

Government Grants and Credits

Government grants are recognized where there is reasonable assurance that the grant will be received and all associated conditions will be complied with. Reimbursements of eligible research and development expenditures pursuant to government assistance programs are recorded as a reduction of research and development costs when the related costs have been incurred and there is reasonable assurance regarding collection of the claim.

Grant claims not settled by the balance sheet date are recorded as receivables, provided their receipt is reasonably assured. The determination of the amount of the claim, and hence the receivable amount, requires management to make calculations based on its interpretation of eligible expenditures in accordance with the terms of the programs. The reimbursement claims submitted by the Company are subject to review by the relevant government agencies. Although the Company has used its best judgment and understanding of the related program agreements in determining the receivable amount, it is possible that the amounts could increase or decrease by a material amount in the near-term dependent on the review and audit by the government agency.

The Company participates in SR&ED Program, a federal tax incentive program that encourages Canadian businesses to conduct research and development in Canada. The benefits of investment tax credits for scientific research and development expenditures are recognized in the year the qualifying expenditure is made provided there is reasonable assurance of recoverability. This investment tax credit reduces the carrying cost of research and development expenditures.

Research and Development Costs

Research and development expenses include costs that the Company incurs for its own and for the Company’s strategic partners’ research and development activities. Research and development expenditures are expensed as incurred. These costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations on the Company’s behalf, investigative sites and consultants that conduct the Company’s clinical trials, the cost of acquiring and manufacturing clinical trial materials and other allocated expenses, share-based compensation expense, and costs associated with nonclinical activities and regulatory approvals.

Income Taxes

The Company accounts for income taxes using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. In estimating future tax consequences, the Company generally considers all expected future events other than enactments of and changes in the tax law or rates. The measurement of deferred tax assets is reduced, if necessary, by the extent of the valuation allowance. The Company uses a two-step approach to determine whether an uncertain tax position should be recorded, consisting of a “more-likely-than-not” recognition criteria, and a measurement attribute that measures a given tax position as the largest amount of tax benefits that are more than 50% likely of being realized upon ultimate settlement.

Interest and tax penalties are expensed as incurred and nil has been incurred to date.

Stock-Based Compensation

The Company recognizes stock-based compensation expense on share awards granted to employees and members of the board of directors based on their estimated grant date fair value using the Black-Scholes option pricing model. The Black-Scholes option pricing model uses various inputs to measure fair value, including estimated fair value of the Company’s underlying common share at the grant date, expected term, estimated volatility, risk-free interest rate and expected dividend yields of the Company’s common shares. The Company recognizes stock-based compensation expense, net of estimated forfeitures, in the consolidated statements of loss and comprehensive loss on a straight-line basis over the requisite service period wherein the cumulative amount of compensation cost recognized at any point in time at least equals the portion of grant date fair value of the options that vested on that date. The Company applies an estimated forfeiture rate derived from historical employee termination behavior. If the actual number of forfeitures differs from those estimated by management, adjustments to compensation expense may be required in future periods.

Stock options granted to individual service providers who are not employees are measured on the date of performance using the Black-Scholes option-pricing model and the awards are periodically remeasured as the underlying options vest. The fair value of the stock-based awards is amortized over the vesting period.

The Company has an employee stock purchase plan which is considered compensatory. Accordingly, the Company recognizes compensation expense on these awards based on their estimated grant date fair value using the Black-Scholes option pricing model. The Company recognizes compensation expense in the consolidated statements of loss and comprehensive loss on a straight-line basis over the requisite service period.

Business Combination and Goodwill

Acquisitions of businesses are accounted for using the acquisition method. The consideration for a business combination is measured, at the date of the exchange, as the aggregate of the fair value of assets given, liabilities incurred or assumed and equity instruments issued by the Company to the former owners of the acquiree in exchange for control of the acquiree. Acquisition related costs incurred for the business combination are expensed as incurred. The acquiree’s net identifiable assets are generally recognized at their fair value at the acquisition date.

Goodwill arising on acquisition is recognized as an asset and initially measured at cost, being the excess of the consideration transferred for the acquisition over the Company’s interest in the fair value of the net identifiable assets acquired. If the Company’s interest in the fair value of the acquiree’s net identifiable assets exceeds the cost of the acquisition, the excess is recognized in earnings or loss immediately. Goodwill is evaluated for impairment on an annual basis or more frequently if an indicator of impairment is present.

Effective December 31, 2018, the Company early adopted ASU 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. This standard simplifies the subsequent measurement of goodwill by eliminating Step 2 from the goodwill impairment test, which required an entity to determine the fair value of its assets and liabilities at the impairment testing date. As amended, the goodwill impairment test consists of one step that requires comparing the fair value of a reporting unit to its carrying amount, which includes goodwill. When the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not to be impaired. If the carrying amount exceeds the fair value of the reporting unit, an entity should recognize a goodwill impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value.

Acquired In-Process Research and Development and Definite-lived Intangible Assets

The in-process research and development intangible asset (“IPR&D”) arose from the acquisition of Kairos on March 18, 2016 (note 5). IPR&D is classified as indefinite-lived and is not amortized. IPR&D becomes definite-lived upon the completion or abandonment of the associated research and development efforts. Intangible assets with finite useful lives are amortized on a basis which reflect the pattern in which the economic benefits are consumed. Amortization begins when intangible assets with finite lives are put into use. Indefinite-lived intangible assets will be evaluated for impairment on an annual basis or more frequently if an indicator of impairment is present. For definite-lived intangibles, if there is a event indicating that the carrying value of intangible assets may be impaired, then management will perform an impairment test. When an impairment test is performed, if the carrying value exceeds the recoverable value, based on the sum of undiscounted future cash flows, then such assets are written down to their fair values. All research and development costs incurred subsequent to the acquisition of IPR&D are immediately expensed as incurred.

Fair Value Measurements

The Company measures certain financial instruments and other items at fair value.

To determine the fair value, the Company uses the fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows:

•

Level 1 inputs are quoted market prices for identical instruments available in active markets.

•

Level 2 inputs are inputs other than Level 1 prices, such as prices for similar asset or liability that are observable either directly or indirectly. If the asset or liability has a contractual term, the input must be observable for substantially the full term. An example includes quoted market prices for similar assets or liabilities in active markets.

•

Level 3 inputs are unobservable inputs for the asset or liability and will reflect management’s assumptions about market assumptions that would be used to price the asset or liability.

Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy.

The Company’s financial instruments consist of cash and cash equivalents, short-term investments, amounts receivable, accounts payable and accrued liabilities, warrants, capital lease obligations, liability classified options and other long-term liabilities.

The carrying values of cash and cash equivalents, short-term investments, amounts receivable and accounts payable and accrued liabilities approximate their fair values due to the immediate or short-term maturity of these financial instruments. Based on the borrowing rates available to the Company for debt with similar terms and consideration of default and credit risk using Level 2 inputs, the carrying value of the Company’s capital lease obligations as of December 31, 2018 approximates its fair value. As quoted prices for the warrants and liability classified stock options are not readily available, the Company has used a Black-Scholes pricing model to estimate fair value, which utilizes level 3 inputs as defined above. Other long-term liabilities for contingent consideration related to business acquisitions are recorded at fair value on the acquisition date and adjusted quarterly to fair value. Changes in the fair value of contingent consideration liabilities can result from changes in anticipated milestone payments and changes in assumed discount periods and rates. These inputs are unobservable in the market and therefore categorized as level 3 inputs as defined above.

The following tables present information about the Company’s liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques used to determine such fair value:


	December 31, 2018		Level 1		Level 2		Level 3
Liabilities
Liability classified stock options	$	12,603	$	—	$	—	$	12,603
Warrant liabilities		—		—		—		—
Liability for contingent consideration		707		—		—		707

Total	$	13,310	$	—	$	—	$	13,310


	December 31, 2017		Level 1		Level 2		Level 3
Liabilities
Liability classified stock options	$	3,945	$	—	$	—	$	3,945
Warrant liabilities		1,348		—		—		1,348
Liability for contingent consideration		470		—		—		470

Total	$	5,763	$	—	$	—	$	5,763

The following table presents the changes in fair value of the Company’s liability for contingent consideration:


	Liability at the beginning of the period		Increase (decrease) in fair value of liability for contingent consideration		Liability at end of the period
Year ended December 31, 2018	$	470	$	237	$	707
Year ended December 31, 2017	$	—	$	470	$	470

The following table presents the changes in fair value of the Company’s warrant liabilities:


	Liability at the beginning of the period		Warrants issued		Reclassification to liability from equity		Increase (decrease) in fair value of warrant liabilities			Exercise of warrants			Liability at end of the period
Year ended December 31, 2018	$	1,348	$	—	$	—	$	3,565		$	(4,913	)	$	—
Year ended December 31, 2017	$	4,342	$	—	$	—	$	(2,450	)	$	(544	)	$	1,348

The following table presents the changes in fair value of the liability classified stock options:


	Liability at beginning of the period		Reclassification to liabilities from equity		Increase (decrease) in fair value of liability classified stock options			Exercise of options			Unrealized foreign currency loss (gain)			Liability at end of the period
Year ended December 31, 2018	$	3,945	$	—	$	9,451		$	(142	)	$	(651	)	$	12,603
Year ended December 31, 2017	$	2,458	$	2,879	$	(1,413	)	$	(300	)	$	321		$	3,945

The change in fair value of liability classified stock options for the period is presented within research and development expenses and general and administrative expenses.

Net Loss Per Share

The Company follows the two-class method when computing net loss per common share as the Company issued redeemable convertible Class A preferred shares in January 2016 that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common shareholders for the year to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company’s redeemable convertible Class A preferred shares were non-cumulative, contractually entitle the holders of such shares to participate in dividends, but do not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss or a net loss attributable to common shareholders resulting from preferred share dividends, net losses are not allocated to participating securities. The Company reported a net loss attributable to common shareholders for all periods presented. The redeemable convertible Class A preferred shares were converted into common share in conjunction with the Company’s IPO.

Basic net loss per share attributable to common shareholders is computed by dividing the net loss attributable to common shareholders by the weighted average number of common shares outstanding for the year. Diluted net loss per share attributable to common shareholders is computed by adjusting net loss attributable to common shareholders to reallocate undistributed earnings based on the potential impact of dilutive securities, including outstanding redeemable convertible Class A preferred shares, stock options and warrants. Diluted net loss per share attributable to common shareholders is computed by dividing the diluted net loss attributable to common shareholders by the weighted-average number of common shares outstanding for the year, including potential dilutive common shares assuming the dilutive effect of outstanding instruments. The if-converted method is used to determine the dilutive effect of the Company’s redeemable convertible Class A preferred shares. The treasury stock method is used to determine the dilutive effect of the Company’s stock option grants and warrants. ASC 260 “Earnings Per Share” requires an adjustment to the numerator for any income or loss related to ASC 815 liability classified warrants and stock options, if dilutive, if they are presumed to be share settled. The redeemable convertible Class A preferred shares and stock options outstanding were all excluded from the calculation of diluted loss per share because their inclusion would have been anti-dilutive.


	Year Ended December 31,
	2018			2017			2016
Numerator:
Net loss attributable to common shareholders:	$	(36,556	)	$	(10,406	)	$	(33,809	)
Deemed dividend due to beneficial conversion feature		—			(520	)		—

Basic	$	(36,556	)	$	(10,926	)	$	(33,809	)
Adjustment for change in fair value of ASC 815 liability classified stock options and warrant		—			(2,757	)		—

Diluted	$	(36,556	)	$	(13,683	)	$	(33,809	)

Denominator:
Weighted-average common shares outstanding:
Basic		29,089,896			21,249,414			12,736,567
Adjustment for dilutive effect of liability classified stock options and warrants		—			71,795			—

Diluted		29,089,896			21,321,209			12,736,567
Net loss per common share—basic	$	(1.26	)	$	(0.51	)	$	(2.65	)
Net loss per common share—diluted	$	(1.26	)	$	(0.64	)	$	(2.65	)

Recent Accounting Pronouncements	12 Months Ended
Recent Accounting Pronouncements	Dec. 31, 2018
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements	3. Recent Accounting Pronouncements Initial adoption of new accounting pronouncements In May 2014, the Financial Accounting Standards Board, or FASB, issued ASU 2014–09, Revenue from Contracts with Customers (Topic 606). The standard, as subsequently amended, is intended to clarify the principles for recognizing revenue for U.S. GAAP by creating a new Topic 606, Revenue from Contracts with Customers and it supersedes the revenue recognition requirements in ASC 605, Revenue Recognition, and supersedes some cost guidance included in Subtopic 605–35, Revenue Recognition—Construction-Type and Production-Type Contracts. For a complete discussion see Note 2 “Revenue” and Note 9, “Research, Collaboration and Licensing Agreements”. The Company adopted the new standard effective January 1, 2018, as required, using the modified retrospective approach under which previously presented financial statements are not restated and the cumulative effect of adopting ASC 606 is recognized by adjusting retained earnings at the effective date. The adoption of ASU 2014–09 did not have a material impact on the Company’s consolidated financial position, results of operations, equity or cash flows as of the adoption date or for the year ended December 31, 2018. In January 2017, the FASB issued ASU 2017–04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. ASU 2017–04 simplifies the subsequent measurement of goodwill by eliminating Step 2 from the goodwill impairment test, which required an entity to determine the fair value of its assets and liabilities at the impairment testing date. ASU 2017–04 is effective for public companies’ annual periods, including interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted. The Company early adopted the new standard effective December 31, 2018. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements. Refer to Note 2 “Business Combination and Goodwill”. In November 2018, the FASB issued ASU 2018–18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606. This ASU provides guidance that clarifies when certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer, and amends ASC 808 to refer to the unit-of-account guidance in ASC 606. The guidance specifically precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. This ASU is effective for public business entities in fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted for entities that have adopted ASC 606. The Company early adopted the new standard effective December 31, 2018. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements as majority of the Company’s existing strategic partnership agreements are not collaboration agreements. Recent accounting pronouncements not yet adopted In February 2016, the FASB issued ASU 2016–02, Leases (Topic 842) and subsequent amendments to the initial guidance: ASU 2017–13, ASU 2018–10 and ASU 2018–11 (collectively, Topic 842). Topic 842 requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous U.S. GAAP. The new guidance retains a distinction between finance leases and operating leases, with cash payments from operating leases classified within operating activities in the statement of cash flows. It also requires lessees to recognize all leases, including operating leases, with a term greater than 12 months on the balance sheet, for the obligations created by those leases and an offsetting right of use asset. The accounting for lessors will remain largely unchanged from the existing accounting standards. Topic 842 will be effective for fiscal years and interim periods within those years, beginning after December 15, 2018. The Company has arrangements currently classified as operating leases which will be recorded as a right of use asset and corresponding liability on the balance sheet and is currently evaluating the impact these changes will have on the consolidated financial statements. In May 2017, the FASB issued ASU 2017–09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting. ASU 2017–09 provides clarification on when modification accounting should be used for changes to the terms or conditions of a share-based payment award. This ASU does not change the accounting for modifications but clarifies that modification accounting guidance should only be applied if there is a change to the value, vesting conditions, or award classification and would not be required if the changes are considered non-substantive. The new guidance is effective for fiscal years beginning after December 15, 2018. The Company is currently assessing the impact that adopting this new accounting standard will have on its consolidated financial statements. In July 2017, the FASB issued ASU 2017–11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception. The ASU was issued to address the complexity associated with applying U.S. GAAP for certain financial instruments with characteristics of liabilities and equity. The ASU, among other things, eliminates the need to consider the effects of down round features when analyzing convertible debt, warrants and other financing instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. The amendments are effective for fiscal years beginning after December 15, 2018, and should be applied retrospectively. Early adoption is permitted, including adoption in an interim period. The Company is currently assessing the impact that adopting this new accounting standard will have on its consolidated financial statements. In June 2018, the FASB issued ASU 2018–07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. The amendments in this ASU expand the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. This new guidance is effective for the Company in fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company is evaluating the effect of adopting this new accounting guidance, but does not expect adoption will have a material impact on the Company’s consolidated financial statements. In August 2018, the FASB issued ASU 2018–13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this ASU eliminate, add and modify certain disclosure requirements for fair value measurements as part of its disclosure framework project. The standard is effective for the Company in fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently assessing the impact the adoption of the standard will have on its consolidated financial statements. In August 2018, the FASB issued ASU 2018–15, Intangibles—Goodwill and Other – Internal Use Software (Subtopic 350–40). This ASU addresses customer’s accounting for implementation costs incurred in a cloud computing arrangement that is a service contract and also adds certain disclosure requirements related to implementation costs incurred for internal-use software and cloud computing arrangements. The amendment aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted. The amendments in this ASU can be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. The Company is evaluating the effect of adopting this new accounting guidance, but does not expect adoption will have a material impact on the Company’s consolidated financial statements. In October 2018, the FASB issued ASU 2018–16—Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (SOFR) Overnight Index Swap (OIS) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes. This ASU provides guidance that adds the overnight index swap rate based on the Secured Overnight Financing Rate to the list of U.S. benchmark interest rates in ASC 815 that are eligible to be hedged. As a result, entities may designate changes in this rate as the hedged risk in hedges of interest rate risk for fixed-rate financial instruments. This ASU is effective when an entity adopts the new hedging guidance in ASU 2017–12. For entities that have not adopted ASU 2017–12, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption, including adoption in an interim period, is permitted, as long as the entity has adopted ASU 2017–12. The Company is evaluating the effect of adopting this new accounting guidance, but does not expect adoption will have a material impact on the Company’s consolidated financial statements. The Company has reviewed other recent accounting pronouncements and concluded that they are either not applicable to the business, or that no material effect is expected on the consolidated financial statements as a result of future adoption.

Short-term Investments	12 Months Ended
Short-term Investments	Dec. 31, 2018
Investments Schedule [Abstract]
Short-term Investments	4. Short-term Investments Short-term investments consist of guaranteed investment certificates (“GICs”) and term deposits held at financial institutions in accordance with the Company’s treasury policy. These GICs and term deposits bear interest rates of 2%-3% per annum with a maturity up to 12 months. The Company may redeem GIC investments 30 days after deposit without penalty.

Acquisition of Kairos

12 Months Ended

Dec. 31, 2018

Business Combinations [Abstract]

Acquisition of Kairos

5. Acquisition of Kairos

Description of the Transaction

On March 18, 2016, the Company completed the acquisition of all remaining issued and outstanding shares of Kairos Therapeutics Inc. (“Kairos”), for $24,778 (C$32,257). This consideration was comprised of $23,043 (C$30,000) in common shares of the Company, and $1,733 (C$2,257) in cash, pursuant to a net working capital adjustment determined at closing. Prior to this acquisition the Company had a 19.99% equity interest in Kairos. The Company recognized IPR&D and Goodwill as part of the purchase price allocation.

Impairment Evaluation for Intangible Assets and Goodwill

All IPR&D acquired in the Kairos business combination is classified as indefinite-lived and is not currently being amortized. IPR&D becomes definite-lived upon the completion of the associated research and development efforts, and will be amortized from that time over an estimated useful life based on respective patent terms. The Company evaluates the recoverable amount of intangible assets on an annual basis and performs an annual evaluation of goodwill as of December 31 each year, unless there is an event or change in the business that could indicate impairment, in which case earlier testing is performed.

For the year ended December 31, 2016, the Company recorded an impairment charge of $768 for the discontinuance of the Co-Development program with Oxford BioTherapeutics (“OBT Co-Development”). Furthermore, for the three months ended March 31, 2017, the Company recorded an impairment charge of $1,536 related to the fair value of IPR&D recognized in relation to the Research Collaboration Agreement with OBT (“OBT Technology Swap Agreement”) as the Company chose not to advance the associated research and development projects within the research term which expired on February 11, 2017.

The Company performed its annual impairment test for IPR&D as of December 31, 2018 and concluded that there were no impairment indicators related to IPR&D for the twelve months ended December 31, 2018. The following table summarizes the carrying value of IPR&D, net of impairment:


	Acquired IPR&D		Accumulated Impairment			Net
Balance at December 31, 2016	$	20,700	$	(768	)	$	19,932
Change during the year		—		(1,536	)		(1,536	)

Balance at December 31, 2017	$	20,700	$	(2,304	)	$	18,396
Change during the period		—		—			—

Balance at December 31, 2018	$	20,700	$	(2,304	)	$	18,396

The Company also performed its annual impairment test for goodwill as of December 31, 2018. As part of the evaluation of the recoverability of goodwill, the Company identified only one reporting unit to which the total carrying amount of goodwill has been assigned. As at December 31, 2018, the Company performed a qualitative assessment for impairment of goodwill, considering factors including industry and market conditions, macro-economic conditions, and the excess of market capitalization over the carrying value of the net assets at December 31, 2018, and concluded that it was not more likely than not that the fair value of the reporting unit was less than its carrying value. Consequently, the step 1 quantitative test was not required.

Property and Equipment

12 Months Ended

Dec. 31, 2018

Property, Plant and Equipment [Abstract]

Property and Equipment

6. Property and Equipment

Property and equipment consists of the following:


	December 31,
	2018			2017
Computer hardware	$	1,439		$	1,575
Furniture and fixtures		747			552
Office equipment		535			484
Laboratory equipment		5,270			4,895
Leasehold improvements		3,377			3,022
Construction in progress		221			196

Property and equipment	$	11,589		$	10,724
Less accumulated depreciation		(5,105	)		(3,546	)

Property and equipment, net	$	6,484		$	7,178

During the year ended December 31, 2018, the Company entered into a new capital lease for office equipment of $10 (2017—$10). Total assets under capital lease were $72 and $78 at December 31, 2018 and 2017, respectively; accumulated depreciation for these assets were $56 and $47 at December 31, 2018 and 2017, respectively. As of December 31, 2018, the total future minimum lease payments for the capital leases are $62 (2017—$73).

Depreciation expense on property and equipment for the years ended December 31, 2018, 2017 and 2016 was $1,880, $1,681 and $541, respectively.

Intangible Assets

12 Months Ended

Dec. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

7. Intangible Assets

Intangible assets consist of the following:


	December 31,
	2018			2017
Computer software and licenses	$	5,429		$	2,812
Less accumulated amortization		(3,815	)		(2,064	)

Intangible assets, net	$	1,614		$	748

Amortization expense on intangible assets for the years ended December 31, 2018, 2017 and 2016 was $1,750, $1,058 and $484, respectively.

Liabilities

12 Months Ended

Dec. 31, 2018

Payables and Accruals [Abstract]

Liabilities

8. Liabilities

Accounts payable and accrued liabilities consist of the following:


	December 31,
	2018		2017
Trade payables	$	2,599	$	1,664
Accrued research expenses		6,633		4,708
Employee compensation and vacation accruals		2,926		1,981
Accrued legal and professional fees		556		308
Payable to CDRD Ventures Inc. (“CVI”) for Kairos SR&ED receivable (note 5)		—		165
Other		689		227

Total	$	13,403	$	9,053

Other current liabilities consisted of the following:


	December 31,
	2018		2017
Current income tax liability	$	299	$	158
Current portion of lease inducements		136		147
Current portion of capital lease liability		15		10

Total	$	450	$	315

Other long term liabilities consisted of the following:


	December 31,
	2018		2017
Liability for contingent consideration (note 15)	$	707	$	470
Lease inducements		197		344
Capital lease liability		42		52

Total	$	946	$	866

Warrant liabilities and long-term debt

12 Months Ended

Dec. 31, 2018

Text Block [Abstract]

Warrant liabilities and long-term debt

9. Warrant liabilities and long-term debt

a. Perceptive Debt

Description of transaction:

On June 2, 2016, the Company entered into a Credit Agreement (the “Perceptive Debt”) with Perceptive Credit Opportunities Fund L.P. and PCOF Phoenix II Fund L.P. (collectively, “Perceptive”). The total credit facility was for $15.0 million consisting of Tranche A and Tranche B term loans for $7.5 million each. The Tranche A term loan was made available to the Company on June 2, 2016, with total net proceeds received of $6,953, after deducting commissions, legal and other administrative costs. The interest rate on the Tranche A term loan was LIBOR plus an applicable margin of 10% per annum with LIBOR to be a minimum of 1% with monthly interest payments. $225 monthly principal payments were originally scheduled to commence on June 2, 2018, with the remaining outstanding principal balance to be paid on June 2, 2020. Under the Credit Agreement, the Company had the option to settle the loan earlier, subject to certain early payment premiums. On June 6, 2017, the Company exercised its option to repay the total outstanding debt ahead of the maturity date.

On June 2, 2016, pursuant to the terms of the Perceptive Debt, the Company also issued Warrant Certificates which entitled Perceptive Credit Opportunities Fund, L.P. to purchase up to 295,009 Redeemable Convertible Class A Preferred Shares of the Company at an exercise price of $11.69 per share, with an expiry term of five years (the “Perceptive Warrants”). These warrants were classified as liabilities and were recorded at their estimated fair value as they contained a down-round provision and because the shares underlying the warrants could have obligated the Company to transfer assets to the holders at a future date under certain circumstances, such as a deemed liquidation event. Changes in fair value are recorded in the consolidated statements of loss and comprehensive loss.

The warrants were initially recorded at their fair value at issuance of $3,266 and the residual balance of the original principal, $4,234, has been recorded as long-term debt. The long-term debt was being accreted to its face value of $7,500 over the four-year term of the Perceptive Debt. On August 3, 2016, the Warrant Certificates were assigned to Perceptive Credit Holdings, LP, an affiliate of Perceptive.

Immediately prior to the consummation of the IPO, in conjunction with the conversion of the Company’s Redeemable Convertible Class A Preferred Shares into common shares (note 10c), the Redeemable Convertible Class A Preferred Share Warrants were converted on a 1.349367-for-1 basis into common share warrants to purchase up to 398,076 common shares of the Company at an exercise price of $8.67 per share. These common share warrants were classified as liabilities as they contained a down-round provision and because of the understanding that in compliance with applicable securities laws, the warrants required the issuance of registered securities upon exercise and did not sufficiently preclude an implied right to net cash settlement.

Early Repayment of the Perceptive Debt:

On June 6, 2017 (the “Repayment Date”), the Company exercised its option to repay the total outstanding debt ahead of the maturity date, pursuant to the terms of the Credit Agreement. On the Repayment Date, the Company paid $7,814 which consisted of the $7,500 outstanding principal balance, a $300 early repayment premium as well as $14 in legal fees. At the time of repayment, all liabilities and obligations of the Company and Perceptive terminated automatically. The repayment did not affect Perceptive’s rights, in connection with the Perceptive Warrants which remained outstanding until exercised.

From January 1, 2017 to June 6, 2017, the Company recorded $360 in interest expense, $248 in accretion expense and $35 in amortization of debt issue costs.


	Year ended December 31, 2017
Long term debt at January 1, 2017	$	4,810
Less: unamortized debt issue costs at January 1, 2017		(393	)

Long term debt at January 1, 2017, net of deferred charges	$	4,417
Accretion during the period up to the Repayment Date		248
Amortization of debt issue costs during the period up to the Repayment Date		35

Carrying value of long term debt on the Repayment Date, net of deferred charges	$	4,700
Repayment, including repayment premium and expenses		(7,814	)

Loss on debt extinguishment	$	(3,114	)

b. Warrant Liabilities

Warrant liabilities from Perceptive warrants (note 9a) were $nil and $1,348 as of December 31, 2018 and December 31, 2017, respectively.

On May 10, 2018, Perceptive exercised a portion of its warrants to purchase 178,076 common shares of the Company on a cashless basis, resulting in a net issuance of 79,481 common shares to Perceptive.

On June 4, 2018, Perceptive exercised the remaining warrants to purchase 220,000 common shares of the Company on a cashless basis, resulting in a net issuance of 126,880 common shares to Perceptive.

The fair value of the Perceptive warrants increased $3,565 during the period from January 1, 2018 leading up to the exercise of these warrants.

As of December 31, 2017, the estimated fair value of the Perceptive warrants was determined using the Black-Scholes option pricing model with the following assumptions:


	December 31, 2017
Dividend yield		0	%
Expected volatility		66.7	%
Risk-free interest rate		2.09	%
Expected term		3.42	years

Redeemable Convertible Class A Preferred Shares and Shareholders' Equity

12 Months Ended

Dec. 31, 2018

Federal Home Loan Banks [Abstract]

Redeemable Convertible Class A Preferred Shares and Shareholders' Equity

10. Redeemable Convertible Class A Preferred Shares and Shareholders’ Equity

The number of shares and per share amounts are presented in actual amounts.

a.	Authorized

On May 2, 2017, the Company’s new Articles of Incorporation were issued under which the Company has an unlimited number of voting Common Shares and Preferred Shares without par value.

Under the Company’s former Articles of Incorporation dated December 21, 2015, the Company had 6,413,265 authorized Redeemable Convertible Class A Preferred Shares.

b.	Redeemable Convertible Class A Preferred Shares

As of December 31, 2018 and 2017, no Redeemable Convertible Preferred Shares were outstanding. The rights and preferences of the historical Redeemable Convertible Class A Preferred Shares were as follows:

The Class A preferred shares accrued dividends at 8% per annum non-cumulative, payable only as, when and if, declared by the Board of Directors of the Company (the “Board”). In addition, holders of the Class A preferred shares would have been entitled to receive, when and as declared by the Board, dividends in an amount equal to any dividend per common share declared by the Board on the common shares multiplied by the number of common shares that would be issued in exchange for the Class A preferred shares upon conversion.

Optional conversion: Each Class A preferred share was convertible at any time at the option of the holders into common shares, which is determined by dividing the Class A original issue price of $11.69 per share by the Class A conversion price in effect at the time of the conversion.

Mandatory conversion: Upon either a) the closing of the sale of common shares to the public at a price of at least 1.4 times the Class A original issue price of $11.69 per share in a firm-commitment underwritten public offering resulting in at least $50 million of gross proceeds, or b) the date and time, or the occurrence of an event, specified by vote or written consent of the holders of at least a majority of the then outstanding Class A Preferred Share, all outstanding Class A preferred shares would have been automatically converted into common shares at the effective conversion rate. However, in the event the common share public issuance price is less than 1.5 times the Class A original issue price of $11.69 per share, then immediately prior to, and contingent upon such conversion, the Class A conversion price would be automatically adjusted to equal the lesser of (a) the quotient obtained by dividing the per share price in such public offering by 1.5 and (b) the Class A conversion price in effect as of immediately prior to such public offering.

Upon the liquidation, dissolution, reorganization or winding-up of the Company, holders of Class A preferred shares were entitled to receive, before any distribution or payment on the common shares, an amount equal to the greater of:

(i) (a)

if such event occurred prior to January 7, 2017, 1.25 times the Class A original issue price of $11.69 per share,

(b)

if such event occurred after January 7, 2017, 1.5 times the Class A original issue price of $11.69 per share, under both cases plus any dividends declared but unpaid.

(ii)	amount per share payable had all Class A preferred shares been converted into common shares in accordance with the conversion mechanism.

The preferences over common shareholders ceased to exist upon conversion of preferred shares into common shares.

Each preferred shareholder was previously entitled to the number of votes that such shareholder would be entitled to if such preferred shares were converted to common shares.

The Company assessed the issued Class A preferred shares for any beneficial conversion features or embedded derivatives, including the conversion option, that would require bifurcation from the applicable series of preferred shares and receive separate accounting treatment. On the date of the issuance of preferred shares, the fair value of the common shares into which the Class A preferred shares were convertible was less than the effective conversion price of such shares and, as such, there was no intrinsic value of the conversion option on the commitment date. There was a contingent beneficial conversion feature that would have become applicable if an initial public offering was completed at an issue price in excess of the conversion price within one year of the date the preferred shares were issued.

Prior to the IPO, the Company classified its preferred shares outside of permanent equity as the redemption of such shares was not solely under the control of the Company.

c.	Conversion of Redeemable Convertible Class A Preferred Shares to Common Shares

Immediately prior to the consummation of the IPO, all outstanding Redeemable Convertible Class A Preferred Shares were converted into 7,098,194 common shares on a 1-for-1.349367 basis. No Redeemable Convertible Class A Preferred Shares were outstanding as of December 31, 2017 or 2018.

The IPO was completed at $13.00 per share issued which resulted in an adjustment to the conversion price and a beneficial conversion feature related to the Class A preferred shares as the fair value of the common shares at the commitment date exceeded the effective conversion price at the IPO date. This beneficial conversion feature of $520 was recorded as an increase to additional paid-in capital and the resulting deemed dividend was reflected as an increase in accumulated deficit.

d.	Preferred Shares

As of December 31, 2018, no preferred shares were issued or outstanding, respectively.

The rights and preferences of the unissued Preferred Shares are as follows:

Holders of Preferred Shares will be entitled to preference with respect to payment of dividends over the Common Shares and any other shares ranking junior to the Preferred Shares with respect to payment of dividends.

In the event of the liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, or any other distribution of the assets of the Company among its shareholders for the purpose of winding up its affairs, the holders of the Preferred Shares will be entitled to preference over the Common Shares and any other shares ranking junior to the Preferred Shares with respect to the repayment of capital paid up on and the payment of unpaid dividends accrued on the Preferred Shares.

The Preferred Shares may also be given such other preferences over the Common Shares and any other shares ranking junior to the Preferred Shares as may be fixed by directors’ resolution as to the respective series authorized to be issued.

e.	Stock-Based Compensation

Original Stock Option Plan:

On July 14, 2006, the shareholders approved an employee stock option plan (the “Original Plan”). The Original Plan provides for the granting of options to directors, officers, employees and consultants. Options to purchase common shares may be granted at an exercise price of each option equal to the last private issuance of common shares immediately preceding the date of the grant. The total number of options outstanding is not to exceed 20% of the issued common shares of the Company.

Options granted under the Original Plan are exercisable at various dates over their ten-year life. New common shares are issued when options are exercised.

For options issued to employees, the shares available for issuance under the Original Plan vest over 4 years. Shares available for issuance under the Original Plan issued to directors vest over 3 years, and shares available for issuance under the Original Plan issued to consultants and members of the Scientific Advisory Board vest immediately upon issuance.

The exercise prices of the Company’s stock options are denominated in Canadian dollars. The U.S. dollar amounts have been translated using the period end rate or the average rate for the period, as applicable, and have been provided for information purposes.

New Stock Option Plan:

On April 10, 2017, the Company’s shareholders approved a new stock option plan, which became effective immediately prior to the consummation of the IPO. This plan allowed for the grant of options to directors, officers, employees and consultants in U.S. or Canadian dollars, and also permitted the Company to grant incentive stock options (“ISOs”), within the meaning of Section 422 of the Code, to its employees. On June 7, 2018, the Company’s shareholders approved an amendment and restatement of this plan (this plan, as amended and restated, the “New Plan”), which includes an article that allows the Company to grant restricted shares, restricted share units (“RSU”) and other share-based awards, in addition to options. All restricted share, RSU or other share-based award terms and conditions will be specified in future grant agreements. To date, no restricted shares, RSUs or other share-based awards have been granted.

The maximum number of common shares reserved for issuance under the New Plan is 5,686,097, which includes 3,985,768 shares issuable upon exercise of options outstanding as of December 31, 2018. Beginning in 2019 and ending in 2028, this maximum number may be increased on the first day of each calendar year by up to 4.0% of the number of outstanding shares on the last day of the immediately preceding calendar year. ISOs may be granted with respect to a maximum fixed amount equal to 20% of the shares reserved for issuance under the New Plan as of June 7, 2018.

All options granted under the New Plan will have an exercise price determined and approved by the Board on the date of the grant, which shall not be less than the market price of the common shares at such time. For the purposes of the New Plan, the market price of a common share shall be the closing sale price of a share on the grant date reported by the stock exchange with the greatest trading volume or, if such day is not a trading day, the closing sale price reported for the immediately preceding trading day. The Company may convert a market price denominated in Canadian currency into United States currency and vice versa and such converted amount shall be the market price.

An option shall be exercisable during a period established by the Board which shall commence on the date of the grant and shall terminate not later than ten years after the date of the granting of the option. The New Plan provides that the exercise period shall automatically be extended if the date on which it is scheduled to terminate shall fall during a black-out period. In such cases, the extended exercise period shall terminate on the tenth business day after the last day of the black-out period, provided that the exercise period shall in no case be extended beyond the tenth anniversary of the date the option was granted. All options shall vest in accordance with the terms of their grant agreements.

The following table summarizes the Company’s stock options granted in Canadian dollars under the Original Plan and the New Plan:


	Number of Options			Weighted- Average Exercise Price (C$)		Weighted- Average Exercise Price ($)		Weighted- Average Contractual Term (years)		Aggregate intrinsic value (C$)		Aggregate intrinsic value ($)
Outstanding, December 31, 2016		1,910,521			11.67		8.69		7.36		20,958		15,609
Granted		731,528			18.91		14.56
Expired		(80,254	)		12.75		9.82
Exercised		(207,777	)		6.02		4.64
Forfeited		(90,306	)		18.23		14.04

Outstanding, December 31, 2017		2,263,712			14.24		11.35		7.53		1,455		1,160
Granted		326,975			16.51		12.74
Expired		(7,908	)		16.22		12.52
Exercised		(94,812	)		8.81		6.80
Forfeited		(41,977	)		18.09		13.96

Outstanding, December 31, 2018		2,445,990			14.66		10.74		6.99		14,421		10,571

December 31, 2018
Exercisable		1,546,911			13.41		9.83		6.15		11,209		8,217
Vested and expected to vest		2,397,824			14.61		10.71		6.95		14,410		10,563

The following table summarizes the Company’s stock options granted in U.S. dollars under the New Plan:


	Number of Options			Weighted- Average Exercise Price ($)		Weighted- Average Contractual Term (years)		Aggregate intrinsic value ($)
Outstanding, December 31, 2016		—			—		—		—
Granted		650,480			9.70
Expired		—			—
Exercised		—			—
Forfeited		(13,885	)		9.82

Outstanding, December 31, 2017		636,595			9.70		9.46		15
Granted		910,783			13.03
Expired		—			—
Exercised		—			—
Forfeited		(7,600	)		9.82

Outstanding, December 31, 2018		1,539,778			11.67		9.02		4,876
December 31, 2018:
Exercisable		285,350			10.04		8.52		1,704
Vested and expected to vest		1,472,436			11.65		9.01		4,876

The Company received cash proceeds of $682 (C$883) (2017: $965 (C$1,250), 2016: $17 (C$22)) from stock options exercised.

The following table summarizes information pertaining to the Company’s stock options granted in Canadian dollars under the Original Plan and the New Plan and outstanding at December 31, 2018 and December 31, 2017:


	As of December 31, 2018
	Options outstanding								Options exercisable
Exercise price (C$)	Number of options outstanding		Weighted- average remaining contractual life (years)		Weighted- average exercise price (C$)		Weighted- average exercise price (US$)		Number of options exercisable		Weighted- average exercise price (C$)		Weighted- average exercise price (US$)
3.58—5.37		219,369		1.84		4.90		3.59		219,369		4.90		3.59
7.26—9.94		141,608		5.87		8.29		6.08		102,087		7.64		5.60
11.60—13.20		877,492		7.11		12.25		8.98		621,958		12.12		8.89
14.44—17.09		531,295		7.74		15.14		11.10		254,080		14.44		10.58
18.33—20.74		214,514		7.98		20.58		15.08		113,802		20.74		15.20
21.05—22.65		461,712		8.20		22.48		16.48		235,615		22.60		16.57

3.58 to 22.65		2,445,990		6.99		14.66		10.74		1,546,911		13.41		9.83


	As of December 31, 2017
	Options outstanding								Options exercisable
Exercise price (C$)	Number of options outstanding		Weighted- average remaining contractual life (years)		Weighted- average exercise price (C$)		Weighted- average exercise price (US$)		Number of options exercisable		Weighted- average exercise price (C$)		Weighted- average exercise price (US$)
3.58—5.37		268,965		2.74		4.88		3.89		268,965		4.88		3.89
7.26—9.94		148,498		6.95		8.32		6.64		89,498		7.26		5.79
11.60—12.10		717,826		7.78		12.02		9.58		410,968		11.96		9.53
13.21—14.44		468,116		7.98		13.98		11.14		247,268		14.44		11.51
20.74—22.65		660,307		9.02		21.98		17.52		119,280		21.58		17.20

3.58 to 22.65		2,263,712		7.53		14.24		11.35		1,135,979		11.46		9.14

The following table summarizes information pertaining to the Company’s stock options granted in U.S. dollars under the New Plan and outstanding at December 31, 2018 and December 31, 2017:


	As of December 31, 2018
	Options outstanding						Options exercisable
Exercise price (US$)	Number of options outstanding		Weighted- average remaining contractual life (years)		Weighted- average exercise price (US$)		Number of options exercisable		Weighted- average exercise price (US$)
6.80—7.76		27,855		8.74		7.11		14,308		6.69
9.81—11.84		1,166,640		8.82		10.79		253,140		9.81
12.77—14.51		113,000		9.77		13.51		—		—
15.01—15.92		159,858		9.78		15.22		17,902		15.78
16.42—17.21		72,425		9.41		16.76		—		—

6.80 to 17.21		1,539,778		9.02		11.67		285,350		10.04


	As of December 31, 2017
	Options outstanding						Options exercisable
Exercise price (US$)	Number of options outstanding		Weighted- average remaining contractual life (years)		Weighted- average exercise price (US$)		Number of options exercisable		Weighted- average exercise price (US$)
6.80		18,855		9.62		6.80		1,396		6.80
7.75		9,000		9.98		7.75		—		—
9.82		608,740		9.45		9.82		—		—

6.80 to 9.82		636,595		9.46		9.70		1,396		6.80

The stock options expire at various dates from February 5, 2019 to December 16, 2028.

A summary of the non-vested stock option activity and related information of the Company’s stock options granted in Canadian dollars is as follows:


	Number of options			Weighted- average fair value price (C$)		Aggregate Fair value (C$)			Weighted- average fair value price (US$)
Non-vested, December 31, 2017		1,127,733			9.64		10,876			7.69
Options granted		326,975			9.96		3,259			7.69
Options vested		(513,652	)		10.14		(5,210	)		7.83
Options forfeited and cancelled		(41,977	)		10.83		(455	)		8.36

Non-vested, December 31, 2018		899,079			10.25		8,470			7.51

A summary of the non-vested stock option activity and related information of the Company’s stock options granted in U.S. dollars is as follows:


	Number of options			Weighted- average fair value price (US$)		Aggregate Fair value (US$)
Non-vested, December 31, 2017		635,199			3.58		2,276
Options granted		910,783			7.99		7,277
Options vested		(283,954	)		5.69		(1,615	)
Options forfeited and cancelled		(7,600	)		5.64		(43	)

Non-vested, December 31, 2018		1,254,428			7.31		7,895

The estimated fair value of options granted to officers, directors, employees and consultants is amortized over the vesting period. Stock-based compensation expense for equity classified instruments, as well as the financial statement impact of the periodic revaluation of liability classified equity instruments (note 2), is recorded in research and development expenses, general and administration expenses and finance expense (income) as follows:


	Year Ended December 31,
	2018		2017			2016
Research and development expenses:
Stock-based compensation for equity classified instruments	$	2,203	$	913		$	2,335
Change in fair value of liability classified equity instruments		2,032		492			280

	$	4,235	$	1,405		$	2,615
General and administrative expenses:
Stock-based compensation for equity classified instruments	$	3,693	$	1,852		$	786
Change in fair value of liability classified equity instruments		5,362		486			889

	$	9,055	$	2,338		$	1,675
Finance expense (income):
Stock-based compensation for equity classified instruments	$	1	$	—		$	—
Change in fair value of liability classified equity instruments		150		(314	)		1

	$	151	$	(314	)	$	1

For the year ended December 31, 2018, $3,876 of share-based compensation expense was recorded in additional paid-in capital and the remaining balance was recorded in the liability classified stock options and ESPP liability accounts (2017: $4,827 in additional paid-in capital and the remaining balance in liability classified stock options and ESPP liability accounts, 2016: $2,797 in additional paid-in capital and the remaining balance in liability classified stock options account).

The estimated fair value of stock options granted in Canadian dollars under the Original Plan and the New Plan was determined using the Black-Scholes option pricing model with the following weighted-average assumptions:


	Year ended December 31,
	2018			2017			2016
Dividend yield		0	%		0	%		0	%
Expected volatility		66.52	%		66.25	%		70.52	%
Risk-free interest rate		2.18	%		1.44	%		1.08	%
Expected average life of options		5.91	years		5.90	years		5.91	years

The estimated fair value of stock options granted in U.S. dollars under the New Plan was determined using the Black-Scholes option pricing model with the following weighted-average assumptions:


	Year ended December 31,
	2018			2017			2016
Dividend yield		0	%		0	%		—
Expected volatility		66.78	%		65.89	%		—
Risk-free interest rate		2.69	%		1.84	%		—
Expected average life of options		5.88	years		5.89	years		—

Expected Volatility—Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. As the Company does not yet have sufficient history of its own volatility, the Company has identified several public entities of similar complexity and stage of development and calculates historical volatility using the volatility of these companies.

Risk-Free Interest Rate—This rate is from the Government of Canada and U.S. Federal Reserve marketable bonds for the month prior to each option grant during the year, having a term that most closely resembles the expected life of the option.

Expected Term—This is the period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of ten years. The Company uses the simplified method to calculate the average expected term, which represents the average of the vesting period and the contractual term.

Share Fair Value—Options granted after the Company’s IPO, are issued at the fair market value of the Company’s stock at the date the grant is approved by the Board. Before the IPO, the Company granted stock options at exercise prices not less than the fair value of its common shares as determined by the Board, with input from management. Management estimated the fair value of its common shares based on a number of objective and subjective factors, including the most recently available valuation of common shares prepared by independent valuation specialists, external market considerations affecting the biotechnology industry and the historic prices at which the Company sold common shares.

The weighted-average Black-Scholes option pricing assumptions for liability classified stock options outstanding at December 31, 2018 and 2017 are as follows:


	December 31, 2018			December 31, 2017
Dividend yield		0	%		0	%
Expected volatility		72.27	%		66.46	%
Risk-free interest rate		1.94	%		1.55	%
Expected average option term		3.59	years		5.89	years
Number of liability classified share options outstanding		1,437,163			1,475,485

The total intrinsic value of options exercised during the year ended December 31, 2018, 2017 and 2016 was $2,388 (C$3,094) (2017: $1,550 (C$2,013), 2016: $38 (C$51)), respectively. At December 31, 2018, the unamortized compensation expense related to unvested options was $8,395 (C$11,452). The remaining unamortized compensation expense as of December 31, 2018 will be recognized over a weighted-average period of 2.0 years.

f.	Employee Stock Purchase Plan:

On April 10, 2017, the employee stock purchase plan, (“ESPP”), was approved by the shareholders of the Company and became effective immediately prior to the consummation of the IPO. On June 7, 2018, certain amendments to the ESPP were approved by shareholders. Prior to these amendments, the ESPP allowed eligible employees to acquire common shares at a discounted purchase price of 85% of the market value of the Company’s common shares on the purchase date. The ESPP, as amended, allows eligible employees to acquire common shares at a discounted purchase price of the lesser of (i) 85% of the market price of a common share on the first day of the applicable purchase period and (ii) 85% of the market price of a common share on the purchase date. The ESPP qualifies as an “employee stock purchase plan” within the meaning of Section 423 of the Code for employees who are United States taxpayers.

The ESPP is implemented through a series of offerings under which eligible employees are granted rights to purchase the Company’s common shares at the end of specified purchase periods at a discounted purchase price. The Company currently holds offerings consisting of a single six-month purchase period commencing on January 1 and July 1 of each calendar year, with a single purchase date at the end of the purchase period on June 30 and December 31 of each calendar year. The first six-month purchase period commenced on July 1, 2017.

Eligible employees are able to contribute up to 15% of their gross base earnings for purchases under the ESPP through regular payroll deductions. Purchases of shares under the ESPP are limited for each employee at $25 worth of the Company’s common shares (determined using the lesser of (i) the market price of a common share on the first day of the applicable purchase period and (ii) the market price of a common share on the purchase date) for each year such purchase right is outstanding.

Common shares purchased under the ESPP will be issued from treasury at a purchase price equal to 85% of the applicable market price of a common share, all in accordance with applicable laws and the terms and conditions of the ESPP. For the purposes of the ESPP, the market price of a common share is defined as the closing sale price of a share on such date reported by the stock exchange with the greatest trading volume or, if such day is not a trading day, the closing sale price reported for the immediately preceding trading day.

The number of common shares reserved for issuance under the ESPP shall not exceed 272,350 common shares, plus the number of common shares that are automatically added on January 1st of each year, commencing on (and including) January 1, 2018 and ending on (and including) January 1, 2027, in an amount equal to the lesser of (i) 1% of the total number of common shares issued and outstanding on December 31st of the preceding calendar year, and (ii) 419,000 common shares. As this plan is considered compensatory, a charge of $114 has been recorded to research and development expense and general and administrative expense accounts. As of December 31, 2018, total amount contributed by the ESPP participants is $359.

Accordingly, the Company recognizes compensation expense on these awards based on their estimated grant date fair value using the Black-Scholes option pricing model. The Company recognizes compensation expense in the consolidated statements of loss and comprehensive loss on a straight-line basis over the requisite service period.

Government Grants and Credits

12 Months Ended

Dec. 31, 2018

Text Block [Abstract]

Government Grants and Credits

11. Government Grants and Credits


	Year Ended December 31,
	2018			2017		2016
SR&ED credits (expense), net	$	(5	)	$	857	$	1,265
IRAP credits		—			218		—

Total	$	(5	)	$	1,075	$	1,265

The Company accrued refundable investment tax credits receivable for the year ended December 31, 2018 of $106 as well as a true-up adjustment of $(111) for year 2016 resulting a net expense of $5 for the year ended December 31, 2018. The SR&ED receivable of $997 as of December 31, 2018, includes $229 and $662 relating to the investment tax credits for 2017 and 2016, respectively that were not collected yet. Although the Company has used its best judgment and understanding of the related income tax legislation in determining its claims, it is possible the amounts could increase or decrease materially in the future, as the Canada Revenue Agency reserves the right to review and audit the investment tax credit claims.

During the current year, the Company did not recognize any amounts under IRAP. Research grants were recorded as a reduction in research and development expenses in the statement of loss and comprehensive loss. The IRAP funding agreement contains contingency clauses which could require repayment of funding if certain conditions are not met. The Company is in compliance with these conditions.

Research Collaboration and Licensing Agreements

12 Months Ended

Dec. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Research Collaboration and Licensing Agreements

12. Research Collaboration and Licensing Agreements

The Company has entered into a number of collaboration and licensing agreements. Promised deliverables within these agreements may include: (i) grants of licenses, or options to obtain licenses, to our intellectual property, (ii) research and development services, (iii) drug product manufacturing, and (iv) participation on joint research and/or development committees. The terms of these agreements typically include one or more of the following types of payments to the Company:

•

non-refundable, upfront license and platform technology access fees;

•

research, development and regulatory milestone payments;

•

commercial milestone payments; and

•

royalties on net sales of licensed products.

The following table presents summarized revenue recognized from the Company’s strategic partnerships.


	Year ended December 31,
	2018		2017		2016
Janssen:
Recognition of upfront fee	$	—	$	50,000	$	—
Merck:
Research support payments		—		1		832
Lilly:
Milestone revenue		2,000		—		2,000
Research support payments		—		15		46
Celgene:
Option payment		4,000		—		—
GSK:
Technology access fee		—		—		6,000
Daiichi Sankyo:
Technology access fee		18,000		—		2,000
Milestone revenue		—		1,000		—
Research support payments		—		700		131
LEO:
Recognition of upfront fee		5,000	$	—	$	—
Research support payments		116		—		—
BeiGene:
Recognition of upfront fee		23,530	$	—	$	—
Other		373		46		—

	$	53,019	$	51,762	$	11,009

As at January 1, 2018 and December 31, 2018, contract assets from research, collaboration and licensing agreements were $nil. Contract liabilities are comprised of $36,471 deferred revenue from BeiGene as of December 31, 2018 (December 31, 2017: nil) as disclosed below.

Research and License Agreement with Merck Sharp & Dohme Research Ltd. (“Merck”)

On August 22, 2011, the Company entered into a Research and License Agreement with Merck providing Merck a worldwide license to develop and commercialize novel bispecific antibodies generated through use of the Company’s Azymetric platform toward certain exclusive therapeutic targets. Both companies will collaborate to advance the therapeutic platforms, with Merck working to progress the bispecific therapeutic antibody candidates through clinical development and commercialization. No joint development activities to advance the therapeutic platforms have occurred since inception and Merck no longer has a right to such joint activities. In 2013, Merck was also provided with a limited, non-exclusivelicense to EFECT, to be used together with the Azymetric platform for developing products.

On December 3, 2014, the Company and Merck jointly amended the agreement, including amending certain terms and exclusivities contained therein. Under the terms of the amended agreement, the Company receives funding for certain internal and external research costs incurred in the project. Additionally, the amendment removed a $2.0 million research milestone from the total milestones the Company would be eligible to receive over the life of the agreement. The new research funding terms were priced at market rate, and the Company concluded that the original agreement was not materially modified. Accordingly, the amendments did not impact the determination of units of accounting or the allocation of the arrangement consideration.

Upon the execution of the agreement, the Company received a one-time, non-refundable upfront payment of $1.25 million. Over the life of the agreement, the Company is eligible to receive payments up to $190.75 million, comprised of the $1.25 million upfront payment, $3.5 million for research phase successes, up to $6.0 million for completion of IND-enablingstudies, up to $66.0 million for development milestones and up to $114.0 million for commercial milestones. In addition, the Company is eligible to receive tiered royalty payments on sales of products. Merck will have exclusive worldwide commercialization rights to products derived from the agreement. The events and conditions resulting in payments for research, development and commercial milestones solely depend on Merck’s performance.

The Company assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Merck, is a customer. The Company identified the following promised goods and services at the inception of the Merck agreement: (1) the research license, (2) the commercial license, (3) the transfer of the Company’s platform technology (Azymetric) (4) research services and technical assistance in connection with the transfer of platform technology to Merck, and (5) research activities to be performed on behalf of Merck. The Company concluded that the licenses and platform technologies together are distinct. Accordingly, the deliverables (1) through (4) were considered as a single performance obligation and the upfront payment of $1.25 million has been allocated to this performance obligation. The upfront payment was recorded as deferred revenue and recognized into revenue on a straight-line basis from October 1, 2011 through June 30, 2012, the period over which the Company performed the procedures for transferring the Company’s know-howand technology and related technical assistance during the transfer process. The research activities to be performed on behalf of Merck after the transfer of the technology are also determined to have stand-alone value as Merck or another third party could provide these services without the Company’s assistance. The revenue from this deliverable is recognized upon performance of such activities at rates consistent with prevailing market rates.

In order to evaluate the appropriate transaction price, the Company determined that the upfront amount constituted the entirety of the consideration to be included in the transaction price and to be allocated to the performance obligations based on the Company’s best estimate of their relative stand-alone selling prices. The Company estimated the best estimate of selling price of the licenses and technology platform based on comparable license and collaboration arrangements. The best estimate of selling price for the other deliverables was estimated using internal estimates of cost to perform the specific services plus a normal profit margin for providing the services.

At execution, the transaction price included only the $1.25 million upfront consideration received. None of the research and development milestones have been included in the transaction price, as all milestone amounts were fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee’s efforts. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Merck and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.

The consideration otherwise allocable to delivered units is limited to the amount that is not contingent on the delivery of additional items or fulfillment of other performance conditions. Consequently, the arrangement consideration related to the research activities to be performed on behalf of Merck after the transfer of the technology was excluded from the allocation arrangement consideration because the consideration and performance are contingent upon Merck requesting performance of the services and these services are priced at an estimated fair value.

The Company received and recorded non-refundable milestone payments from Merck in the amounts of $2.0 million and $1.5 million on September 20, 2012 and April 22, 2013, respectively. These milestone payments were received upon the achievement of certain development activities during the course of the research program and were recorded as revenue upon achievement of the milestone as the Company had no remaining performance obligations under the arrangement. No additional milestone payments or royalties have been received to date.

During the year ended December 31, 2018, the Company recorded $nil (2017: $1 and 2016: $832) in research support payments from Merck, under the terms of the amended agreement.

Licensing and Collaboration Agreement with Eli Lilly and Company (“Lilly”)

On December 17, 2013, the Company entered into a Licensing and Collaboration Agreement with Lilly to develop novel bispecific antibody therapeutics using the Company’s proprietary Azymetric platform. The Company will apply its Azymetric platform in combination with Lilly’s proprietary targets to create novel bispecific antibodies which Lilly will have the right to develop and commercialize worldwide.

Upon the execution of the agreement, the Company received a one-time, non-refundable upfront payment of $1.0 million. Over the life of the agreement, the Company will receive funding for internal and external research costs incurred on behalf of Lilly on the project, and is eligible to receive potential milestone payments for each product, comprised of $1.0 million for research phase success, $2.0 million for IND submission, $8.0 million for development milestones and up to $40.0 million for commercial milestones. In addition, the Company is eligible to receive tiered royalty payments on the sale of products. Lilly will have exclusive worldwide commercialization rights to products derived from the collaboration. The Company determined that other than the research milestone, the events and conditions resulting in payments for development and commercial milestones solely depend on Lilly’s performance.

The Company assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Lilly, is a customer. The Company identified the following promised goods and services at the inception of the Lilly agreement: (1) the research license, (2) the commercial license, (3) the transfer of the Company’s platform technology (Azymetric), (4) the research services and technical assistance to be provided by the Company in connection with the transfer of intellectual property to Lilly, and (5) research activities to be performed on behalf of Lilly. The Company concluded that the licenses and platform technology together are distinct. Accordingly, the deliverables (1) through (4) were considered as a single performance obligation and the upfront payment of $1.0 million has been allocated to this performance obligation. The payment was recorded as deferred revenue and recognized into revenue on a straight-line basis from December 31, 2013 to June 30, 2014, the period over which the Company performed the procedures for transferring the Company’s know-how and technology and related technical assistance during the transfer process. The research activities to be performed on behalf of Lilly after the transfer of the technology are also determined to be distinct as Lilly or another third party could provide these services without the Company’s assistance. The revenue from this deliverable is recognized upon performance of such activities at rates consistent with prevailing market rates.

At execution, the transaction price included only the $1.0 million upfront consideration received. None of the research and development milestones have been included in the transaction price, as all milestone amounts were fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee’s efforts. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Lilly and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.

The consideration otherwise allocable to delivered units is limited to the amount that is not contingent on the delivery of additional items or fulfillment of other performance conditions. Consequently, the arrangement consideration related to the research activities to be performed on behalf of Lilly after the transfer of the technology was excluded from the allocation arrangement consideration because the consideration and performance are contingent upon Lilly requesting performance of the services and these services are priced at an estimated fair value.

On December 11, 2015, the Company recorded non-refundable substantive research milestone revenue from Lilly in the amount of $1.0 million upon the achievement of certain research activities during the course of the research program. Subsequently, on August 31, 2018, the Company recorded a non-refundable fee of $2.0 million which was received upon Lilly’s filing of IND application to the FDA for a bispecific antibody enabled by the Azymetric platform.

During the year ended December 31, 2018, the Company recorded $nil (2017: $15 and 2016: $46) in research support revenue from Lilly which was a related party during 2018. Lilly is not considered a related party as of December 31, 2018.

Licensing and Collaboration Agreement with Lilly

On October 22, 2014, the Company entered into a second Licensing and Collaboration Agreement with Lilly to develop novel bispecific antibody therapeutics using the Company’s proprietary Azymetric platform. This agreement did not alter or amend the initial agreement entered into on December 17, 2013. Under the terms of this agreement, the Company will apply its Azymetric platform in combination with Lilly’s proprietary targets to create novel bispecific antibodies which Lilly will develop and commercialize. In 2017 Lilly nominated a bispecific antibody from this agreement for preclinical development and discontinued the research of two other bispecific antibodies due to strategic portfolio realignment in those particular disease areas. Each of the two agreements with Lilly were negotiated independently and the deliverables covered by the respective contracts are unrelated to one another as they cover different product candidates. Accordingly, the second Licensing and Collaboration Agreement with Lilly has been accounted for as a new arrangement.

The Company is eligible to receive potential milestone payments totaling up to $125.0 million, comprised of up to $2.0 million for research success milestone, up to $8.0 million for IND submission milestones, up to $20.0 million for development milestones and up to $95.0 million for commercial milestones. In addition, the Company is eligible to receive tiered royalty payments on the sale of products. Lilly will have exclusive worldwide commercialization rights to products derived from the collaboration. No license, research, development and commercial milestones or royalty payments have been received to date. The Company determined that other than the research milestone, the events and conditions resulting in payments for development and commercial milestones solely depend on Lilly’s performance.

The Company assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Lilly, is a customer. At execution, there was no upfront fee received. None of the research and development milestones have been included in the transaction price, as all milestone amounts were fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee’s efforts. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Lilly and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.

On December 1, 2016, the Company recorded a non-refundable fee of $2.0 million which was received upon achievement of a critical success criteria point milestone under the research plan.

No other research, development or commercial milestone payments or royalties have been received to date.

Licensing and Collaboration Agreement with Celgene Corporation & Celgene Alpine Investment Co. LLC (“Celgene”)

On December 23, 2014, the Company entered into an agreement with Celgene to develop novel bispecific antibody therapeutics using the Company’s proprietary Azymetric platform. The Company will apply its Azymetric platform in combination with Celgene’s proprietary targets to create novel bispecific antibodies for which Celgene has an option to develop and commercialize a certain number of products (“Commercial License Option”).

Upon the execution of the Agreement, the Company received a one-time, non-refundable payment of $8.0 million. Over the life of the agreement, the Company is eligible to receive potential milestone payments totaling up to $164.0 million per each therapeutic candidate, comprised of a payment of $7.5 million upon Celgene exercising a Commercial License Option, up to $101.5 million for development milestones and up to $55.0 million for commercial milestones. In addition, the Company is eligible to receive tiered royalties calculated upon the global net sales of the resulting products. Celgene will have exclusive worldwide commercialization rights to products derived from the agreement if Celgene elects to exercise a Commercial License Option for each product. The Company determined that, the events and conditions resulting in payments for research, development and commercial milestones solely depend on Celgene’s performance.

The Company assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Celgene, is a customer. The Company identified the following promised goods and services at the inception of the Celgene agreement: (1) the non-exclusive research license, (2) the transfer of the Company’s platform technology (Azymetric) and relevant know-how, and (3) technical assistance if required by Celgene in connection with the transfer of technology. The Company concluded that the license and platform technology together are distinct. Accordingly, all the deliverables are considered a single performance obligation and the upfront payment of $8.0 million has been allocated to this performance obligation. The upfront payment was recognized as revenue ratably over the six-month period ended June 30, 2015, the period during which the Company transferred its technical know-how and technology to Celgene.

At execution, the transaction price included only the $8.0 million upfront consideration received. None of the research and development milestones have been included in the transaction price, as all milestone amounts were fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee’s efforts. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Celgene and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. The Company concluded that, at the inception of the agreement, Celgene’s option to obtain a Commercial License did not represent a deliverable because it is a substantive option and does not contain a significant or incremental discount.

On April 22, 2018, Celgene exercised its right to increase the number of potential products it can develop and commercialize from eight to ten and extended the research program term by 24 months until April 2020, for which the Company received an expansion fee of $4.0 million and is eligible to receive up to $164.0 million per additional product in development and commercial milestones plus royalties on worldwide sales in accordance with the terms of the licensing and collaboration agreement. The research period extension commenced on April 22, 2018.

No development or commercial milestone payments or royalties have been received to date.

Collaboration and License Agreement with GlaxoSmithKline Intellectual Property Development Ltd. (“GSK”)

On December 1, 2015, the Company entered into a Collaboration and License Agreement with GSK for the research, development, and commercialization of novel Fc-engineeredmonoclonal and bispecific antibody therapeutics, which have been optimized for specific therapeutic effects. The Company and GSK will collaborate to further develop the Company’s Effector Function Enhancement and Control Technology (EFECT) platform through the design, engineering, and testing of novel engineered Fc domains tailored to induce specific antibody-mediated immune responses.

At the conclusion of the research collaboration, both GSK and the Company will have the right to develop and commercialize monoclonal and bispecific antibody candidates that incorporate the Company’s optimized immune-modulating Fc domains.

Under the terms of the agreement, GSK will have the right to develop a minimum of four products across multiple disease areas, and the Company will be eligible to receive research, development, and commercial milestones of up to $110.0 million for each product. In addition, the Company is eligible to receive tiered sales royalties. Under the terms of the agreement, each party is liable for their own internal and external research costs incurred in the project. Furthermore, the Company will have the right to develop up to four products with the intellectual property arising from the collaboration without any royalty or milestone payment to GSK. The Company determined that, the events and conditions resulting in payments for research, development and commercial milestones solely depend on GSK’s performance.

The Company assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, GSK, is a customer. At execution, there was no upfront fee received. None of the research and development milestones have been included in the transaction price, as all milestone amounts were fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee’s efforts. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to GSK and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.

No development or commercial milestone payments or royalties have been received to date.

Platform Technology Transfer and License Agreement with GSK

On April 21, 2016, the Company entered into a Platform Technology Transfer and License Agreement with GSK for the research, development, and commercialization of novel bispecific antibodies enabled using the Company’s Azymetric platform. Each of the two agreements with GSK were negotiated independently and the deliverables covered by the respective contracts utilize different therapeutic platforms and are unrelated to one another. Accordingly, the Platform Technology and License Agreement with GSK has been accounted for as a new arrangement.

Upon execution of the agreement, the Company received a technology access fee of $6.0 million on May 3, 2016. The Company is also eligible to receive up to $30.0 million in research milestone payments; up to $152.0 million in development milestone payments; and up to $720.0 million in commercial sales milestone payments. In addition, the Company is entitled to receive tiered royalties on potential sales. The Company determined that, the events and conditions resulting in payments for research, development and commercial milestones solely depend on GSK’s performance.

The Company assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, GSK, is a customer. The Company identified the following promised goods and services at the inception of the GSK agreement: (1) the non-exclusive research license, (2) commercial license (3) transfer of the Company’s platform technology (Azymetric) and relevant know-how, (4) technical assistance if required by GSK in connection with the transfer of technology, and (5) the obligation to provide future technology improvement and updates, when and if available. The Company concluded that the licenses and platform technologies together are distinct. Accordingly, deliverables (1) through (4) were considered as a single performance obligation and the technology access fee of $6.0 million has been allocated to this performance obligation and has been recognized as revenue upon completion of the transfer of the Company’s technology and technical know-how to GSK.

In order to evaluate the appropriate transaction price, the Company determined that the upfront amount constituted the entirety of the consideration to be included in the transaction price and to be allocated to the performance obligations based on the Company’s best estimate of their relative stand-alone selling prices. The Company estimated the best estimate of selling price of the licenses and technology platform based on comparable license and collaboration arrangements. The Company concluded that the best estimate of selling price for the obligation to deliver future technology improvements and updates was a nominal amount, as the Company has no intention of performing and has made no commitment to perform or provide additional update work on the applicable technology platform. Accordingly, no arrangement consideration was allocated to this deliverable.

At execution, the transaction price included only the $6.0 million upfront consideration received. None of the research and development milestones have been included in the transaction price, as all milestone amounts were fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee’s efforts. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to GSK and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.

No research, development or commercial milestone payments or royalties have been received to date.

Collaboration and Cross License Agreement with Daiichi Sankyo, Co., Ltd. (“Daiichi Sankyo”)

On September 26, 2016, the Company entered into a Collaboration and Cross License Agreement with Daiichi Sankyo for the research, development, and commercialization of novel bispecific antibodies enabled using the Company’s Azymetric and EFECT platforms. Additionally, the Company will license immuno-oncology antibodies from Daiichi Sankyo, with the right to research, develop and commercialize multiple products globally in exchange for royalties on product sales. Under the agreement, Daiichi Sankyo will have the option to develop and commercialize a single bispecific immuno-oncology therapeutic.

Upon execution of the agreement, the Company received a technology access fee of $2.0 million. The Company is also eligible to receive up to $66.9 million in research and development milestone payments and commercial license option; and up to $80.0 million in commercial sales milestone payments. In addition, the Company is eligible to receive tiered royalties on potential product sales. The Company determined that other than a research milestone for $1.0 million, the events and conditions resulting in payments for research, development and commercial milestones solely depend on Daiichi Sankyo’s performance.

The Company assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Daiichi Sankyo, is a customer. The Company identified the following promised goods and services at the inception of the Daiichi Sankyo agreement: (1) the research license, (2) the transfer of the Company’s platform technologies (Azymetric and EFECT) and relevant know-how, and (3) research activities to be performed on behalf of Daiichi Sankyo. The Company concluded that the licenses and platform technologies together are distinct and the licenses are functional intellectual property because the Company’s platform technologies are not expected to substantively change during the licensing period. Accordingly, the deliverables (1) and (2) were considered as a single performance obligation and the technology access fee of $2.0 million was allocated to this performance obligation and was recognized as revenue at a point in time upon delivery of the licenses and transfer of the relevant technology. The research activities to be performed on behalf of Daiichi Sankyo after the transfer of the technology are also determined to be distinct as Daiichi Sankyo or another third party could provide these services without the Company’s assistance. The revenue to be received from Daiichi Sankyo from delivery of these services is recognized upon performance of such activities at rates consistent with prevailing market rates. The Company concluded that, at the inception of the agreement, Daiichi Sankyo’s option to obtain a Commercial License did not represent a deliverable because it is a substantive option and did not contain a significant or incremental discount.

At execution, the transaction price included only the $2.0 million upfront consideration received. None of the research and development milestones have been included in the transaction price, as all milestone amounts were fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee’s efforts. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Daiichi Sankyo and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.

The consideration otherwise allocable to delivered units is limited to the amount that is not contingent on the delivery of additional items or fulfillment of other performance conditions. Consequently, the arrangement consideration related to the research activities to be performed on behalf of Daiichi Sankyo after the transfer of the technology was excluded from the allocation arrangement consideration because the consideration and performance are contingent upon Daiichi Sankyo requesting performance of the services and these services are priced at an estimated fair value.

On June 26, 2017, the Company recorded non-refundable milestone revenue from Daiichi Sankyo in the amount of $1.0 million upon the achievement of a research milestone.

During the year ended December 31, 2018, the Company recorded $nil in research support revenue from Daiichi Sankyo (2017: $700 and 2016: $131).

Second License Agreement with Daiichi Sankyo

In May 2018, the Company entered into a second license agreement with Daiichi Sankyo to research, develop and commercialize two bispecific antibodies generated through the use of the Azymetric and EFECT platforms. Under the terms of the agreement, the Company granted Daiichi Sankyo a worldwide, royalty-bearing, antibody sequence pair-specific, exclusive license to research, develop and commercialize certain products. Under the agreement, Daiichi Sankyo will be solely responsible for the research, development, manufacturing and commercialization of the products.

Upon execution of the agreement, the Company received a non-refundable upfront technology access fee of $18.0 million. The Company is also eligible to receive up to $126.7 million in development milestone payments and up to $340.0 million in commercial milestone payments. In addition, the Company is eligible to receive tiered royalties ranging from the low single digits up to 10% on product sales, with the royalty term being, on a product-by-product and country-by-country basis, either (i) for as long as there is Zymeworks platform patent coverage on products, or (ii) for 10 years beginning from the first commercial sale, whichever period is longer. If there is no Zymeworks patent coverage on products, royalty rates may be reduced.

At execution, the transaction price included only the $18.0 million upfront consideration received. None of the research and development milestones have been included in the transaction price, as all milestone amounts were fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee’s efforts. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Daiichi Sanyo and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.

No development or commercial milestone payments or royalties have been received to date.

Collaboration and License Agreement with Janssen Biotech, Inc. (“Janssen”)

On November 13, 2017, the Company entered into a Collaboration and License Agreement with Janssen to research, develop and commercialize up to six bispecific antibodies generated through the use of the Azymetric and EFECT platforms. Under the terms of the agreement, the Company granted Janssen a worldwide, royalty-bearing, antibody sequence pair-specific exclusive license to research, develop and commercialize certain products. Janssen also has the option to develop two additional bispecific antibodies under this agreement subject to a future option payment. Under the agreement, Janssen will be solely responsible for the research, development, manufacturing and commercialization of the products.

Upon execution of the agreement, the Company received a non-refundable upfront fee of $50.0 million. The Company is also eligible to receive up to $282.0 million in development milestone payments and up to $1,119.0 million in commercial milestone payments. In addition, Company is eligible to receive tiered royalties in the mid-single digits on product sales, with the royalty term being, on a product-by-product and country-by-country basis, either (i) for as long as there is Zymeworks platform patent coverage on products, or (ii) for 10 years, beginning from the first commercial sale, whichever period is longer. If there is no Zymeworks patent coverage on products, royalty rates may be potentially reduced. Janssen has the right, prior to the first dosing of a patient in a Phase 3 clinical trial for a product, to buy down the royalty relating to such product by one percentage point with a payment of $10.0 million. The Company determined that, the events and conditions resulting in payments for research, development and commercial milestones solely depend on Janssen’s performance.

The Company assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Janssen, is a customer. The Company identified the following promised goods and services at the inception of the Janssen agreement: (1) the research and commercial license, (2) the transfer of the Company’s platform technologies (Azymetric and EFECT) and relevant know-how. The Company concluded that the licenses and platform technologies together are distinct. Accordingly, the deliverables (1) and (2) were considered as a single performance obligation and the upfront fee of $50.0 million was allocated to this performance obligation and was recognized as revenue upon delivery of the licenses and transfer of the relevant technology.

At execution, the transaction price included only the $50.0 million upfront consideration received. None of the research and development milestones have been included in the transaction price, as all milestone amounts were fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee’s efforts. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Janssen and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.

No research, development or commercial milestone payments or royalties have been received to date.

Research and License Agreement with LEO Pharma A/S (“LEO”)

On October 23, 2018, the Company entered into a collaboration agreement with LEO. The Company granted LEO a worldwide, royalty-bearing, antibody sequence pair-specific exclusive license to research, develop and commercialize two bispecific antibodies, generated through the use of the Azymetric and EFECT platforms, for dermatologic indications. Zymeworks will retain rights to develop antibodies resulting from this collaboration in all other therapeutic areas. Zymeworks and LEO are jointly responsible for certain research activities, with Zymeworks’ cost to be fully reimbursed by LEO. Each party is solely responsible for the development, manufacturing, and commercialization of their own products.

Pursuant to this agreement, the Company received an upfront payment of $5.0 million. In addition, (i) for the first therapeutic candidate, the Company is eligible to receive preclinical and development milestone payments of up to $74.0 million and commercial milestone payments of up to $157.0 million together with tiered royalties on future sales of up to 20% in the United States and up to high single digits elsewhere, and (ii) for the second therapeutic candidate, the Company is eligible to receive preclinical and development milestone payments of up to $86.5 million and commercial milestone payments of up to $157.0 million together with tiered royalties on future sales of up to low double digits globally. For products developed by Zymeworks outside of dermatology, LEO is eligible to receive commercial milestone payments and up to single-digit royalties on future sales. No development or commercial milestone payments or royalties have been received to date.

The Company assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, LEO, is a customer. The Company identified the following promised goods and services at the inception of the LEO agreement: (1) the research and commercial license, (2) the transfer of the Company’s platform technologies (Azymetric and EFECT) and relevant know-how (3) participation in the Joint Steering Committee (“JSC”), and (4) performance of research activities under the Research Program. The Company concluded that the licenses and platform technologies together are distinct while the Company’s participation to the JSC is a protective right. Accordingly, the deliverables (1) and (2) were considered as a single performance obligation and the upfront fee of $5.0 million was allocated to this performance obligation and was recognized as revenue upon delivery of the licenses and transfer of the relevant technology. The research activities to be performed on behalf of LEO after the transfer of the technology are also determined to be distinct as LEO or another third party could provide these services without the Company’s assistance. The revenue to be received from LEO from delivery of these services is recognized upon performance of such activities at rates consistent with prevailing market rates

At execution, the transaction price included only the $5.0 million upfront consideration received. None of the research and development milestones have been included in the transaction price, as all milestone amounts were fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee’s efforts. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to LEO and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.

The consideration otherwise allocable to delivered units is limited to the amount that is not contingent on the delivery of additional items or fulfillment of other performance conditions. Consequently, the arrangement consideration related to the research activities to be performed on behalf of LEO after the transfer of the technology was excluded from the allocation arrangement consideration because the consideration and performance are contingent upon LEO requesting performance of the services and these services are priced at an estimated fair value.

During the year ended December 31, 2018, the Company recorded $116 in research support revenue from LEO.

Collaboration and License Agreements with BeiGene, Ltd. (“BeiGene”)

On November 26, 2018, the Company entered into three concurrent agreements with BeiGene whereby the Company granted BeiGene royalty-bearing exclusive licenses for the research, development and commercialization of its bispecific therapeutic candidates, ZW25 (“ZW25 Agreement”) and ZW49 (“ZW49 Agreement”) in Asia (excluding Japan but including the People’s Republic of China, South Korea and other countries), Australia and New Zealand. In addition, the Company also granted BeiGene a worldwide, royalty-bearing, antibody sequence pair-specific license to research, develop and commercialize globally three bispecific antibodies generated through the use of the Azymetric and EFECT platforms. Pursuant to these agreements, Zymeworks received an upfront payment of $60.0 million in 2018 for the totality of the rights described. The Company considered the fair value of performance obligations based on the Company’s best estimate of their relative stand-alone selling prices, and allocated $40.0 million of transaction price to the License and Collaboration Agreements for ZW25 and ZW49 while $20.0 million has been allocated to the Company’s performance obligations under the Research and Licensing Agreement for Azymetric and EFECT Platforms.

License and Collaboration Agreements for ZW25 and ZW49

The Company is also eligible to receive development and commercial milestone payments of $390 million, together with tiered royalties from high single digits and up to 20% on future sales of the products. No development or commercial milestone payments or royalties have been received to date. Under the agreement, Zymeworks and BeiGene are collaborating on certain global clinical studies and both Zymeworks and BeiGene will be independently conducting other clinical studies in their own respective territories. Each of Zymeworks and BeiGene are responsible for all the development and commercialization costs in their own territories.

The Company assessed the ZW25 and ZW49 agreements in accordance with ASC 606 and ASC 808, as certain performance obligations for research and development activities of these agreements fall under ASC 808. ASC 808 does not address recognition or measurement matters. Pursuant to ASU 2018-18 which clarified the interaction between ASC 808 and ASC 606, the Company applied ASC 606 to recognize revenue from such collaboration activities as BeiGene meets the definition of a customer.

In relation to the ZW25 Agreement, the Company identified the following promised goods and services at the inception of the BeiGene agreement that are material: (1) development and commercial licenses, (2) initial transfer of the Company’s technologies and relevant know-how, (3) continuing technology transfer (4) participation in the Joint Steering Committee (“JSC”) and other sub-committees, (5) manufacturing technology transfer, (6) provision of development supply, (7) provision of commercial supply, and (8) transfer of future rights related to the development and commercial license. The Company concluded that the licenses and initial technology transfer are distinct together while the continuing technology transfer and the Company’s participation to the JSC and other sub-committees’ activities together are distinct. Manufacturing technology transfer, provisions of development supply and commercial supply, and the transfer of future rights related to the development and commercial license were individually determined to be distinct. Accordingly, performance obligations from the ZW25 were determined as described below.

The Company determined that at the inception of the development and commercial license and upon completion of the initial transfer of the Company’s technologies and relevant know-how (performance obligations (1) and (2)), BeiGene obtained control over certain initial rights, with control over future rights dependent upon the completion of certain collaborative activities.

With respect to the initial rights controlled by BeiGene, deliverables (1) and (2) were considered as a single performance obligation. BeiGene received control of the license and began to benefit from the initial rights at inception of the agreement. The consideration allocated to these performance obligations will be recognized as revenue over a two month period which is the expected period to complete the delivery of the license and transfer of the relevant technology. Deliverables (3) and (4) together were considered as a single performance obligation and the consideration allocated to this performance obligation will be recognized as revenue over time as these performance obligations are completed. Deliverables (5), (6) and (7) are considered individually distinct and the revenue will be recognized as delivery occurs. Remaining deliverable (8) is considered individually distinct and will be recognized as the future rights are transferred to BeiGene.

In order to evaluate the appropriate transaction price, the Company determined that the upfront amount constituted the entirety of the consideration to be included in the transaction price and to be allocated to the performance obligations based on the Company’s best estimate of their relative stand-alone selling prices. The Company estimated selling price of the deliverables based on comparable license and collaboration arrangements as well as using internal estimates of cost to perform the specific services plus a normal profit margin for providing the services. The Company allocated the transaction price for the ZW25 Agreement to performance obligations under deliverables (1) and (2), (3) and (4) and (8). Out of $7.1 million which was allocated to deliverables (1) and (2) of the ZW25 Agreement, the Company recognized $3.5 million for the year ended December 31, 2018.

In relation to the ZW49 Agreement, the Company identified the following promised goods and services at the inception of the BeiGene agreement that are material: (1) development and commercial licenses, (2) initial transfer of the Company’s technologies and relevant know-how, (3) continuing technology transfer (4) participation in the Joint Steering Committee (“JSC”) and other sub-committees, (5) manufacturing technology transfer, (6) provision of development supply, (7) provision of commercial supply, and (8) transfer of future rights related to the development and commercial license. The Company concluded that the licenses and initial technology transfer together are distinct together while the continuing technology transfer and the Company’s participation to the JSC and other sub-committees’ activities together are distinct. Manufacturing technology transfer, provisions of development supply and commercial supply were individually determined to be distinct. Accordingly, performance obligations from the ZW49 were determined as below:

Deliverables (1) and (2) were considered as a single performance obligation while deliverables (3) and (4) together were considered as a single performance obligation. Remaining deliverables of (5), (6) and (7) were considered individually distinct. Deliverable (8) is considered individually distinct and will be recognized as the future rights are transferred to BeiGene. No performance obligations were completed by the Company as of December 31, 2018 as the initial transfer of technologies and relevant know-how is not going to start until the completion of the Company’s Phase-1 clinical studies for ZW49. Accordingly, no revenue was recognized from the ZW49 Agreement for the year ended December 31, 2018.

As of December 31, 2018, approximately $36.5 million of upfront fees from the ZW25 and ZW49 agreements was recorded as deferred revenue on the Company’s consolidated financial statements. Amounts not expected to be recognized as revenue within the next twelve months of the consolidated balance sheet date are classified as long-term deferred revenue.

Research and Licensing Agreement for Azymetric and EFECT Platforms

For the development and commercialization licenses of up to three bispecific antibody therapeutics using the Azymetric and EFECT platforms, the Company received an upfront payment of $20.0 million. The Company is also eligible to receive development and commercial milestone payments of up to $702.0 million. In addition, the Company is eligible to receive tiered royalties in the mid-single digits on product sales. No development or commercial milestone payments or royalties have been received to date. BeiGene is solely responsible for the research, development, manufacturing, and commercialization of the products.

The Company assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, BeiGene, is a customer. The Company identified the following promised goods and services at the inception of the BeiGene agreement: (1) the research and commercial license, (2) the transfer of the Company’s platform technologies (Azymetric and EFECT) and relevant know-how, and (3) participation in the Information Sharing Committee (“ISC”). The Company concluded that the licenses and platform technologies together are distinct while the Company’s participation to the ISC is a protective right. Accordingly, the deliverables (1) and (2) were considered as a single performance obligation and the upfront fee of $20.0 million was allocated to this performance obligation and was recognized as revenue upon delivery of the licenses and transfer of the relevant technology.

At execution, the transaction price included only the $20.0 million upfront consideration received. None of the research and development milestones have been included in the transaction price, as all milestone amounts were fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee’s efforts. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to BeiGene and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.

Financial Instruments	12 Months Ended
Financial Instruments	Dec. 31, 2018
Investments, All Other Investments [Abstract]
Financial Instruments	13. Financial Instruments The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the fair value hierarchy. The fair market values of the financial instruments included in the financial statements, which include cash and cash equivalents, short-term investments, accounts receivable, accounts payable and accrued liabilities, approximate their carrying values at December 31, 2018 and 2017, due to their short-term maturities. See note 2 for a summary of the fair value balances. *Concentration of Credit Risk* Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents, short-term investments and accounts receivable. Cash and cash equivalents and short-term investments are invested in accordance with the Company’s Treasury Policy with the primary objective being the preservation of capital and maintenance of liquidity. The Treasury Policy includes guidelines on the quality of financial instruments and defines allowable investments that the Company believes minimizes the exposure to concentration of credit risk. The Company limits its exposure to credit loss by placing its cash and cash equivalents and short-term investments with high credit quality financial institutions. The Company does not currently maintain a provision for bad debts on accounts receivable. The maximum exposure to credit risk for accounts receivable at the reporting date was $0.4 million (2017: $0.2 million) and all account receivables are due within a year. *Liquidity Risk* Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Company’s approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due. The ability to do this relies on the Company collecting its trade receivables in a timely manner, by maintaining sufficient cash and cash equivalents and securing additional financing as needed. The Company’s financial obligations include accounts payable and accrued liabilities which generally fall due within 45 days and the Company’s current portion of capital lease obligations which fall due within the next 12 months. *Foreign Currency Risk* The Company undertakes certain transactions in currencies other than U.S. dollars and as such is subject to risk due to fluctuations in exchange rates. The Company does not use derivative instruments to hedge exposure to foreign exchange rate risk due to the low volume of transactions denominated in foreign currencies. Non-U.S. dollar denominated payables are paid at the converted rate as due. The operating results and financial position of the Company are reported in U.S. dollars in the Company’s financial statements. The fluctuation of the U.S. dollar in relation to the Canadian dollar and other foreign currencies will consequently have an impact upon the Company’s loss and may also affect the value of the Company’s assets and the amount of shareholders’ equity.

Income Taxes

12 Months Ended

Dec. 31, 2018

Income Tax Disclosure [Abstract]

Income Taxes

14. Income Taxes

a. Income tax expense (recovery) varies from the amounts that would be computed by applying the expected income tax rate of 27% (2017: 26%) to loss before income taxes as shown in the following tables:


	Year Ended December 31,
	2018			2017			2016
Computed taxes at Canadian tax rate (27%)	$	(9,284	)	$	(2,587	)	$	(10,070	)
Non-deductible expenses		4,311			259			1,343
Difference between domestic and foreign tax rate		(14	)		(11	)		95
Effect of change in tax rates		2			(860	)		—
Adjustments to prior year		543			(313	)		439
Change in valuation allowance		9,340			8,510			3,948
Share issuance costs in equity		(1,906	)		(2,547	)		158
Change in recognition and measurement of tax positions		672			—			—
Changes due to SR&ED		(1,668	)		(1,973	)		(588	)
Other		175			(34	)		(400	)

Income tax expense (recovery)	$	2,171		$	444		$	(5,075	)


	Year Ended December 31,
	2018			2017		2016
Current income tax expense	$	2,188		$	429	$	430
Deferred income tax (recovery) expense		(17	)		15		(5,505	)

Income tax expense (recovery)	$	2,171		$	444	$	(5,075	)

Current income tax expense for the years ended December 31, 2018, 2017 and 2016 arose from the operations of Zymeworks Biopharmaceuticals Inc., the Company’s wholly owned subsidiary in the United States, and from the withholding taxes paid by the Company abroad in 2018, 2017 and 2016.

b. Deferred income tax assets and liabilities result from the temporary differences between the amounts of assets and liabilities recognized for financial statement and income tax purposes. The significant components of the deferred income tax assets and liabilities are as follows:


	December 31, 2018		December 31, 2017
Deferred tax assets:
Non-capital losses carried forward	$	6,680	$	11,719
Deferred revenue		9,848		—
Share issue costs		3,428		2,571
Property and equipment		1,167		956
Research and development deductions and credits		20,749		17,267
Contingent consideration		191		127
Stock options		220		102
Other		314		34

	$	42,597	$	32,776


	December 31, 2018			December 31, 2017
Deferred tax liabilities:
Property and equipment		(54	)		(70	)
IPR&D		(4,967	)		(4,619	)
Other		(132	)		—

	$	(5,153	)	$	(4,689	)

		37,444			28,087
Less: valuation allowance		(37,360	)		(28,020	)

Net deferred tax assets (liabilities)	$	84		$	67

The realization of deferred income tax assets is dependent upon the generation of sufficient taxable income during future periods in which the temporary differences are expected to reverse. The valuation allowance is reviewed on a quarterly basis and if the assessment of the “more likely than not” criteria changes, the valuation allowance is adjusted accordingly. Following the Company’s amalgamation with Zymeworks Biochemistry Inc. on January 1, 2017, deferred income tax assets and liabilities have been presented on a net basis on the consolidated balance sheet.

c. At December 31, 2018, the Company has net operating losses carried forward for tax purposes in Canada, which are available to reduce taxable income of future years of approximately $24.7 million (December 31, 2017: $43.4 million) expiring commencing 2035 through 2038.

At December 31, 2018, the Company also has unclaimed tax deductions for scientific research and experimental development expenditures of approximately $50.3 million (2017: $43.7 million), with no expiry. At December 31, 2018, the Company has approximately $9.0 million (2017: $7.0 million) of investment tax credits available to offset Canadian federal and provincial taxes payable expiring commencing in 2019 through 2038.

d. The investment tax credits and non-capital losses and net operating losses for income tax purposes expire as follows:


Expiry date	Investment tax credits		Non-capital losses
2021	$	86	$	—
2022		158		—
2023		94		—
2024		—		—
2025		309		—
2026		247		—
2027		511		—
2028		814		—
2029		—		—
2030		10		—
2031		133		—
2032		489		—
2033		557		—
2034		381		—
2035		1,068		—
2036		862		14,116
2037		1,777		10,625
2038		1,513		—

	$	9,009	$	24,741

e. The benefit of an uncertain tax position that is more likely than not of being sustained upon audit by the relevant taxing authority must be recognized at the largest amount that is more likely than not to be sustained. No portion of the benefit of an uncertain tax position may be recognized if the position has less than a 50% likelihood of being sustained.

A reconciliation of the beginning and ending amount of total unrecognized tax benefits for the years ended December 31, 2018, 2017, and 2016 are as follows:


	Year Ended December 31,
	2018		2017		2016
Balance, beginning of year	$	—	$	—	$	—
Increases related to prior year tax positions		142		—		—
Increases related to current year tax positions		530		—		—

Balance, end of year	$	672	$	—	$	—

Included in the balance of unrecognized tax benefits at December 31, 2018 are potential benefits of $nil that, if recognized, would affect the effective tax rate on income from continuing operations. This is due to recognition of potential benefits would result in a deferred tax asset in the form of net operating loss carry-forward, which would be subject to a valuation allowance based on conditions existing at the reporting date.

We recognize interest expense and penalties related to unrecognized tax benefits within the provision for income tax expense on the consolidated statements of loss and comprehensive loss. At December 31, 2018, we had accrued $nil (2017—$nil) interest and penalties.

The Company currently files income tax returns in Canada and the US, the jurisdiction in which the Company believes that it is subject to tax. Further, while the statute of limitations in each jurisdiction where an income tax return has been filed generally limits the examination period, as a result of loss carry-forwards, the limitation period for examination generally does not expire until several years after the loss carry-forwards are utilized. Other than routine audits by tax authorities for tax credits and tax refunds that Zymeworks have claimed, management is not aware of any other material income tax examination currently in progress by any taxing jurisdiction. Tax years ranging from 2006 to 2018 remain subject to Canadian income tax examinations. Tax years ranging from 2015 to 2018 remain subject to U.S. income tax examinations.

Commitments and Contingencies

12 Months Ended

Dec. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

15. Commitments and Contingencies

Lease Commitments

The Company leases office premises in Vancouver, British Columbia and Seattle, Washington that expire in August 2021 and February 2022, respectively. The Company has also entered into a lease for laboratory space in Vancouver, British Columbia that will expire in August 2021. The leases contain rent escalation clauses. The Company also leases office equipment under capital lease agreements. Future minimum lease payments under the non-cancellable operating leases and capital leases at December 31, 2018 are as follows:


	Payments due by period
	Less Than 1 Year		1 to 2 Years		2 to 3 Years		3 to 4 Years		5 Years		Total
	(dollars in thousands)
Capital lease obligations	$	21	$	27	$	12	$	2	$	—	$	62
Operating lease obligations		1,860		1,871		1,429		87		—		5,247

Total contractual obligations	$	1,881	$	1,898	$	1,441	$	89	$	—	$	5,309

Other Commitments

The Company has entered into research collaboration agreements with strategic partners in the ordinary course of operations that may include contractual milestone payments related to the achievement of pre-specified research, development, regulatory and commercialization events and indemnification provisions, which are common in such agreements. Pursuant to the agreements, the Company is obligated to make research and development and regulatory milestone payments upon the occurrence of certain events and royalty payments based on net sales. The maximum amount of potential future indemnification is unlimited, however, the Company currently holds commercial and product liability insurance. This insurance limits the Company’s liability and may enable it to recover a portion of any future amounts paid. Historically, the Company has not made any indemnification payments under such agreements and the Company believes that the fair value of these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations for any period presented.

In August 2016, the Company entered into a license agreement with Innovative Targeting Solutions Inc., or ITS, to use ITS’ protein engineering technology for the development and commercialization of antibody and protein therapeutics. Pursuant to the agreement, the Company agreed to pay an aggregate of $12.0 million in annual licensing fees to ITS over a five-year period of which $4.5 million was paid to December 31, 2018. Licensing fees paid to ITS are recorded in intangible assets and are amortized over a twelve-month period. The Company may also be required to make payments to ITS upon the achievement of certain development and commercial milestones, as well as royalty payments on net sales. No liabilities have been recorded for any amounts payable as of December 31, 2018.

In connection with the Kairos acquisition, the Company may be required to make future payments to CVI upon the direct achievement of certain development milestones for products incorporating certain Kairos intellectual property, as well as royalty payments on the net sales of such products. For out-licensed products and technologies incorporating certain Kairos intellectual property, the Company may be required to pay CVI a mid-single digit percentage of the future revenue as a result of a revenue sharing agreement. As of December 31, 2018, the contingent consideration had an estimated fair value of approximately $707, which has been recorded within Other long-term liabilities (note 8) (2017: $470). The contingent consideration was calculated using a probability weighted assessment of the likelihood the milestones would be met, a probability adjusted discount rate that reflects the stage of the development and time to complete the development. Contingent consideration is a financial liability and measured at its fair value at each reporting period, with any changes in fair value from the previous reporting period recorded in the statement of loss and comprehensive loss.

Contingencies

From time to time, the Company may be subject to various legal proceedings and claims related to matters arising in the ordinary course of business. The Company does not believe it is currently subject to any material matters where there is at least a reasonable possibility that a material loss may be incurred.

Subsequent events	12 Months Ended
Subsequent events	Dec. 31, 2018
Subsequent Events [Abstract]
Subsequent events	16. Subsequent events On January 17, 2019, the Company reported the achievement of a new development milestone in its collaboration with Lilly. In accordance with the Company’s 2014 licensing and collaboration agreement with Lilly, the Company will receive a milestone payment of US$8.0 million for Lilly’s submission of an IND application for an immuno-oncology bispecific antibody enabled by the Company’s proprietary Azymetric platform. On January 25, 2019, the Company entered into an Indenture of Lease (the “Lease”) to lease approximately 57,180 rentable square feet of office and laboratory space and 2,780 rentable square feet of storage space in Vancouver, B.C., Canada. The term of the Lease will commence no later than September 1, 2021, with an initial term of ten years and two five-year extension options. The base rent for the office and laboratory space ranges between C$39.50 and C$44.50 per square foot annually during the initial term. The base rent for the storage space ranges between C$25.00 to C$35.00 per square foot annually during the initial term.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Basis of Presentation and Principles of Consolidation

Basis of Presentation and Principles of Consolidation

Use of Estimates

Use of Estimates

Foreign Currency Translation and Functional Currency Conversion

Foreign Currency Translation and Functional Currency Conversion

Prior to January 1, 2016, the Company’s functional currency was the Canadian dollar.

The functional currency of Zymeworks Biopharmaceuticals Inc. and Zymeworks Biochemistry Inc. is also the U.S. dollar.

Liability Classified Awards

Liability Classified Awards

Upon the change of the compensation currency for certain executives from Canadian dollars to U.S. dollars effective January 1, 2017, options held by such executives which were previously classified as equity awards with a total fair value of $7,371 on January 1, 2017 have been reclassified as liability awards of which $2,879 was reclassified from additional paid-in capital and the remaining $4,492 was recorded to the statement of loss on January 1, 2017 as under ASC 718, upon the change in classification, the change in fair value of the options while they were classified as equity is recorded as an adjustment to the statement of loss.

Revenue Recognition

Revenue Recognition

Research and development milestones in the Company’s collaboration agreements may include some, but not necessarily all, of the following types of events:

•

completion of preclinical research and development work leading to selection of product candidates;

•

initiation of Phase 1, Phase 2 and Phase 3 clinical trials; and

•

achievement of certain other technical, scientific or development criteria.

Regulatory milestone payments may include the following types of events:

•

marketing approval in major markets, such as the United States, Europe or Japan.

Contract assets and liabilities

Contract assets and liabilities

Contract assets are mainly comprised of trade receivables net of allowance for doubtful debts, which includes amounts billed and currently due from customers.

Prior to ASC 606 Adoption

Prior to ASC 606 Adoption

Since inception, the Company did not have any royalty income.

Cash and Cash Equivalents

Cash and Cash Equivalents

Short-Term Investments

Short-Term Investments

Accounts Receivable

Accounts Receivable

Deferred Financing Costs

Deferred Financing Costs

Segment Information

Segment Information

Property and Equipment

Property and Equipment

The Company records depreciation using the straight-line method over the estimated useful lives of the capital assets as follows:


Asset Class		Rate
Computer hardware		3 years
Office equipment		3 years
Furniture and fixtures		5 years
Laboratory equipment		7 years
Leasehold improvements		Shorter of the initial lease term or useful life

Property and equipment, acquired or disposed of during the year, are depreciated proportionately for the period they are in use.

Patents and Intellectual Property Costs

Patents and Intellectual Property Costs

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

Government Grants and Credits

Government Grants and Credits

Research and Development Costs

Research and Development Costs

Income Taxes

Income Taxes

Interest and tax penalties are expensed as incurred and nil has been incurred to date.

Stock-Based Compensation

Stock-Based Compensation

Business Combination and Goodwill

Business Combination and Goodwill

Acquired In-Process Research and Development and Definite-lived Intangible Assets

Acquired In-Process Research and Development and Definite-lived Intangible Assets

Fair Value Measurements

Fair Value Measurements

The Company measures certain financial instruments and other items at fair value.

•

Level 1 inputs are quoted market prices for identical instruments available in active markets.

•

Level 3 inputs are unobservable inputs for the asset or liability and will reflect management’s assumptions about market assumptions that would be used to price the asset or liability.


	December 31, 2018		Level 1		Level 2		Level 3
Liabilities
Liability classified stock options	$	12,603	$	—	$	—	$	12,603
Warrant liabilities		—		—		—		—
Liability for contingent consideration		707		—		—		707

Total	$	13,310	$	—	$	—	$	13,310


	December 31, 2017		Level 1		Level 2		Level 3
Liabilities
Liability classified stock options	$	3,945	$	—	$	—	$	3,945
Warrant liabilities		1,348		—		—		1,348
Liability for contingent consideration		470		—		—		470

Total	$	5,763	$	—	$	—	$	5,763

The following table presents the changes in fair value of the Company’s liability for contingent consideration:


	Liability at the beginning of the period		Increase (decrease) in fair value of liability for contingent consideration		Liability at end of the period
Year ended December 31, 2018	$	470	$	237	$	707
Year ended December 31, 2017	$	—	$	470	$	470

The following table presents the changes in fair value of the Company’s warrant liabilities:


	Liability at the beginning of the period		Warrants issued		Reclassification to liability from equity		Increase (decrease) in fair value of warrant liabilities			Exercise of warrants			Liability at end of the period
Year ended December 31, 2018	$	1,348	$	—	$	—	$	3,565		$	(4,913	)	$	—
Year ended December 31, 2017	$	4,342	$	—	$	—	$	(2,450	)	$	(544	)	$	1,348

The following table presents the changes in fair value of the liability classified stock options:


	Liability at beginning of the period		Reclassification to liabilities from equity		Increase (decrease) in fair value of liability classified stock options			Exercise of options			Unrealized foreign currency loss (gain)			Liability at end of the period
Year ended December 31, 2018	$	3,945	$	—	$	9,451		$	(142	)	$	(651	)	$	12,603
Year ended December 31, 2017	$	2,458	$	2,879	$	(1,413	)	$	(300	)	$	321		$	3,945

The change in fair value of liability classified stock options for the period is presented within research and development expenses and general and administrative expenses.

Net Loss Per Share

Net Loss Per Share


	Year Ended December 31,
	2018			2017			2016
Numerator:
Net loss attributable to common shareholders:	$	(36,556	)	$	(10,406	)	$	(33,809	)
Deemed dividend due to beneficial conversion feature		—			(520	)		—

Basic	$	(36,556	)	$	(10,926	)	$	(33,809	)
Adjustment for change in fair value of ASC 815 liability classified stock options and warrant		—			(2,757	)		—

Diluted	$	(36,556	)	$	(13,683	)	$	(33,809	)

Denominator:
Weighted-average common shares outstanding:
Basic		29,089,896			21,249,414			12,736,567
Adjustment for dilutive effect of liability classified stock options and warrants		—			71,795			—

Diluted		29,089,896			21,321,209			12,736,567
Net loss per common share—basic	$	(1.26	)	$	(0.51	)	$	(2.65	)
Net loss per common share—diluted	$	(1.26	)	$	(0.64	)	$	(2.65	)

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Schedule of Estimated Useful Lives

The Company records depreciation using the straight-line method over the estimated useful lives of the capital assets as follows:


Asset Class		Rate
Computer hardware		3 years
Office equipment		3 years
Furniture and fixtures		5 years
Laboratory equipment		7 years
Leasehold improvements		Shorter of the initial lease term or useful life

Schedule of Financial Liabilities Measured at Fair Value on a Recurring Basis


	December 31, 2018		Level 1		Level 2		Level 3
Liabilities
Liability classified stock options	$	12,603	$	—	$	—	$	12,603
Warrant liabilities		—		—		—		—
Liability for contingent consideration		707		—		—		707

Total	$	13,310	$	—	$	—	$	13,310


	December 31, 2017		Level 1		Level 2		Level 3
Liabilities
Liability classified stock options	$	3,945	$	—	$	—	$	3,945
Warrant liabilities		1,348		—		—		1,348
Liability for contingent consideration		470		—		—		470

Total	$	5,763	$	—	$	—	$	5,763

Summary of Changes in Fair Value of the Company's Liability for Contingent Consideration

The following table presents the changes in fair value of the Company’s liability for contingent consideration:


	Liability at the beginning of the period		Increase (decrease) in fair value of liability for contingent consideration		Liability at end of the period
Year ended December 31, 2018	$	470	$	237	$	707
Year ended December 31, 2017	$	—	$	470	$	470

Schedule of Changes in Fair Value of Warrant Liabilities

The following table presents the changes in fair value of the Company’s liability for contingent consideration:


	Liability at the beginning of the period		Increase (decrease) in fair value of liability for contingent consideration		Liability at end of the period
Year ended December 31, 2018	$	470	$	237	$	707
Year ended December 31, 2017	$	—	$	470	$	470

Schedule of Changes in Fair Value of Liability Classified Stock Options

The following table presents the changes in fair value of the liability classified stock options:


	Liability at beginning of the period		Reclassification to liabilities from equity		Increase (decrease) in fair value of liability classified stock options			Exercise of options			Unrealized foreign currency loss (gain)			Liability at end of the period
Year ended December 31, 2018	$	3,945	$	—	$	9,451		$	(142	)	$	(651	)	$	12,603
Year ended December 31, 2017	$	2,458	$	2,879	$	(1,413	)	$	(300	)	$	321		$	3,945

Summary of Calculation of Diluted Loss Per Share

The redeemable convertible Class A preferred shares and stock options outstanding were all excluded from the calculation of diluted loss per share because their inclusion would have been anti-dilutive.


	Year Ended December 31,
	2018			2017			2016
Numerator:
Net loss attributable to common shareholders:	$	(36,556	)	$	(10,406	)	$	(33,809	)
Deemed dividend due to beneficial conversion feature		—			(520	)		—

Basic	$	(36,556	)	$	(10,926	)	$	(33,809	)
Adjustment for change in fair value of ASC 815 liability classified stock options and warrant		—			(2,757	)		—

Diluted	$	(36,556	)	$	(13,683	)	$	(33,809	)

Denominator:
Weighted-average common shares outstanding:
Basic		29,089,896			21,249,414			12,736,567
Adjustment for dilutive effect of liability classified stock options and warrants		—			71,795			—

Diluted		29,089,896			21,321,209			12,736,567
Net loss per common share—basic	$	(1.26	)	$	(0.51	)	$	(2.65	)
Net loss per common share—diluted	$	(1.26	)	$	(0.64	)	$	(2.65	)

Acquisition of Kairos (Tables)

12 Months Ended

Dec. 31, 2018

Business Combinations [Abstract]

Summary of Carrying Value of IPR&D, Net of Impairment

The following table summarizes the carrying value of IPR&D, net of impairment:


	Acquired IPR&D		Accumulated Impairment			Net
Balance at December 31, 2016	$	20,700	$	(768	)	$	19,932
Change during the year		—		(1,536	)		(1,536	)

Balance at December 31, 2017	$	20,700	$	(2,304	)	$	18,396
Change during the period		—		—			—

Balance at December 31, 2018	$	20,700	$	(2,304	)	$	18,396

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2018

Property, Plant and Equipment [Abstract]

Components of Property and Equipment

Property and equipment consists of the following:


	December 31,
	2018			2017
Computer hardware	$	1,439		$	1,575
Furniture and fixtures		747			552
Office equipment		535			484
Laboratory equipment		5,270			4,895
Leasehold improvements		3,377			3,022
Construction in progress		221			196

Property and equipment	$	11,589		$	10,724
Less accumulated depreciation		(5,105	)		(3,546	)

Property and equipment, net	$	6,484		$	7,178

Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets

Intangible assets consist of the following:


	December 31,
	2018			2017
Computer software and licenses	$	5,429		$	2,812
Less accumulated amortization		(3,815	)		(2,064	)

Intangible assets, net	$	1,614		$	748

Liabilities (Tables)

12 Months Ended

Dec. 31, 2018

Payables and Accruals [Abstract]

Schedule of Accounts Payable and Accrued Liabilities

Accounts payable and accrued liabilities consist of the following:


	December 31,
	2018		2017
Trade payables	$	2,599	$	1,664
Accrued research expenses		6,633		4,708
Employee compensation and vacation accruals		2,926		1,981
Accrued legal and professional fees		556		308
Payable to CDRD Ventures Inc. (“CVI”) for Kairos SR&ED receivable (note 5)		—		165
Other		689		227

Total	$	13,403	$	9,053

Schedule of Other Current Liabilities

Other current liabilities consisted of the following:


	December 31,
	2018		2017
Current income tax liability	$	299	$	158
Current portion of lease inducements		136		147
Current portion of capital lease liability		15		10

Total	$	450	$	315

Schedule of Other Long-term Liabilities

Other long term liabilities consisted of the following:


	December 31,
	2018		2017
Liability for contingent consideration (note 15)	$	707	$	470
Lease inducements		197		344
Capital lease liability		42		52

Total	$	946	$	866

Warrant liabilities and long-term debt (Tables)

12 Months Ended

Dec. 31, 2018

Text Block [Abstract]

Summary of Debt

From January 1, 2017 to June 6, 2017, the Company recorded $360 in interest expense, $248 in accretion expense and $35 in amortization of debt issue costs.


	Year ended December 31, 2017
Long term debt at January 1, 2017	$	4,810
Less: unamortized debt issue costs at January 1, 2017		(393	)

Long term debt at January 1, 2017, net of deferred charges	$	4,417
Accretion during the period up to the Repayment Date		248
Amortization of debt issue costs during the period up to the Repayment Date		35

Carrying value of long term debt on the Repayment Date, net of deferred charges	$	4,700
Repayment, including repayment premium and expenses		(7,814	)

Loss on debt extinguishment	$	(3,114	)

Summary of Assumptions used in Estimating Fair value of Warrants determined using Black-Scholes Option Pricing Model

As of December 31, 2017, the estimated fair value of the Perceptive warrants was determined using the Black-Scholes option pricing model with the following assumptions:


	December 31, 2017
Dividend yield		0	%
Expected volatility		66.7	%
Risk-free interest rate		2.09	%
Expected term		3.42	years

Redeemable Convertible Class A Preferred Shares and Shareholders' Equity (Tables)

12 Months Ended

Dec. 31, 2018

Summary of Stock Options Granted

The following table summarizes the Company’s stock options granted in Canadian dollars under the Original Plan and the New Plan:


	Number of Options			Weighted- Average Exercise Price (C$)		Weighted- Average Exercise Price ($)		Weighted- Average Contractual Term (years)		Aggregate intrinsic value (C$)		Aggregate intrinsic value ($)
Outstanding, December 31, 2016		1,910,521			11.67		8.69		7.36		20,958		15,609
Granted		731,528			18.91		14.56
Expired		(80,254	)		12.75		9.82
Exercised		(207,777	)		6.02		4.64
Forfeited		(90,306	)		18.23		14.04

Outstanding, December 31, 2017		2,263,712			14.24		11.35		7.53		1,455		1,160
Granted		326,975			16.51		12.74
Expired		(7,908	)		16.22		12.52
Exercised		(94,812	)		8.81		6.80
Forfeited		(41,977	)		18.09		13.96

Outstanding, December 31, 2018		2,445,990			14.66		10.74		6.99		14,421		10,571

December 31, 2018
Exercisable		1,546,911			13.41		9.83		6.15		11,209		8,217
Vested and expected to vest		2,397,824			14.61		10.71		6.95		14,410		10,563

Summary of Range of Stock Options Granted


	As of December 31, 2018
	Options outstanding								Options exercisable
Exercise price (C$)	Number of options outstanding		Weighted- average remaining contractual life (years)		Weighted- average exercise price (C$)		Weighted- average exercise price (US$)		Number of options exercisable		Weighted- average exercise price (C$)		Weighted- average exercise price (US$)
3.58—5.37		219,369		1.84		4.90		3.59		219,369		4.90		3.59
7.26—9.94		141,608		5.87		8.29		6.08		102,087		7.64		5.60
11.60—13.20		877,492		7.11		12.25		8.98		621,958		12.12		8.89
14.44—17.09		531,295		7.74		15.14		11.10		254,080		14.44		10.58
18.33—20.74		214,514		7.98		20.58		15.08		113,802		20.74		15.20
21.05—22.65		461,712		8.20		22.48		16.48		235,615		22.60		16.57

3.58 to 22.65		2,445,990		6.99		14.66		10.74		1,546,911		13.41		9.83


	As of December 31, 2017
	Options outstanding								Options exercisable
Exercise price (C$)	Number of options outstanding		Weighted- average remaining contractual life (years)		Weighted- average exercise price (C$)		Weighted- average exercise price (US$)		Number of options exercisable		Weighted- average exercise price (C$)		Weighted- average exercise price (US$)
3.58—5.37		268,965		2.74		4.88		3.89		268,965		4.88		3.89
7.26—9.94		148,498		6.95		8.32		6.64		89,498		7.26		5.79
11.60—12.10		717,826		7.78		12.02		9.58		410,968		11.96		9.53
13.21—14.44		468,116		7.98		13.98		11.14		247,268		14.44		11.51
20.74—22.65		660,307		9.02		21.98		17.52		119,280		21.58		17.20

3.58 to 22.65		2,263,712		7.53		14.24		11.35		1,135,979		11.46		9.14

Schedule of Non-Vested Stock Option Activity

A summary of the non-vested stock option activity and related information of the Company’s stock options granted in Canadian dollars is as follows:


	Number of options			Weighted- average fair value price (C$)		Aggregate Fair value (C$)			Weighted- average fair value price (US$)
Non-vested, December 31, 2017		1,127,733			9.64		10,876			7.69
Options granted		326,975			9.96		3,259			7.69
Options vested		(513,652	)		10.14		(5,210	)		7.83
Options forfeited and cancelled		(41,977	)		10.83		(455	)		8.36

Non-vested, December 31, 2018		899,079			10.25		8,470			7.51

A summary of the non-vested stock option activity and related information of the Company’s stock options granted in U.S. dollars is as follows:


	Number of options			Weighted- average fair value price (US$)		Aggregate Fair value (US$)
Non-vested, December 31, 2017		635,199			3.58		2,276
Options granted		910,783			7.99		7,277
Options vested		(283,954	)		5.69		(1,615	)
Options forfeited and cancelled		(7,600	)		5.64		(43	)

Non-vested, December 31, 2018		1,254,428			7.31		7,895

Schedule of Stock-based Compensation Expense for Equity Classified Instruments

Stock-based compensation expense for equity classified instruments, as well as the financial statement impact of the periodic revaluation of liability classified equity instruments (note 2), is recorded in research and development expenses, general and administration expenses and finance expense (income) as follows:


	Year Ended December 31,
	2018		2017			2016
Research and development expenses:
Stock-based compensation for equity classified instruments	$	2,203	$	913		$	2,335
Change in fair value of liability classified equity instruments		2,032		492			280

	$	4,235	$	1,405		$	2,615
General and administrative expenses:
Stock-based compensation for equity classified instruments	$	3,693	$	1,852		$	786
Change in fair value of liability classified equity instruments		5,362		486			889

	$	9,055	$	2,338		$	1,675
Finance expense (income):
Stock-based compensation for equity classified instruments	$	1	$	—		$	—
Change in fair value of liability classified equity instruments		150		(314	)		1

	$	151	$	(314	)	$	1

New Stock Option Plan [Member]

Summary of Stock Options Granted

The following table summarizes the Company’s stock options granted in U.S. dollars under the New Plan:


	Number of Options			Weighted- Average Exercise Price ($)		Weighted- Average Contractual Term (years)		Aggregate intrinsic value ($)
Outstanding, December 31, 2016		—			—		—		—
Granted		650,480			9.70
Expired		—			—
Exercised		—			—
Forfeited		(13,885	)		9.82

Outstanding, December 31, 2017		636,595			9.70		9.46		15
Granted		910,783			13.03
Expired		—			—
Exercised		—			—
Forfeited		(7,600	)		9.82

Outstanding, December 31, 2018		1,539,778			11.67		9.02		4,876
December 31, 2018:
Exercisable		285,350			10.04		8.52		1,704
Vested and expected to vest		1,472,436			11.65		9.01		4,876

Summary of Range of Stock Options Granted

The following table summarizes information pertaining to the Company’s stock options granted in U.S. dollars under the New Plan and outstanding at December 31, 2018 and December 31, 2017:


	As of December 31, 2018
	Options outstanding						Options exercisable
Exercise price (US$)	Number of options outstanding		Weighted- average remaining contractual life (years)		Weighted- average exercise price (US$)		Number of options exercisable		Weighted- average exercise price (US$)
6.80—7.76		27,855		8.74		7.11		14,308		6.69
9.81—11.84		1,166,640		8.82		10.79		253,140		9.81
12.77—14.51		113,000		9.77		13.51		—		—
15.01—15.92		159,858		9.78		15.22		17,902		15.78
16.42—17.21		72,425		9.41		16.76		—		—

6.80 to 17.21		1,539,778		9.02		11.67		285,350		10.04


	As of December 31, 2017
	Options outstanding						Options exercisable
Exercise price (US$)	Number of options outstanding		Weighted- average remaining contractual life (years)		Weighted- average exercise price (US$)		Number of options exercisable		Weighted- average exercise price (US$)
6.80		18,855		9.62		6.80		1,396		6.80
7.75		9,000		9.98		7.75		—		—
9.82		608,740		9.45		9.82		—		—

6.80 to 9.82		636,595		9.46		9.70		1,396		6.80

Schedule of Estimated Fair Value of Stock Options Assumptions

The estimated fair value of stock options granted in U.S. dollars under the New Plan was determined using the Black-Scholes option pricing model with the following weighted-average assumptions:


	Year ended December 31,
	2018			2017			2016
Dividend yield		0	%		0	%		—
Expected volatility		66.78	%		65.89	%		—
Risk-free interest rate		2.69	%		1.84	%		—
Expected average life of options		5.88	years		5.89	years		—

Employee Stock Option [Member]

Schedule of Estimated Fair Value of Stock Options Assumptions


	Year ended December 31,
	2018			2017			2016
Dividend yield		0	%		0	%		0	%
Expected volatility		66.52	%		66.25	%		70.52	%
Risk-free interest rate		2.18	%		1.44	%		1.08	%
Expected average life of options		5.91	years		5.90	years		5.91	years

Liability Classified Stock Options [Member]

Schedule of Estimated Fair Value of Stock Options Assumptions

The weighted-average Black-Scholes option pricing assumptions for liability classified stock options outstanding at December 31, 2018 and 2017 are as follows:


	December 31, 2018			December 31, 2017
Dividend yield		0	%		0	%
Expected volatility		72.27	%		66.46	%
Risk-free interest rate		1.94	%		1.55	%
Expected average option term		3.59	years		5.89	years
Number of liability classified share options outstanding		1,437,163			1,475,485

Government Grants and Credits (Tables)

12 Months Ended

Dec. 31, 2018

Text Block [Abstract]

Component of Government Grants and Credits


	Year Ended December 31,
	2018			2017		2016
SR&ED credits (expense), net	$	(5	)	$	857	$	1,265
IRAP credits		—			218		—

Total	$	(5	)	$	1,075	$	1,265

Research Collaboration and Licensing Agreements (Tables)

12 Months Ended

Dec. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Revenue Recognized from Strategic Partnerships

The following table presents summarized revenue recognized from the Company’s strategic partnerships.


	Year ended December 31,
	2018		2017		2016
Janssen:
Recognition of upfront fee	$	—	$	50,000	$	—
Merck:
Research support payments		—		1		832
Lilly:
Milestone revenue		2,000		—		2,000
Research support payments		—		15		46
Celgene:
Option payment		4,000		—		—
GSK:
Technology access fee		—		—		6,000
Daiichi Sankyo:
Technology access fee		18,000		—		2,000
Milestone revenue		—		1,000		—
Research support payments		—		700		131
LEO:
Recognition of upfront fee		5,000	$	—	$	—
Research support payments		116		—		—
BeiGene:
Recognition of upfront fee		23,530	$	—	$	—
Other		373		46		—

	$	53,019	$	51,762	$	11,009

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2018

Income Tax Disclosure [Abstract]

Schedule of Income Tax Expense (Recovery)

Income tax expense (recovery) varies from the amounts that would be computed by applying the expected income tax rate of 27% (2017: 26%) to loss before income taxes as shown in the following tables:


	Year Ended December 31,
	2018			2017			2016
Computed taxes at Canadian tax rate (27%)	$	(9,284	)	$	(2,587	)	$	(10,070	)
Non-deductible expenses		4,311			259			1,343
Difference between domestic and foreign tax rate		(14	)		(11	)		95
Effect of change in tax rates		2			(860	)		—
Adjustments to prior year		543			(313	)		439
Change in valuation allowance		9,340			8,510			3,948
Share issuance costs in equity		(1,906	)		(2,547	)		158
Change in recognition and measurement of tax positions		672			—			—
Changes due to SR&ED		(1,668	)		(1,973	)		(588	)
Other		175			(34	)		(400	)

Income tax expense (recovery)	$	2,171		$	444		$	(5,075	)


	Year Ended December 31,
	2018			2017		2016
Current income tax expense	$	2,188		$	429	$	430
Deferred income tax (recovery) expense		(17	)		15		(5,505	)

Income tax expense (recovery)	$	2,171		$	444	$	(5,075	)

Schedule of Significant Components of the Deferred Income Tax Assets and Liabilities

The significant components of the deferred income tax assets and liabilities are as follows:


	December 31, 2018		December 31, 2017
Deferred tax assets:
Non-capital losses carried forward	$	6,680	$	11,719
Deferred revenue		9,848		—
Share issue costs		3,428		2,571
Property and equipment		1,167		956
Research and development deductions and credits		20,749		17,267
Contingent consideration		191		127
Stock options		220		102
Other		314		34

	$	42,597	$	32,776


	December 31, 2018			December 31, 2017
Deferred tax liabilities:
Property and equipment		(54	)		(70	)
IPR&D		(4,967	)		(4,619	)
Other		(132	)		—

	$	(5,153	)	$	(4,689	)

		37,444			28,087
Less: valuation allowance		(37,360	)		(28,020	)

Net deferred tax assets (liabilities)	$	84		$	67

Schedule of Expiry Details of Investment Tax Credits, Non-Capital Losses and Net Operating Losses for Income Tax Purposes

The investment tax credits and non-capital losses and net operating losses for income tax purposes expire as follows:


Expiry date	Investment tax credits		Non-capital losses
2021	$	86	$	—
2022		158		—
2023		94		—
2024		—		—
2025		309		—
2026		247		—
2027		511		—
2028		814		—
2029		—		—
2030		10		—
2031		133		—
2032		489		—
2033		557		—
2034		381		—
2035		1,068		—
2036		862		14,116
2037		1,777		10,625
2038		1,513		—

	$	9,009	$	24,741

Schedule of Reconciliation of Beginning and Ending Amounts of Unrecognized Tax Benefits

A reconciliation of the beginning and ending amount of total unrecognized tax benefits for the years ended December 31, 2018, 2017, and 2016 are as follows:


	Year Ended December 31,
	2018		2017		2016
Balance, beginning of year	$	—	$	—	$	—
Increases related to prior year tax positions		142		—		—
Increases related to current year tax positions		530		—		—

Balance, end of year	$	672	$	—	$	—

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

Future Minimum Lease Payments Under Non-Cancellable Operating Leases and Capital Leases

Future minimum lease payments under the non-cancellable operating leases and capital leases at December 31, 2018 are as follows:


	Payments due by period
	Less Than 1 Year		1 to 2 Years		2 to 3 Years		3 to 4 Years		5 Years		Total
	(dollars in thousands)
Capital lease obligations	$	21	$	27	$	12	$	2	$	—	$	62
Operating lease obligations		1,860		1,871		1,429		87		—		5,247

Total contractual obligations	$	1,881	$	1,898	$	1,441	$	89	$	—	$	5,309

Nature of Operations - Additional Information (Detail)							12 Months Ended
Nature of Operations - Additional Information (Detail)	Jun. 11, 2018 USD ($) shares	Jun. 06, 2018 USD ($) shares	May 31, 2017 shares	May 03, 2017 USD ($) shares	Apr. 28, 2017 $ / shares shares	Apr. 13, 2017	Dec. 31, 2018 shares	Dec. 31, 2017 shares	Jun. 07, 2018 $ / shares	May 24, 2018 USD ($)
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Date of incorporation							Sep. 08, 2003
Description on share consolidation						(i) every 2.3866 common shares were combined into one common share, (ii) every 2.3866 redeemable convertible preferred shares were combined into one redeemable convertible preferred share, (iii) the number of common shares into which each outstanding option and warrant to purchase common shares and the number of preferred shares into which each outstanding warrant to purchase preferred shares is exercisable were proportionately decreased on a 1 for 2.3866 basis, and (iv) the exercise price for each such outstanding option and warrant to purchase common shares or preferred shares were proportionately increased on a 1 for 2.3866 basis.
Common stock issued upon conversion of redeemable convertible preferred stock					7,098,194
Number of shares issuable upon exercise of outstanding warrants					398,076
Warrant exercise price \| $ / shares					$ 8.67
Final prospectus supplement, shares price \| $ / shares					13.00
Maximum [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Aggregate offering price \| $										$ 250,000,000
IPO [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Share issued, price per share \| $ / shares					13.00
Number of shares issued				4,894,467
Net proceeds from issuance \| $				$ 54,200,000
Over-Allotment Option [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Number of shares issued to underwriters	810,000		394,467
Offering [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Net proceeds from issuance \| $	$ 90,800,000
Preliminary prospectus supplement, shares authorized		85,000,000
Final prospectus supplement, shares price \| $ / shares									$ 15.75
Number of shares issued	6,210,000
Offering [Member] \| Maximum [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Over-allotment option exercised \| $		$ 12,800,000
Redeemable Convertible Preferred Stock [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Reverse share split, conversion ratio						0.419006117
Final prospectus supplement, shares price \| $ / shares					$ 11.69
Common Shares [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Reverse share split, conversion ratio						0.419006117
Common stock issued upon conversion of redeemable convertible preferred stock								7,098,194
Number of shares issued							6,210,000	4,894,467

Summary of Significant Accounting Policies - Additional Information (Detail)		12 Months Ended
	Jan. 01, 2017 USD ($)	Dec. 31, 2018 USD ($) Segment	Dec. 31, 2017 USD ($)	Dec. 12, 2016 USD ($)	Nov. 09, 2016 USD ($)
Schedule Of Accounting Policies [Line Items]
Equity awards reclassified as liability awards				$ 251,000
Common share warrants reclassified as liability awards				$ 268,000
Number of operating Segment \| Segment		1
Intangible assets capitalized		$ 0
Asset impairment charges		0	$ 0
Assets held for sale		0	$ 0
Interest tax penalties expensed		$ 0
Director [Member]
Schedule Of Accounting Policies [Line Items]
Equity awards reclassified as liability awards					$ 1,341,000
Executive Officer [Member]
Schedule Of Accounting Policies [Line Items]
Equity awards reclassified as liability awards	$ 7,371,000
Additional paid in capital reclassified as liability awards	2,879,000
Equity awards reclassified as loss	$ 4,492,000

Summary of Significant Accounting Policies - Summary of Estimated Useful Lives (Detail)	12 Months Ended
	Dec. 31, 2018
Computer hardware [Member]
Property, Plant and Equipment [Line Items]
Property and equipment estimated useful lives	3 years
Office equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment estimated useful lives	3 years
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment estimated useful lives	5 years
Laboratory equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment estimated useful lives	7 years
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment estimated useful lives	Shorter of the initial lease term or useful life

Summary of Significant Accounting Policies - Schedule of Financial Liabilities Measured at Fair Value on a Recurring Basis (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Liabilities
Financial liabilities measured at fair value	$ 13,310	$ 5,763
Liability Classified Stock Options [Member]
Liabilities
Financial liabilities measured at fair value	12,603	3,945
Liability for Contingent Consideration [Member]
Liabilities
Financial liabilities measured at fair value	707	470
Warrant liabilities [Member]
Liabilities
Financial liabilities measured at fair value		1,348
Level 3 [Member]
Liabilities
Financial liabilities measured at fair value	13,310	5,763
Level 3 [Member] \| Liability Classified Stock Options [Member]
Liabilities
Financial liabilities measured at fair value	12,603	3,945
Level 3 [Member] \| Liability for Contingent Consideration [Member]
Liabilities
Financial liabilities measured at fair value	$ 707	470
Level 3 [Member] \| Warrant liabilities [Member]
Liabilities
Financial liabilities measured at fair value		$ 1,348

Summary of Significant Accounting Policies - Summary of Changes in Fair Value of the Company's Liability for Contingent Consideration (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Liability at the beginning of the period	$ 470
Increase (decrease) in fair value of liability for contingent consideration	237	$ 470
Liability at end of the period	$ 707	$ 470

Summary of Significant Accounting Policies - Schedule of Changes in Fair Value of Warrant Liabilities (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Liability at the beginning of the period	$ 1,348	$ 4,342
Warrants issued	0	0
Reclassification to liability from equity	0	0
Increase (decrease) in fair value of warrant liabilities	3,565	(2,450)
Exercise of warrants	$ (4,913)	(544)
Liability at end of the period		$ 1,348

Summary of Significant Accounting Policies - Schedule of Changes in Fair Value of Liability Classified Stock Options (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liability at beginning of the period	$ 3,945
Reclassification to liabilities from equity	0	$ 0
Liability at end of the period	12,603	3,945
Liability Classified Stock Options [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liability at beginning of the period	3,945	2,458
Reclassification to liabilities from equity		2,879
Increase (decrease) in fair value of liability classified stock options	9,451	(1,413)
Exercise of options	(142)	(300)
Unrealized foreign currency loss (gain)	(651)	321
Liability at end of the period	$ 12,603	$ 3,945

Summary of Significant Accounting Policies - Summary of Calculation of Diluted Loss Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Earnings Per Share [Abstract]
Net loss attributable to common shareholders:	$ (36,556)	$ (10,406)	$ (33,809)
Deemed dividend due to beneficial conversion feature		(520)
Basic	(36,556)	(10,926)	(33,809)
Adjustment for change in fair value of ASC 815 liability classified stock options and warrant		(2,757)
Diluted	$ (36,556)	$ (13,683)	$ (33,809)
Weighted-average common shares outstanding:
Basic	29,089,896	21,249,414	12,736,567
Adjustment for dilutive effect of liability classified stock options and warrants		71,795
Diluted	29,089,896	21,321,209	12,736,567
Net loss per common share-basic	$ (1.26)	$ (0.51)	$ (2.65)
Net loss per common share-diluted	$ (1.26)	$ (0.64)	$ (2.65)

Short-term Investments - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2018
Short-Term Investments [Line Items]
Short-term investments maturity term	12 months
Description on short-term investments maturity	The Company may redeem GIC investments 30 days after deposit without penalty.
Minimum [Member]
Short-Term Investments [Line Items]
Short-term investments interest rate	2.00%
Maximum [Member]
Short-Term Investments [Line Items]
Short-term investments interest rate	3.00%

Acquisition of Kairos - Additional Information (Detail) $ in Thousands			3 Months Ended	12 Months Ended
	Mar. 18, 2016 USD ($)	Mar. 18, 2016 CAD ($)	Mar. 31, 2017 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)
Acquired Indefinite-lived Intangible Assets [Line Items]
Impairment of intangible assets and goodwill					$ 1,536,000	$ 768,000
IPR&D [Member]
Acquired Indefinite-lived Intangible Assets [Line Items]
Impairment of intangible assets and goodwill			$ 1,536,000	$ 0		$ 768,000
Kairos [Member]
Acquired Indefinite-lived Intangible Assets [Line Items]
Consideration transferred	$ 24,778,000	$ 32,257
Cash consideration in connection with acquisition	$ 1,733,000	$ 2,257
Equity interest percentage before acquisition	19.99%	19.99%
Kairos [Member] \| Common Shares [Member]
Acquired Indefinite-lived Intangible Assets [Line Items]
Common shares issued in connection with acquisition	$ 23,043,000	$ 30,000

Acquisition of Kairos - Summary of Carrying Value of IPR&D, Net of Impairment (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Acquired Indefinite-lived Intangible Assets [Line Items]
Beginning balance	$ 18,396
Ending balance	18,396	$ 18,396
IPR&D [Member]
Acquired Indefinite-lived Intangible Assets [Line Items]
Acquired IPR&D, beginning balance	20,700	20,700
Acquired IPR&D, Change during the period
Acquired IPR&D, ending balance	20,700	20,700
Beginning balance	(2,304)	(768)
Change during the period		(1,536)
Ending balance	(2,304)	(2,304)
Beginning balance	18,396	19,932
Change during the period		(1,536)
Ending balance	$ 18,396	$ 18,396

Property and Equipment - Components of Property and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Property and equipment	$ 11,589	$ 10,724
Less accumulated depreciation	(5,105)	(3,546)
Property and equipment, net	6,484	7,178
Computer hardware [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	1,439	1,575
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	747	552
Office equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	535	484
Laboratory equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	5,270	4,895
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	3,377	3,022
Construction in progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$ 221	$ 196

Property and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Capital lease	$ 72	$ 78
Accumulated depreciation for the asset	56	47
Total future minimum lease payments	62	73
Depreciation expense	1,880	1,681	$ 541
Office equipment [Member]
Property, Plant and Equipment [Line Items]
Capital lease	$ 10	$ 10

Intangible Assets - Schedule of Intangible Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Computer software and licenses	$ 5,429	$ 2,812
Less accumulated amortization	(3,815)	(2,064)
Intangible assets, net	$ 1,614	$ 748

Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense on intangible assets	$ 1,750	$ 1,058	$ 484

Liabilities - Schedule of Accounts Payable and Accrued Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Accounts Payable and Accrued Liabilities, Current [Abstract]
Trade payables	$ 2,599	$ 1,664
Accrued research expenses	6,633	4,708
Employee compensation and vacation accruals	2,926	1,981
Accrued legal and professional fees	556	308
Payable to CDRD Ventures Inc. ("CVI") for Kairos SR&ED receivable (note 5)		165
Other	689	227
Total	$ 13,403	$ 9,053

Liabilities - Schedule of Other Current Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Other Liabilities, Current [Abstract]
Current income tax liability	$ 299	$ 158
Current portion of lease inducements	136	147
Current portion of capital lease liability	15	10
Total	$ 450	$ 315

Liabilities - Schedule of Other Long-term Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Other Liabilities, Noncurrent [Abstract]
Liability for contingent consideration (note 15)	$ 707	$ 470
Lease inducements	197	344
Capital lease liability	42	52
Total	$ 946	$ 866

Warrant Liabilities and Long-term Debt - Perceptive Debt - Additional Information (Detail)				5 Months Ended	12 Months Ended
	Jun. 06, 2017 USD ($)	Apr. 28, 2017 $ / shares shares	Jun. 02, 2016 USD ($) $ / shares shares	Jun. 06, 2017 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)
Line of Credit Facility [Line Items]
Interest rate description					LIBOR plus an applicable margin of 10% per annum with LIBOR to be a minimum of 1% with monthly interest payments.
Monthly principal payments			$ 225,000
Warrants issued to purchase shares \| shares		398,076
Warrants exercise price \| $ / shares		$ 8.67
Warrant liabilities from perceptive warrants					$ 0	$ 1,348,000
Residual balance of original principal recorded as long-term debt						4,700,000
Conversion of redeemable convertible class A preferred share warrants into common share warrants					1.349367-for-1 basis
Conversion ratio		1.349367
Repayment of debt						7,814,000
Accretion expense						248,000	$ 576,000
Amortization of debt issue costs						$ 35,000
Perceptive Debt [Member]
Line of Credit Facility [Line Items]
Credit facility			15,000,000
Warrant liabilities from perceptive warrants			3,266,000
Residual balance of original principal recorded as long-term debt			$ 4,234,000
Debt principal balance	$ 7,500,000			$ 7,500,000
Term of debt			4 years
Repayment of debt	7,814,000
Early repayment premium	300,000
Legal fees	$ 14,000
Interest expense				360,000
Accretion expense				248,000
Amortization of debt issue costs				$ 35,000
Perceptive Debt [Member] \| Long-term Debt [Member]
Line of Credit Facility [Line Items]
Debt principal balance			$ 7,500,000
Redeemable Convertible Class A Preferred Shares [Member]
Line of Credit Facility [Line Items]
Warrants issued to purchase shares \| shares			295,009
Warrants exercise price \| $ / shares			$ 11.69
Warrants expiry term			5 years
Redeemable Convertible Class A Preferred Shares [Member] \| Warrant liabilities [Member]
Line of Credit Facility [Line Items]
Conversion ratio		1.349367
LIBOR [Member]
Line of Credit Facility [Line Items]
Debt, basis spread on variable rate			10.00%
Floor interest rate			1.00%
Tranche A Term Loans [Member]
Line of Credit Facility [Line Items]
Net proceeds received			$ 6,953,000
Tranche A Term Loans [Member] \| Perceptive Debt [Member]
Line of Credit Facility [Line Items]
Credit facility			7,500,000
Tranche B Term Loans [Member] \| Perceptive Debt [Member]
Line of Credit Facility [Line Items]
Credit facility			$ 7,500,000

Warrant liabilities and long-term debt - Summary of Debt (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Debt Instruments [Abstract]
Long term debt at January 1, 2017	$ 4,810
Less: unamortized debt issue costs at January 1, 2017	(393)
Long term debt at January 1, 2017, net of deferred charges	4,417
Accretion during the period up to the Repayment Date	248	$ 576
Amortization of debt issue costs during the period up to the Repayment Date	35
Carrying value of long term debt on the Repayment Date, net of deferred charges	4,700
Repayment, including repayment premium and expenses	(7,814)
Loss on debt extinguishment	$ (3,114)

Warrant Liabilities and Long-term Debt - Warrant Liabilities - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Jun. 04, 2018	May 10, 2018	Apr. 28, 2017
Line of Credit Facility [Line Items]
Warrant liabilities from perceptive warrants	$ 0	$ 1,348,000
Warrants issued to purchase shares						398,076
Increase (decrease) in fair value of warrants	3,565,000	$ (2,450,000)	$ 808,000
Perceptive Warrants [Member]
Line of Credit Facility [Line Items]
Warrants issued to purchase shares				220,000	178,076
Common stock issued upon exercise of warrants				126,880	79,481
Increase (decrease) in fair value of warrants	$ 3,565,000

Warrant Liabilities and Long-term Debt - Summary of Assumptions Used in Estimating Fair Value of Warrants Determined Using Black-Scholes Option Pricing Model (Detail) - Perceptive Warrants [Member] - Valuation Technique, Option Pricing Model [Member]	Dec. 31, 2018 yr
Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement input	0.00
Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement input	0.667
Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement input	0.0209
Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement input	3.42

Redeemable Convertible Class A Preferred Shares, and Shareholders' Equity - Additional Information (Detail) $ / shares in Units, $ in Thousands			12 Months Ended
	Apr. 28, 2017 USD ($) $ / shares shares	Jul. 14, 2006	Dec. 31, 2018 USD ($) shares	Dec. 31, 2018 CAD ($) shares	Dec. 31, 2017 USD ($) shares	Dec. 31, 2017 CAD ($) shares	Dec. 31, 2016 USD ($)	Dec. 31, 2016 CAD ($)	Dec. 21, 2015 shares
Temporary Equity [Line Items]
Redeemable convertible preferred shares, authorized									6,413,265
Convertible preferred stock outstanding			0		0	0
Share issued price per share \| $ / shares	$ 13.00
Gross proceeds from conversion \| $	$ 50,000,000
Mandatory conversion description			Upon either a) the closing of the sale of common shares to the public at a price of at least 1.4 times the Class A original issue price of $11.69 per share in a firm-commitment underwritten public offering resulting in at least $50 million of gross proceeds, or b) the date and time, or the occurrence of an event, specified by vote or written consent of the holders of at least a majority of the then outstanding Class A Preferred Share, all outstanding Class A preferred shares would have been automatically converted into common shares at the effective conversion rate. However, in the event the common share public issuance price is less than 1.5 times the Class A original issue price of $11.69 per share, then immediately prior to, and contingent upon such conversion, the Class A conversion price would be automatically adjusted to equal the lesser of (a) the quotient obtained by dividing the per share price in such public offering by 1.5 and (b) the Class A conversion price in effect as of immediately prior to such public offering.	Upon either a) the closing of the sale of common shares to the public at a price of at least 1.4 times the Class A original issue price of $11.69 per share in a firm-commitment underwritten public offering resulting in at least $50 million of gross proceeds, or b) the date and time, or the occurrence of an event, specified by vote or written consent of the holders of at least a majority of the then outstanding Class A Preferred Share, all outstanding Class A preferred shares would have been automatically converted into common shares at the effective conversion rate. However, in the event the common share public issuance price is less than 1.5 times the Class A original issue price of $11.69 per share, then immediately prior to, and contingent upon such conversion, the Class A conversion price would be automatically adjusted to equal the lesser of (a) the quotient obtained by dividing the per share price in such public offering by 1.5 and (b) the Class A conversion price in effect as of immediately prior to such public offering.
Conversion of preferred stock to common stock	7,098,194
Share conversion ratio	1.349367
Beneficial conversion feature \| $	$ 520,000
Preferred stock, shares issued			0
Preferred stock, shares outstanding			0
Shares granted with respect to maximum fixed amount equal, percentage		20.00%
Options granted under original plan exercisable period			10 years	10 years
Shares available for issuance under the Original Plan vesting period		4 years
Proceeds from stock options exercised			$ 682,000	$ 883	$ 965,000	$ 1,250	$ 17,000	$ 22
Share based compensation \| $			3,876,000		4,827,000		2,797,000
Option exercised intrinsic value			2,388,000	3,094	1,550,000	$ 2,013	38,000	$ 51
Unamortized compensation expense related to unvested options			$ 8,395,000	$ 11,452
Remaining unamortized compensation expense, weighted-average period			2 years	2 years
Total amount contributed by ESPP participants \| $			$ 359,000
Maximum [Member]
Temporary Equity [Line Items]
Stock options expiration date			Dec. 16, 2028	Dec. 16, 2028
Minimum [Member]
Temporary Equity [Line Items]
Stock options expiration date			Feb. 05, 2019	Feb. 05, 2019
New Stock Option Plan [Member]
Temporary Equity [Line Items]
Shares granted with respect to maximum fixed amount equal, percentage			20.00%	20.00%
Maximum number of common shares reserved for issuance			5,686,097
Shares issuable upon exercise of stock options			3,985,768
Maximum number of common shares reserved for issuance increase in percentage			4.00%	4.00%
Employees Stock Purchase Plan [Member]
Temporary Equity [Line Items]
Shares granted with respect to maximum fixed amount equal, percentage			1.00%	1.00%
Percentage of discounted purchase price of average market price			85.00%	85.00%
Share-based compensation arrangement by share-based payment award, plan modification, description and terms			On June 7, 2018, certain amendments to the ESPP were approved by shareholders. Prior to these amendments, the ESPP allowed eligible employees to acquire common shares at a discounted purchase price of 85% of the market value of the Company’s common shares on the purchase date. The ESPP, as amended, allows eligible employees to acquire common shares at a discounted purchase price of the lesser of (i) 85% of the market price of a common share on the first day of the applicable purchase period and (ii) 85% of the market price of a common share on the purchase date.	On June 7, 2018, certain amendments to the ESPP were approved by shareholders. Prior to these amendments, the ESPP allowed eligible employees to acquire common shares at a discounted purchase price of 85% of the market value of the Company’s common shares on the purchase date. The ESPP, as amended, allows eligible employees to acquire common shares at a discounted purchase price of the lesser of (i) 85% of the market price of a common share on the first day of the applicable purchase period and (ii) 85% of the market price of a common share on the purchase date.
Maximum eligible employees contribution under ESPP			15.00%
Purchase of shares under ESPP, maximum limit for each employee \| $			$ 25,000
Additional common shares authorized for issuance			419,000	419,000
Compensation charge \| $			$ 114,000
Employees Stock Purchase Plan [Member] \| Prior To Amendment [Member]
Temporary Equity [Line Items]
Percentage of discounted purchase price of average market price			85.00%	85.00%
Employees Stock Purchase Plan [Member] \| After Amendment [Member]
Temporary Equity [Line Items]
Percentage of discounted purchase price of average market price			85.00%	85.00%
Employees Stock Purchase Plan [Member] \| Maximum [Member]
Temporary Equity [Line Items]
Number of common shares reserved for issuance			272,350
Additional Paid-in Capital [Member]
Temporary Equity [Line Items]
Beneficial conversion feature \| $					520,000
Share based compensation \| $			$ 3,876,000		$ 4,827,000		$ 2,797,000
Director [Member]
Temporary Equity [Line Items]
Shares available for issuance under the Original Plan vesting period		3 years
Redeemable Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Convertible preferred stock outstanding			0		0	0
Accrued dividends percentage	8.00%
Share issued price per share \| $ / shares	$ 11.69

Redeemable Convertible Class A Preferred Shares, and Shareholders' Equity - Summary of Stock Options Granted (Detail) $ / shares in Units, $ / shares in Units, $ in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2018 USD ($) $ / shares shares	Dec. 31, 2018 CAD ($) $ / shares shares	Dec. 31, 2017 USD ($) $ / shares shares	Dec. 31, 2017 USD ($) $ / shares shares	Dec. 31, 2016 USD ($) $ / shares shares	Dec. 31, 2016 USD ($) $ / shares shares	Dec. 31, 2018 USD ($)	Dec. 31, 2018 CAD ($)	Dec. 31, 2017 CAD ($)	Dec. 31, 2016 CAD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding, Beginning balance	2,263,712	2,263,712	1,910,521	1,910,521
Weighted-Average Exercise Price, Outstanding, Beginning balance \| (per share)	$ 11.35	$ 14.24	$ 8.69	$ 11.67
Number of Options, Granted	326,975	326,975	731,528	731,528
Number of Options, Expired	(7,908)	(7,908)	(80,254)	(80,254)
Number of Options, Exercised	(94,812)	(94,812)	(207,777)	(207,777)
Number of Options, Forfeited	(41,977)	(41,977)	(90,306)	(90,306)
Number of Options Outstanding, Ending balance	2,445,990	2,445,990	2,263,712	2,263,712	1,910,521	1,910,521
Number of Options, Exercisable	1,546,911	1,546,911
Number of Options, Vested and expected to vest	2,397,824	2,397,824
Weighted-Average Exercise Price, Granted \| (per share)	$ 12.74	$ 16.51	$ 14.56	$ 18.91
Weighted-Average Exercise Price, Expired \| (per share)	12.52	16.22	9.82	12.75
Weighted-Average Exercise Price, Exercised \| (per share)	6.80	8.81	4.64	6.02
Weighted-Average Exercise Price, Forfeited \| (per share)	13.96	18.09	14.04	18.23
Weighted-Average Exercise Price, Outstanding, Ending balance \| (per share)	10.74	14.66	$ 11.35	$ 14.24	$ 8.69	$ 11.67
Weighted-Average Exercise Price, Exercisable \| (per share)	9.83	13.41
Weighted-Average Exercise Price, Vested and expected to vest \| (per share)	$ 10.71	$ 14.61
Weighted-Average Contractual Term, Outstanding	6 years 11 months 26 days	6 years 11 months 26 days	7 years 6 months 10 days	7 years 6 months 10 days	7 years 4 months 9 days	7 years 4 months 9 days
Aggregate intrinsic value Outstanding			$ 1,160	$ 1,160	$ 15,609	$ 15,609	$ 10,571	$ 14,421	$ 1,455	$ 20,958
Weighted-Average Contractual Term, Exercisable	6 years 1 month 24 days	6 years 1 month 24 days
Aggregate intrinsic value Exercisable	$ 8,217	$ 11,209
Exercisable	$ 8,217	$ 11,209					8,217	$ 11,209
Weighted-Average Contractual Term, Vested and expected to vest	6 years 11 months 12 days	6 years 11 months 12 days
Aggregate intrinsic value Vested and expected to vest \| $		$ 14,410
Vested and expected to vest \| $							10,563
New Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding, Beginning balance	636,595	636,595
Weighted-Average Exercise Price, Outstanding, Beginning balance \| $ / shares	$ 9.70
Number of Options, Granted	910,783	910,783	650,480	650,480
Number of Options, Forfeited	(7,600)	(7,600)	(13,885)	(13,885)
Number of Options Outstanding, Ending balance	1,539,778	1,539,778	636,595	636,595
Number of Options, Exercisable	285,350	285,350
Number of Options, Vested and expected to vest	1,472,436	1,472,436
Weighted-Average Exercise Price, Granted \| $ / shares	$ 13.03		$ 9.70
Weighted-Average Exercise Price, Forfeited \| $ / shares	9.82		9.82
Weighted-Average Exercise Price, Outstanding, Ending balance \| $ / shares	11.67		$ 9.70
Weighted-Average Exercise Price, Exercisable \| $ / shares	10.04
Weighted-Average Exercise Price, Vested and expected to vest \| $ / shares	$ 11.65
Weighted-Average Contractual Term, Outstanding	9 years 7 days	9 years 7 days	9 years 5 months 15 days	9 years 5 months 15 days	0 years	0 years
Aggregate intrinsic value Outstanding \| $			$ 15	$ 15			4,876
Weighted-Average Contractual Term, Exercisable	8 years 6 months 7 days	8 years 6 months 7 days
Aggregate intrinsic value Exercisable \| $	$ 1,704
Exercisable \| $	$ 1,704						$ 1,704
Weighted-Average Contractual Term, Vested and expected to vest	9 years 3 days	9 years 3 days
Aggregate intrinsic value Vested and expected to vest \| $	$ 4,876

Redeemable Convertible Class A Preferred Shares, and Shareholders' Equity - Summary of Range of Stock Options Granted (Detail)	12 Months Ended
	Dec. 31, 2018 $ / shares shares	Dec. 31, 2018 $ / shares $ / shares shares	Dec. 31, 2017 $ / shares shares	Dec. 31, 2017 $ / shares $ / shares shares	Dec. 31, 2016 $ / shares shares	Dec. 31, 2018 $ / shares shares	Dec. 31, 2017 $ / shares shares	Dec. 31, 2016 $ / shares shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of options, outstanding \| shares	2,445,990	2,445,990	2,263,712	2,263,712	1,910,521	2,445,990	2,263,712	1,910,521
Weighted- average exercise price (C$) \| (per share)	$ 10.74	$ 10.74	$ 11.35	$ 11.35	$ 8.69	$ 14.66	$ 14.24	$ 11.67
Number of options, exercisable \| shares	1,546,911	1,546,911				1,546,911
Weighted-average exercise price (US$) \| (per share)	$ 9.83	$ 9.83				$ 13.41
Weighted- average exercise price (C$) \| (per share)	$ 6.80	$ 8.81	$ 4.64	$ 6.02
Weighted average remaining contractual life (years)	6 years 11 months 26 days	6 years 11 months 26 days	7 years 6 months 10 days	7 years 6 months 10 days	7 years 4 months 9 days
3.58 - 5.37 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based compensation, exercise price, lower		$ 3.58		$ 3.58
Share-based compensation, exercise price, upper		$ 5.37		$ 5.37
Number of options, outstanding \| shares	219,369	219,369	268,965	268,965		219,369	268,965
Weighted- average exercise price (C$) \| (per share)	$ 3.59	$ 3.59	$ 3.89	$ 3.89		$ 4.90	$ 4.88
Number of options, exercisable \| shares	219,369	219,369	268,965	268,965		219,369	268,965
Weighted- average exercise price (C$) \| (per share)	$ 3.59	$ 4.90	$ 3.89	$ 4.88
Weighted average remaining contractual life (years)	1 year 10 months 2 days	1 year 10 months 2 days	2 years 8 months 26 days	2 years 8 months 26 days
7.26 - 9.94 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based compensation, exercise price, lower		$ 7.26		$ 7.26
Share-based compensation, exercise price, upper		$ 9.94		$ 9.94
Number of options, outstanding \| shares	141,608	141,608	148,498	148,498		141,608	148,498
Weighted- average exercise price (C$) \| (per share)	$ 6.08	$ 6.08	$ 6.64	$ 6.64		$ 8.29	$ 8.32
Number of options, exercisable \| shares	102,087	102,087	89,498	89,498		102,087	89,498
Weighted- average exercise price (C$) \| (per share)	$ 5.60	$ 7.64	$ 5.79	$ 7.26
Weighted average remaining contractual life (years)	5 years 10 months 13 days	5 years 10 months 13 days	6 years 11 months 12 days	6 years 11 months 12 days
11.60 - 13.20 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based compensation, exercise price, lower		$ 11.6
Share-based compensation, exercise price, upper		$ 13.2
Number of options, outstanding \| shares	877,492	877,492				877,492
Weighted- average exercise price (C$) \| (per share)	$ 8.98	$ 8.98				$ 12.25
Number of options, exercisable \| shares	621,958	621,958				621,958
Weighted- average exercise price (C$) \| (per share)	$ 8.89	$ 12.12
Weighted average remaining contractual life (years)	7 years 1 month 9 days	7 years 1 month 9 days
11.60 - 12.10 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based compensation, exercise price, lower				$ 11.6
Share-based compensation, exercise price, upper				$ 12.1
Number of options, outstanding \| shares			717,826	717,826			717,826
Weighted- average exercise price (C$) \| (per share)			$ 9.58	$ 9.58			$ 12.02
Number of options, exercisable \| shares			410,968	410,968			410,968
Weighted- average exercise price (C$) \| (per share)			$ 9.53	$ 11.96
Weighted average remaining contractual life (years)			7 years 9 months 10 days	7 years 9 months 10 days
14.44 - 17.09 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based compensation, exercise price, lower		$ 14.44
Share-based compensation, exercise price, upper		$ 17.09
Number of options, outstanding \| shares	531,295	531,295				531,295
Weighted- average exercise price (C$) \| (per share)	$ 11.10	$ 11.10				$ 15.14
Number of options, exercisable \| shares	254,080	254,080				254,080
Weighted- average exercise price (C$) \| (per share)	$ 10.58	$ 14.44
Weighted average remaining contractual life (years)	7 years 8 months 26 days	7 years 8 months 26 days
13.21 - 14.44 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based compensation, exercise price, lower				$ 13.21
Share-based compensation, exercise price, upper				$ 14.44
Number of options, outstanding \| shares			468,116	468,116			468,116
Weighted- average exercise price (C$) \| (per share)			$ 11.14	$ 11.14			$ 13.98
Number of options, exercisable \| shares			247,268	247,268			247,268
Weighted- average exercise price (C$) \| (per share)			$ 11.51	$ 14.44
Weighted average remaining contractual life (years)			7 years 11 months 23 days	7 years 11 months 23 days
18.33 - 20.74 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based compensation, exercise price, lower		$ 18.33
Share-based compensation, exercise price, upper		$ 20.74
Number of options, outstanding \| shares	214,514	214,514				214,514
Weighted- average exercise price (C$) \| (per share)	$ 15.08	$ 15.08				$ 20.58
Number of options, exercisable \| shares	113,802	113,802				113,802
Weighted- average exercise price (C$) \| (per share)	$ 15.20	$ 20.74
Weighted average remaining contractual life (years)	7 years 11 months 23 days	7 years 11 months 23 days
21.05 - 22.65 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based compensation, exercise price, lower		$ 21.05
Share-based compensation, exercise price, upper		$ 22.65
Number of options, outstanding \| shares	461,712	461,712				461,712
Weighted- average exercise price (C$) \| (per share)	$ 16.48	$ 16.48				$ 22.48
Number of options, exercisable \| shares	235,615	235,615				235,615
Weighted- average exercise price (C$) \| (per share)	$ 16.57	$ 22.60
Weighted average remaining contractual life (years)	8 years 2 months 12 days	8 years 2 months 12 days
20.74 - 22.65 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based compensation, exercise price, lower				$ 20.74
Share-based compensation, exercise price, upper				$ 22.65
Number of options, outstanding \| shares			660,307	660,307			660,307
Weighted- average exercise price (C$) \| (per share)			$ 17.52	$ 17.52			$ 21.98
Number of options, exercisable \| shares			119,280	119,280			119,280
Weighted- average exercise price (C$) \| (per share)			$ 17.20	$ 21.58
Weighted average remaining contractual life (years)			9 years 7 days	9 years 7 days
3.58 to 22.65 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based compensation, exercise price, lower		$ 3.58		$ 3.58
Share-based compensation, exercise price, upper		$ 22.65		$ 22.65
Number of options, outstanding \| shares	2,445,990	2,445,990	2,263,712	2,263,712		2,445,990	2,263,712
Weighted- average exercise price (C$) \| (per share)	$ 10.74	$ 10.74	$ 11.35	$ 11.35		$ 14.66	$ 14.24
Number of options, exercisable \| shares	1,546,911	1,546,911	1,135,979	1,135,979		1,546,911	1,135,979
Weighted- average exercise price (C$) \| (per share)	$ 9.83	$ 13.41	$ 9.14	$ 11.46
Weighted average remaining contractual life (years)	6 years 11 months 26 days	6 years 11 months 26 days	7 years 6 months 10 days	7 years 6 months 10 days
6.80 - 7.76 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based compensation, exercise price, lower	$ 6.8
Share-based compensation, exercise price, upper	7.76
9.81 - 11.84 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based compensation, exercise price, lower	9.81
Share-based compensation, exercise price, upper	11.84
12.77 - 14.51 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based compensation, exercise price, lower	12.77
Share-based compensation, exercise price, upper	14.51
15.01 - 15.92 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based compensation, exercise price, lower	15.01
Share-based compensation, exercise price, upper	15.92
16.42 - 17.21 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based compensation, exercise price, lower	16.42
Share-based compensation, exercise price, upper	17.21
6.80 to 17.21 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based compensation, exercise price, lower	6.8
Share-based compensation, exercise price, upper	$ 17.21
6.80 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based compensation, exercise price			$ 6.8
7.75 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based compensation, exercise price			7.75
9.82 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based compensation, exercise price			9.82
6.80 to 9.82 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based compensation, exercise price, lower			6.8
Share-based compensation, exercise price, upper			$ 9.82
New Stock Option Plan [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of options, outstanding \| shares	1,539,778	1,539,778	636,595	636,595		1,539,778	636,595
Weighted- average exercise price (C$)	$ 11.67	$ 11.67	$ 9.70	$ 9.70
Number of options, exercisable \| shares	285,350	285,350				285,350
Weighted-average exercise price (US$)	$ 10.04	$ 10.04
Weighted average remaining contractual life (years)	9 years 7 days	9 years 7 days	9 years 5 months 15 days	9 years 5 months 15 days	0 years
New Stock Option Plan [Member] \| 6.80 - 7.76 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of options, outstanding \| shares	27,855	27,855				27,855
Weighted- average exercise price (C$)	$ 7.11	$ 7.11
Number of options, exercisable \| shares	14,308	14,308				14,308
Weighted-average exercise price (US$)	$ 6.69	$ 6.69
Weighted average remaining contractual life (years)	8 years 8 months 26 days	8 years 8 months 26 days
New Stock Option Plan [Member] \| 9.81 - 11.84 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of options, outstanding \| shares	1,166,640	1,166,640				1,166,640
Weighted- average exercise price (C$)	$ 10.79	$ 10.79
Number of options, exercisable \| shares	253,140	253,140				253,140
Weighted-average exercise price (US$)	$ 9.81	$ 9.81
Weighted average remaining contractual life (years)	8 years 9 months 25 days	8 years 9 months 25 days
New Stock Option Plan [Member] \| 12.77 - 14.51 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of options, outstanding \| shares	113,000	113,000				113,000
Weighted- average exercise price (C$)	$ 13.51	$ 13.51
Weighted average remaining contractual life (years)	9 years 9 months 7 days	9 years 9 months 7 days
New Stock Option Plan [Member] \| 15.01 - 15.92 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of options, outstanding \| shares	159,858	159,858				159,858
Weighted- average exercise price (C$)	$ 15.22	$ 15.22
Number of options, exercisable \| shares	17,902	17,902				17,902
Weighted-average exercise price (US$)	$ 15.78	$ 15.78
Weighted average remaining contractual life (years)	9 years 9 months 10 days	9 years 9 months 10 days
New Stock Option Plan [Member] \| 16.42 - 17.21 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of options, outstanding \| shares	72,425	72,425				72,425
Weighted- average exercise price (C$)	$ 16.76	$ 16.76
Weighted average remaining contractual life (years)	9 years 4 months 28 days	9 years 4 months 28 days
New Stock Option Plan [Member] \| 6.80 to 17.21 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of options, outstanding \| shares	1,539,778	1,539,778				1,539,778
Weighted- average exercise price (C$)	$ 11.67	$ 11.67
Number of options, exercisable \| shares	285,350	285,350				285,350
Weighted-average exercise price (US$)	$ 10.04	$ 10.04
Weighted average remaining contractual life (years)	9 years 7 days	9 years 7 days
New Stock Option Plan [Member] \| 6.80 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of options, outstanding \| shares			18,855	18,855			18,855
Weighted- average exercise price (C$)			$ 6.80	$ 6.80
Number of options, exercisable \| shares			1,396	1,396			1,396
Weighted-average exercise price (US$)			$ 6.80	$ 6.80
Weighted average remaining contractual life (years)			9 years 7 months 13 days	9 years 7 months 13 days
New Stock Option Plan [Member] \| 7.75 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of options, outstanding \| shares			9,000	9,000			9,000
Weighted- average exercise price (C$)			$ 7.75	$ 7.75
Weighted average remaining contractual life (years)			9 years 11 months 23 days	9 years 11 months 23 days
New Stock Option Plan [Member] \| 9.82 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of options, outstanding \| shares			608,740	608,740			608,740
Weighted- average exercise price (C$)			$ 9.82	$ 9.82
Weighted average remaining contractual life (years)			9 years 5 months 12 days	9 years 5 months 12 days
New Stock Option Plan [Member] \| 6.80 to 9.82 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of options, outstanding \| shares			636,595	636,595			636,595
Weighted- average exercise price (C$)			$ 9.70	$ 9.70
Number of options, exercisable \| shares			1,396	1,396			1,396
Weighted-average exercise price (US$)			$ 6.80	$ 6.80
Weighted average remaining contractual life (years)			9 years 5 months 15 days	9 years 5 months 15 days

Redeemable Convertible Class A Preferred Shares, and Shareholders' Equity - Schedule of Non-Vested Stock Option Activity (Detail)	12 Months Ended
	Dec. 31, 2018 USD ($) $ / shares shares	Dec. 31, 2018 CAD ($) $ / shares shares	Dec. 31, 2017 USD ($) $ / shares shares	Dec. 31, 2017 CAD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options, Non-vested,Beginning balance \| shares	1,127,733	1,127,733
Number of Options granted \| shares	326,975	326,975	731,528	731,528
Number of Options vested \| shares	(513,652)	(513,652)
Number of Options forfeited and cancelled \| shares	(41,977)	(41,977)
Number of options, Non-vested,Ending balance \| shares	899,079	899,079	1,127,733	1,127,733
Weighted- average fair value price, Non-vested,Beginning balance \| (per share)	$ 7.69	$ 9.64
Weighted- average fair value price, Options granted \| (per share)	7.69	9.96
Weighted- average fair value price, Options vested \| (per share)	7.83	10.14
Weighted- average fair value price, Options forfeited and cancelled \| (per share)	8.36	10.83
Weighted- average fair value price, Non-vested,Ending balance \| (per share)	$ 7.51	$ 10.25	$ 7.69	$ 9.64
Aggregate Fair value, Non-vested,Beginning balance \| $		$ 10,876
Aggregate Fair value, Options granted \| $		3,259
Aggregate Fair value, Options vested \| $		(5,210)
Aggregate Fair value, Options forfeited and cancelled \| $		(455)
Aggregate Fair value, Non-vested,Ending balance \| $		$ 8,470		$ 10,876
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options, Non-vested,Beginning balance \| shares	635,199	635,199
Number of Options granted \| shares	910,783	910,783
Number of Options vested \| shares	(283,954)	(283,954)
Number of Options forfeited and cancelled \| shares	(7,600)	(7,600)
Number of options, Non-vested,Ending balance \| shares	1,254,428	1,254,428	635,199	635,199
Weighted- average fair value price, Non-vested,Beginning balance \| $ / shares	$ 3.58
Weighted- average fair value price, Options granted \| $ / shares	7.99
Weighted- average fair value price, Options vested \| $ / shares	5.69
Weighted- average fair value price, Options forfeited and cancelled \| $ / shares	5.64
Weighted- average fair value price, Non-vested,Ending balance \| $ / shares	$ 7.31		$ 3.58
Aggregate Fair value, Non-vested,Beginning balance \| $	$ 2,276
Aggregate Fair value, Options granted \| $	7,277
Aggregate Fair value, Options vested \| $	(1,615)
Aggregate Fair value, Options forfeited and cancelled \| $	(43)
Aggregate Fair value, Non-vested,Ending balance \| $	$ 7,895		$ 2,276

Redeemable Convertible Class A Preferred Shares, and Shareholders' Equity - Schedule of Stock-based Compensation Expense for Equity Classified Instruments (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Research and development expenses	$ 56,684	$ 41,749	$ 36,816
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation for equity classified instruments	2,203	913	2,335
Change in fair value of liability classified equity instruments	2,032	492	280
Research and development expenses	4,235	1,405	2,615
General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation for equity classified instruments	3,693	1,852	786
Change in fair value of liability classified equity instruments	5,362	486	889
General and administrative expenses	9,055	2,338	1,675
Finance Expense (Income) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation for equity classified instruments	1
Change in fair value of liability classified equity instruments	150	(314)	1
Finance expenses	$ 151	$ (314)	$ 1

Redeemable Convertible Class A Preferred Shares, and Shareholders' Equity - Schedule of Estimated Fair Value of Stock Options Assumptions (Detail) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%	0.00%	0.00%
Expected volatility	66.52%	66.25%	70.52%
Risk-free interest rate	2.18%	1.44%	1.08%
Expected average life of option	5 years 10 months 28 days	5 years 10 months 24 days	5 years 10 months 28 days
Number of liability classified share options outstanding	2,445,990	2,263,712	1,910,521
Liability Classified Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%	0.00%
Expected volatility	72.27%	66.46%
Risk-free interest rate	1.94%	1.55%
Expected average life of option	3 years 7 months 2 days	5 years 10 months 20 days
Number of liability classified share options outstanding	1,437,163	1,475,485
New Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%	0.00%
Expected volatility	66.78%	65.89%
Risk-free interest rate	2.69%	1.84%
Expected average life of option	5 years 10 months 17 days	5 years 10 months 20 days	0 years
Number of liability classified share options outstanding	1,539,778	636,595

Government Grants and Credits - Component of Government Grants and Credits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Movement Of Allowance For Finance Lease Receivables [Line Items]
Government grants and credits	$ (5)	$ 1,075	$ 1,265
Scientific Research And Experimental Development Tax Credit (Expense) [Member]
Movement Of Allowance For Finance Lease Receivables [Line Items]
Government grants and credits	$ (5)	857	$ 1,265
IRAP Credits [Member]
Movement Of Allowance For Finance Lease Receivables [Line Items]
Government grants and credits		$ 218

Government Grants and Credits - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Receivables [Abstract]
Accrued refundable investment tax credits	$ 106
Income tax expense benefit true up adjustment			$ (111)
Government grants and credits	(5)	$ 1,075	1,265
Investment tax credits		229	$ 662
SR&ED receivable	$ 997	$ 2,092

Research, Collaboration and Licensing Agreements - Schedule Of Collaborative Arrangements and Noncollaborative Arrangement Transactions (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized	$ 53,019,000	$ 51,762,000	$ 11,009,000
Janssen Biotech, Inc. [Member] \| Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized		50,000,000
Merck Sharp & Dohme Research Ltd. [Member] \| Research Support Payments [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized	0	1,000	832,000
Eli Lilly and Company [Member] \| Research Support Payments [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized		15,000	46,000
Eli Lilly and Company [Member] \| Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized	2,000,000		2,000,000
Celgene [Member] \| License Option [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized	4,000,000
Gsk [Member] \| Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized			6,000,000
Daiichi Sankyo, Co., Ltd. [Member] \| Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized	18,000,000		2,000,000
Daiichi Sankyo, Co., Ltd. [Member] \| Research Support Payments [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized		700,000	$ 131,000
Daiichi Sankyo, Co., Ltd. [Member] \| Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized		1,000,000
LEO Pharma [Member] \| Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized	5,000,000
LEO Pharma [Member] \| Research Support Payments [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized	116,000
Bei Gene [Member] \| Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized	23,530,000
Other [Member] \| Service, Other [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized	$ 373,000	$ 46,000

Research, Collaboration and Licensing Agreements - Additional Information - Merck (Detail) - USD ($)						9 Months Ended	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 03, 2014	Apr. 22, 2013	Sep. 20, 2012	Jun. 30, 2012	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Jan. 01, 2018	Aug. 22, 2011
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract assets	$ 0						$ 0			$ 0
Deferred revenue							36,471,000
Revenue							53,019,000	$ 51,762,000	$ 11,009,000
Merck Sharp & Dohme Research Ltd. [Member] \| Research Support Payments [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue							0	$ 1,000	$ 832,000
Merck Sharp & Dohme Research Ltd. [Member] \| Research and License Agreement [Member] \| Non-collaborative Arrangement Transactions [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone removed from total milestones			$ 2,000,000
Remaining performance obligation	0						0
Merck Sharp & Dohme Research Ltd. [Member] \| Research and License Agreement [Member] \| Non-collaborative Arrangement Transactions [Member] \| Research Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue				$ 1,500,000	$ 2,000,000
Merck Sharp & Dohme Research Ltd. [Member] \| Research and License Agreement [Member] \| Non-collaborative Arrangement Transactions [Member] \| Investigational New Drug [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue							0
Merck Sharp & Dohme Research Ltd. [Member] \| Research and License Agreement [Member] \| Non-collaborative Arrangement Transactions [Member] \| Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue							0
Merck Sharp & Dohme Research Ltd. [Member] \| Research and License Agreement [Member] \| Non-collaborative Arrangement Transactions [Member] \| Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue							0
Merck Sharp & Dohme Research Ltd. [Member] \| Research and License Agreement [Member] \| Non-collaborative Arrangement Transactions [Member] \| Royalty [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue							0
Merck Sharp & Dohme Research Ltd. [Member] \| Research and License Agreement [Member] \| Non-collaborative Arrangement Transactions [Member] \| Eligible to Receive [Member] \| Research Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			3,500,000
Merck Sharp & Dohme Research Ltd. [Member] \| Research and License Agreement [Member] \| Non-collaborative Arrangement Transactions [Member] \| Eligible to Receive [Member] \| Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			190,750,000
Merck Sharp & Dohme Research Ltd. [Member] \| Research and License Agreement [Member] \| Non-collaborative Arrangement Transactions [Member] \| Eligible to Receive [Member] \| Maximum [Member] \| Investigational New Drug [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			6,000,000
Merck Sharp & Dohme Research Ltd. [Member] \| Research and License Agreement [Member] \| Non-collaborative Arrangement Transactions [Member] \| Eligible to Receive [Member] \| Maximum [Member] \| Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			66,000,000
Merck Sharp & Dohme Research Ltd. [Member] \| Research and License Agreement [Member] \| Non-collaborative Arrangement Transactions [Member] \| Eligible to Receive [Member] \| Maximum [Member] \| Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			$ 114,000,000
Merck Sharp & Dohme Research Ltd. [Member] \| Research and License Agreement [Member] \| Non-collaborative Arrangement Transactions [Member] \| Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities											$ 1,250,000
Performance obligation recognized						$ 1,250,000
Merck Sharp & Dohme Research Ltd. [Member] \| Research and License Agreement [Member] \| Non-collaborative Arrangement Transactions [Member] \| Up-front Technology Access Fee [Member] \| Eligible to Receive [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue						$ 1,250,000
Bei Gene [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred revenue	$ 36,471,000	$ 0
Bei Gene [Member] \| Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue							23,530,000
Bei Gene [Member] \| Research and License Agreement [Member] \| Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Performance obligation recognized							$ 20,000,000

Research, Collaboration and Licensing Agreements - Additional Information - Lilly (Detail) - USD ($)				6 Months Ended	12 Months Ended
	Aug. 31, 2018	Dec. 11, 2015	Dec. 17, 2013	Jun. 30, 2014	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue					$ 53,019,000	$ 51,762,000	$ 11,009,000
Eli Lilly and Company [Member] \| Research Support Payments [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue						15,000	46,000
Eli Lilly and Company [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Project One [Member] \| Research Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 2,000,000	$ 1,000,000
Eli Lilly and Company [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Project One [Member] \| Research Support Payments [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue					$ 0	$ 15,000	$ 46,000
Eli Lilly and Company [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Project One [Member] \| Eligible to Receive [Member] \| Research Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			$ 1,000,000
Eli Lilly and Company [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Project One [Member] \| Eligible to Receive [Member] \| Investigational New Drug [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			2,000,000
Eli Lilly and Company [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Project One [Member] \| Eligible to Receive [Member] \| Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			8,000,000
Eli Lilly and Company [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Project One [Member] \| Eligible to Receive [Member] \| Maximum [Member] \| Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			40,000,000
Eli Lilly and Company [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Project One [Member] \| Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities			$ 1,000,000
Performance obligation recognized				$ 1,000,000

Research, Collaboration and Licensing Agreements - Additional Information - Lilly Two (Detail) - USD ($)			12 Months Ended
	Dec. 01, 2016	Oct. 22, 2014	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			$ 53,019,000	$ 51,762,000	$ 11,009,000
Eli Lilly and Company [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Project Two [Member] \| Research Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 2,000,000
Eli Lilly and Company [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Project Two [Member] \| Investigational New Drug [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			0
Eli Lilly and Company [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Project Two [Member] \| Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			0
Eli Lilly and Company [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Project Two [Member] \| Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			$ 0
Eli Lilly and Company [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Project Two [Member] \| Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities		$ 0
Eli Lilly and Company [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Project Two [Member] \| Eligible to Receive [Member] \| Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		125,000,000
Eli Lilly and Company [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Project Two [Member] \| Eligible to Receive [Member] \| Maximum [Member] \| Research Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		2,000,000
Eli Lilly and Company [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Project Two [Member] \| Eligible to Receive [Member] \| Maximum [Member] \| Investigational New Drug [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		8,000,000
Eli Lilly and Company [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Project Two [Member] \| Eligible to Receive [Member] \| Maximum [Member] \| Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		20,000,000
Eli Lilly and Company [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Project Two [Member] \| Eligible to Receive [Member] \| Maximum [Member] \| Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		$ 95,000,000

Research, Collaboration and Licensing Agreements - Additional Information - Celgene (Detail)				6 Months Ended	12 Months Ended
	Apr. 22, 2018 USD ($) Product	Apr. 21, 2018 Product	Dec. 23, 2014 USD ($)	Jun. 30, 2015 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue					$ 53,019,000	$ 51,762,000	$ 11,009,000
Celgene [Member] \| License Option [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue					4,000,000
Celgene [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of potential products to developed and commercialized \| Product	10	8
Extended research program term	24 months
Collaborative agreement expansion fee	$ 4,000,000
Extended research program maturity period	2020-04
Celgene [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue					0
Celgene [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue					0
Celgene [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Royalty [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue					$ 0
Celgene [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payment	$ 164,000,000
Celgene [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Eligible to Receive [Member] \| License Option [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			$ 7,500,000
Celgene [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Eligible to Receive [Member] \| Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			164,000,000
Celgene [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Eligible to Receive [Member] \| Maximum [Member] \| Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			101,500,000
Celgene [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Eligible to Receive [Member] \| Maximum [Member] \| Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			55,000,000
Celgene [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities			$ 8,000,000
Performance obligation recognized				$ 8,000,000

Research, Collaboration and Licensing Agreements - Additional Information - GSK (Detail) - USD ($)		12 Months Ended
	Dec. 01, 2015	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		$ 53,019,000	$ 51,762,000	$ 11,009,000
Glaxo Smith Kline Intellectual Property Development Ltd [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		0
Glaxo Smith Kline Intellectual Property Development Ltd [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		0
Glaxo Smith Kline Intellectual Property Development Ltd [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Royalty [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		$ 0
Glaxo Smith Kline Intellectual Property Development Ltd [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities	$ 0
Glaxo Smith Kline Intellectual Property Development Ltd [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Eligible to Receive [Member] \| Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 110,000,000

Research, Collaboration and Licensing Agreements - Additional Information - GSK Two (Detail) - USD ($)			12 Months Ended
	May 03, 2016	Apr. 21, 2016	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			$ 53,019,000	$ 51,762,000	$ 11,009,000
Glaxo Smith Kline Intellectual Property Development Ltd [Member] \| Platform Technology Transfer and License Agreement [Member] \| Non-collaborative Arrangement Transactions [Member] \| Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities	$ 6,000,000
Performance obligation recognized	$ 6,000,000
Glaxo Smith Kline Intellectual Property Development Ltd [Member] \| Platform Technology Transfer and License Agreement [Member] \| Non-collaborative Arrangement Transactions [Member] \| Research Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			0
Glaxo Smith Kline Intellectual Property Development Ltd [Member] \| Platform Technology Transfer and License Agreement [Member] \| Non-collaborative Arrangement Transactions [Member] \| Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			0
Glaxo Smith Kline Intellectual Property Development Ltd [Member] \| Platform Technology Transfer and License Agreement [Member] \| Non-collaborative Arrangement Transactions [Member] \| Commercial Sales Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			0
Glaxo Smith Kline Intellectual Property Development Ltd [Member] \| Platform Technology Transfer and License Agreement [Member] \| Non-collaborative Arrangement Transactions [Member] \| Royalty [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			$ 0
Glaxo Smith Kline Intellectual Property Development Ltd [Member] \| Platform Technology Transfer and License Agreement [Member] \| Non-collaborative Arrangement Transactions [Member] \| Eligible to Receive [Member] \| Maximum [Member] \| Research Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		$ 30,000,000
Glaxo Smith Kline Intellectual Property Development Ltd [Member] \| Platform Technology Transfer and License Agreement [Member] \| Non-collaborative Arrangement Transactions [Member] \| Eligible to Receive [Member] \| Maximum [Member] \| Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		152,000,000
Glaxo Smith Kline Intellectual Property Development Ltd [Member] \| Platform Technology Transfer and License Agreement [Member] \| Non-collaborative Arrangement Transactions [Member] \| Eligible to Receive [Member] \| Maximum [Member] \| Commercial Sales Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		$ 720,000,000

Research, Collaboration and Licensing Agreements - Additional Information - Daiichi Sankyo (Detail) - USD ($)			12 Months Ended
	Jun. 26, 2017	Sep. 26, 2016	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			$ 53,019,000	$ 51,762,000	$ 11,009,000
Daiichi Sankyo, Co., Ltd [Member] \| Cross License Agreement [Member] \| Collaborative Arrangement [Member] \| Eligible to Receive [Member] \| Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payment		$ 1,000,000
Daiichi Sankyo, Co., Ltd [Member] \| Cross License Agreement [Member] \| Collaborative Arrangement [Member] \| Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities		2,000,000
Performance obligation recognized		2,000,000
Daiichi Sankyo, Co., Ltd [Member] \| Cross License Agreement [Member] \| Collaborative Arrangement [Member] \| Research, Development, Commercial License Option Milestone [Member] \| Eligible to Receive [Member] \| Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		66,900,000
Daiichi Sankyo, Co., Ltd [Member] \| Cross License Agreement [Member] \| Collaborative Arrangement [Member] \| Commercial Milestones [Member] \| Eligible to Receive [Member] \| Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		$ 80,000,000
Daiichi Sankyo, Co., Ltd [Member] \| Cross License Agreement [Member] \| Collaborative Arrangement [Member] \| Research Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 1,000,000
Daiichi Sankyo, Co., Ltd [Member] \| Cross License Agreement [Member] \| Collaborative Arrangement [Member] \| Research Support Payments [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research support revenue			$ 0	$ 700,000	$ 131,000

Research, Collaboration and Licensing Agreements - Additional Information - Daiichi Sankyo Two (Detail) - USD ($)		12 Months Ended
	May 30, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		$ 53,019,000	$ 51,762,000	$ 11,009,000
Daiichi Sankyo, Co., Ltd [Member] \| License Agreement [Member] \| Non-collaborative Arrangement Transactions [Member] \| Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		0
Daiichi Sankyo, Co., Ltd [Member] \| License Agreement [Member] \| Non-collaborative Arrangement Transactions [Member] \| Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		0
Daiichi Sankyo, Co., Ltd [Member] \| License Agreement [Member] \| Non-collaborative Arrangement Transactions [Member] \| Royalty [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		$ 0
Daiichi Sankyo, Co., Ltd [Member] \| License Agreement [Member] \| Non-collaborative Arrangement Transactions [Member] \| Eligible to Receive [Member] \| Royalty [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty agreement term	10 years
Daiichi Sankyo, Co., Ltd [Member] \| License Agreement [Member] \| Non-collaborative Arrangement Transactions [Member] \| Eligible to Receive [Member] \| Maximum [Member] \| Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 126,700,000
Daiichi Sankyo, Co., Ltd [Member] \| License Agreement [Member] \| Non-collaborative Arrangement Transactions [Member] \| Eligible to Receive [Member] \| Maximum [Member] \| Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 340,000,000
Daiichi Sankyo, Co., Ltd [Member] \| License Agreement [Member] \| Non-collaborative Arrangement Transactions [Member] \| Eligible to Receive [Member] \| Maximum [Member] \| Royalty [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty percentage earned from sales of product	10.00%
Daiichi Sankyo, Co., Ltd [Member] \| License Agreement [Member] \| Non-collaborative Arrangement Transactions [Member] \| Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities	$ 18,000,000
Performance obligation recognized	$ 18,000,000

Research, Collaboration and Licensing Agreements - Additional Information - Janssen (Detail) - USD ($)		12 Months Ended
	Nov. 13, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		$ 53,019,000	$ 51,762,000	$ 11,009,000
Janssen Biotech, Inc. [Member] \| Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			$ 50,000,000
Janssen Biotech, Inc. [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities	$ 50,000,000
Performance obligation recognized	50,000,000
Janssen Biotech, Inc. [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Research Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		0
Janssen Biotech, Inc. [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		0
Janssen Biotech, Inc. [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Development Milestone [Member] \| Eligible to Receive [Member] \| Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	282,000,000
Janssen Biotech, Inc. [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		0
Janssen Biotech, Inc. [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Commercial Milestones [Member] \| Eligible to Receive [Member] \| Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 1,119,000,000
Janssen Biotech, Inc. [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Royalty [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		$ 0
Janssen Biotech, Inc. [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Royalty [Member] \| Eligible to Receive [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty agreement term	10 years
Payment for royalty	$ 10,000,000
Royalty payment percentage	1.00%

Research, Collaboration and Licensing Agreements - Additional Information - LEO (Detail) - USD ($) $ in Thousands		12 Months Ended
	Oct. 23, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		$ 53,019	$ 51,762	$ 11,009
LEO Pharma [Member] \| Research Support Payments [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		116
LEO Pharma [Member] \| Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		5,000
LEO Pharma [Member] \| Research and License Agreement [Member] \| Collaborative Arrangement [Member] \| Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 0
LEO Pharma [Member] \| Research and License Agreement [Member] \| Collaborative Arrangement [Member] \| Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	0
LEO Pharma [Member] \| Research and License Agreement [Member] \| Collaborative Arrangement [Member] \| Investigational New Drug [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 0
LEO Pharma [Member] \| Research and License Agreement [Member] \| Collaborative Arrangement [Member] \| Research Support Payments [Member] \| Project One [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		$ 116
LEO Pharma [Member] \| Research and License Agreement [Member] \| Collaborative Arrangement [Member] \| First Therapeutic [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty payments on future global net sales	20.00%
LEO Pharma [Member] \| Research and License Agreement [Member] \| Collaborative Arrangement [Member] \| First Therapeutic [Member] \| Maximum [Member] \| Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 74,000
LEO Pharma [Member] \| Research and License Agreement [Member] \| Collaborative Arrangement [Member] \| First Therapeutic [Member] \| Maximum [Member] \| Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	157,000
LEO Pharma [Member] \| Research and License Agreement [Member] \| Collaborative Arrangement [Member] \| Second Therapeutic [Member] \| Maximum [Member] \| Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	86,500
LEO Pharma [Member] \| Research and License Agreement [Member] \| Collaborative Arrangement [Member] \| Second Therapeutic [Member] \| Maximum [Member] \| Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	157,000
LEO Pharma [Member] \| Research and License Agreement [Member] \| Collaborative Arrangement [Member] \| Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities	5,000
LEO Pharma [Member] \| Research and License Agreement [Member] \| Collaborative Arrangement [Member] \| Up-front Technology Access Fee [Member] \| Project One [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Performance obligation recognized	$ 5,000

Research, Collaboration and Licensing Agreements - Additional Information - BeiGene (Detail)	12 Months Ended
	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Nov. 26, 2018 Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 53,019,000	$ 51,762,000	$ 11,009,000
Bei Gene [Member] \| Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	23,530,000
Bei Gene [Member] \| Research and License Agreement [Member] \| Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Performance obligation recognized	20,000,000
Bei Gene [Member] \| Research and License Agreement [Member] \| Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Fair value of consideration allocated to a group of contracts that were considered as a single contract	40,000,000
Bei Gene [Member] \| Research and License Agreement [Member] \| Collaborative Arrangement [Member] \| Bispecific Therapeutic [Member] \| Maximum [Member] \| Commercial and Development Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	702,000,000
Bei Gene [Member] \| Research and License Agreement [Member] \| Collaborative Arrangement [Member] \| Up-front Technology Access Fee [Member] \| Bispecific Therapeutic [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities	20,000,000
Bei Gene [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of agreements \| Agreement				3
Bei Gene [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	0
Bei Gene [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	0
Bei Gene [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Royalty [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	0
Bei Gene [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| ZW25 Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Fair value of consideration allocated to a single performance obligation	7,100,000
Bei Gene [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| ZW49 Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	0
Bei Gene [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| ZW25 and ZW49 Agreements [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Performance obligation recognized	$ 20,000,000
Royalty payments on future global net sales	20.00%
Bei Gene [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| ZW25 and ZW49 Agreements [Member] \| Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 390,000,000
Bei Gene [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payment received	60,000,000
Bei Gene [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Up-front Technology Access Fee [Member] \| ZW25 Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Performance obligation recognized	3,500,000
Contract liabilities	36,500,000
Bei Gene [Member] \| License Agreement [Member] \| Collaborative Arrangement [Member] \| Up-front Technology Access Fee [Member] \| ZW49 Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities	$ 36,500,000

Financial Instruments - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Financial Instruments [Line Items]
Maximum exposure to credit risk for accounts receivable	$ 0.4	$ 0.2
Capital lease due, period	12 months
Accounts Payable and Accrued Liabilities [Member]
Financial Instruments [Line Items]
Financial obligation due, period	45 days

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Line Items]
Expected income tax rate	27.00%	26.00%
Net operating loss carry forwards	$ 24,700,000	$ 43,400,000
Unclaimed tax deductions for scientific research and experimental development expenditures	20,749,000	17,267,000
Tax credit carryforward, amount	9,009,000	7,000,000
Potential tax benefits	0
Accrued interest and penalties	$ 0	$ 0
Earliest Tax Year [Member]
Income Tax Disclosure [Line Items]
Operating loss carry forwards, expiration year	2035
Tax credit carryforward, expiration year	2019
Earliest Tax Year [Member] \| CANADA
Income Tax Disclosure [Line Items]
Income tax examination, year under examination	2006
Earliest Tax Year [Member] \| UNITED STATES
Income Tax Disclosure [Line Items]
Income tax examination, year under examination	2015
Latest Tax Year [Member]
Income Tax Disclosure [Line Items]
Operating loss carry forwards, expiration year	2038
Tax credit carryforward, expiration year	2038
Latest Tax Year [Member] \| CANADA
Income Tax Disclosure [Line Items]
Income tax examination, year under examination	2018
Latest Tax Year [Member] \| UNITED STATES
Income Tax Disclosure [Line Items]
Income tax examination, year under examination	2018
Maximum [Member]
Income Tax Disclosure [Line Items]
Sustainability threshold for uncertain tax position	50.00%

Income Taxes - Schedule of Income Tax Expense (Recovery) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Computed taxes at Canadian tax rate (27%)	$ (9,284)	$ (2,587)	$ (10,070)
Non-deductible expenses	4,311	259	1,343
Difference between domestic and foreign tax rate	(14)	(11)	95
Effect of change in tax rates	2	(860)
Adjustments to prior year	543	(313)	439
Change in valuation allowance	9,340	8,510	3,948
Share issuance costs in equity	(1,906)	(2,547)	158
Change in recognition and measurement of tax positions	672
Changes due to SR&ED	(1,668)	(1,973)	(588)
Other	175	(34)	(400)
Income tax expense (recovery)	2,171	444	(5,075)
Current income tax expense	2,188	429	430
Deferred income tax (recovery) expense	(17)	15	(5,505)
Income tax expense (recovery)	$ 2,171	$ 444	$ (5,075)

Income Taxes - Schedule of Income Tax Expense (Recovery) (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Effective Income Tax Rate	27.00%

Income Taxes - Summary of Significant Components of Deferred Income Tax Assets and Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Deferred tax assets:
Non-capital losses carried forward	$ 6,680	$ 11,719
Deferred revenue	9,848
Share issue costs	3,428	2,571
Property and equipment	1,167	956
Research and development deductions and credits	20,749	17,267
Contingent consideration	191	127
Stock options	220	102
Other	314	34
Deferred tax assets, Gross	42,597	32,776
Deferred tax liabilities:
Property and equipment	(54)	(70)
IPR&D	(4,967)	(4,619)
Other	(132)
Deferred tax liabilities, Gross	(5,153)	(4,689)
Deferred tax assets, Net	37,444	28,087
Less: valuation allowance	(37,360)	(28,020)
Net deferred tax assets (liabilities)	$ 84	$ 67

Income Taxes - Summary of Expiry Details of Investment Tax Credits, Non-Capital Losses and Net Operating Losses for Income Tax Purposes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards [Line Items]
Investment tax credits	$ 9,009	$ 7,000
Non-capital losses	$ 24,741
Tax Year 2021 [Member]
Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards [Line Items]
Expiry Date	2021
Investment tax credits	$ 86
Tax Year 2022 [Member]
Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards [Line Items]
Expiry Date	2022
Investment tax credits	$ 158
Tax Year 2023 [Member]
Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards [Line Items]
Expiry Date	2023
Investment tax credits	$ 94
Tax Year 2024 [Member]
Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards [Line Items]
Expiry Date	2024
Tax Year 2025 [Member]
Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards [Line Items]
Expiry Date	2025
Investment tax credits	$ 309
Tax Year 2026 [Member]
Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards [Line Items]
Expiry Date	2026
Investment tax credits	$ 247
Tax Year 2027 [Member]
Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards [Line Items]
Expiry Date	2027
Investment tax credits	$ 511
Tax Year 2028 [Member]
Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards [Line Items]
Expiry Date	2028
Investment tax credits	$ 814
Tax Year 2029 [Member]
Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards [Line Items]
Expiry Date	2029
Tax Year 2030 [Member]
Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards [Line Items]
Expiry Date	2030
Investment tax credits	$ 10
Tax Year 2031 [Member]
Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards [Line Items]
Expiry Date	2031
Investment tax credits	$ 133
Tax Year 2032 [Member]
Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards [Line Items]
Expiry Date	2032
Investment tax credits	$ 489
Tax Year 2033 [Member]
Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards [Line Items]
Expiry Date	2033
Investment tax credits	$ 557
Tax Year 2034 [Member]
Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards [Line Items]
Expiry Date	2034
Investment tax credits	$ 381
Tax Year 2035 [Member]
Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards [Line Items]
Expiry Date	2035
Investment tax credits	$ 1,068
Tax Year 2036 [Member]
Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards [Line Items]
Expiry Date	2036
Investment tax credits	$ 862
Non-capital losses	$ 14,116
Tax Year 2037 [Member]
Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards [Line Items]
Expiry Date	2037
Investment tax credits	$ 1,777
Non-capital losses	$ 10,625
Tax Year 2038 [Member]
Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards [Line Items]
Expiry Date	2038
Investment tax credits	$ 1,513

Income Taxes - Schedule of Reconciliation of Beginning and Ending Amounts of Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Balance, beginning of year
Increases related to prior year tax positions	142
Increases related to current year tax positions	530
Balance, end of year	$ 672

Commitments and Contingencies - Future Minimum Lease Payments Under Non-Cancellable Operating Leases and Capital Leases (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Contractual Obligation, Fiscal Year Maturity Schedule [Abstract]
Capital lease obligations, less than 1 year	$ 21
Capital lease obligations, 1 to 2 years	27
Capital lease obligations, 2 to 3 years	12
Capital lease obligations, 3 to 4 years	2
Capital lease obligations, 5 years	0
Capital lease obligations, Total	62	$ 73
Operating lease obligations, less than 1 year	1,860
Operating lease obligations, 1 to 2 years	1,871
Operating lease obligations, 2 to 3 years	1,429
Operating lease obligations, 3 to 4 years	87
Operating lease obligations, 5 years	0
Operating lease obligations, Total	5,247
Total contractual obligations, less than 1 year	1,881
Total contractual obligations, 1 to 2 years	1,898
Total contractual obligations, 2 to 3 years	1,441
Total contractual obligations, 3 to 4 years	89
Total contractual obligations, 5 years	0
Total contractual obligations	$ 5,309

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Aug. 31, 2016	Dec. 31, 2018	Dec. 31, 2017
Contractual Obligation, Fiscal Year Maturity Schedule [Abstract]
Aggregate payment for annual licensing fees	$ 12,000	$ 4,500
Annual licensing fees payment period		Five-year period
Amortization period of intangible assets	12 months
Estimated fair value of contingent consideration		$ 707	$ 470

Subsequent Events - Additional Information (Detail) - Eli Lilly and Company [Member] - Subsequent Event [Member] $ in Millions	Jan. 25, 2019 ft² $ / ft²	Jan. 17, 2019 USD ($)
Lease Agreements [Member]
Subsequent Event [Line Items]
Lease start date	Sep. 01, 2021
Lease agreement period	10 years
Office And Laboratory Space [Member] \| Lease Agreements [Member]
Subsequent Event [Line Items]
Area of space \| ft²	57,180
Office And Laboratory Space [Member] \| Lease Agreements [Member] \| Minimum [Member]
Subsequent Event [Line Items]
Annual base rent	39.50
Office And Laboratory Space [Member] \| Lease Agreements [Member] \| Maximum [Member]
Subsequent Event [Line Items]
Annual base rent	44.50
Storage Space [Member] \| Lease Agreements [Member]
Subsequent Event [Line Items]
Area of space \| ft²	2,780
Storage Space [Member] \| Lease Agreements [Member] \| Minimum [Member]
Subsequent Event [Line Items]
Annual base rent	25.00
Storage Space [Member] \| Lease Agreements [Member] \| Maximum [Member]
Subsequent Event [Line Items]
Annual base rent	35.00
License Agreement [Member] \| Collaborative Arrangement [Member]
Subsequent Event [Line Items]
Receivables from customers \| $		$ 8.0